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ABSTRACT 
 
A growing body of evidence suggests that a diet rich in flavonoids, naturally occurring 
plant-based compounds, is associated with improved health outcomes. However, 
current knowledge relating to the measurement of dietary flavonoid intake is limited 
and studies assessing the association of flavonoid-rich food supplementation with 
cognitive and physical health outcomes are scarce. This doctoral thesis outlines six 
studies that were developed to address two main research questions. Firstly, what 
methods should be employed to measure flavonoid intake? Secondly, how does the 
consumption of dietary flavonoid impact cognitive and physical outcomes? 
 
In order to associate the impact of dietary flavonoids on health outcomes, accurate 
dietary assessment is fundamental. A systematic literature review evaluates the 
various methods employed by current literature to measure flavonoid intake. The 
review emphasises the reliance of studies utilising unsound dietary assessment 
methods to measure flavonoid intake and demonstrates that few studies utilise 
objectives biomarkers as a measure of flavonoid intake.  
 
Dietary flavonoid intake estimates in Australia are limited, and specifically the 
estimations of flavonoid intake in older Australians are inadequate.  A Food Frequency 
Questionnaire for the measurement of dietary flavonoid intake in this cohort was 
developed, based on secondary data analysis of detailed dietary information in older 
adults.  The tool is validated against food records and assessed for reliability in a group 
of older Australians, showing to be a relatively useful instrument to measure flavonoid 
intake.  
 
In response to the lack of biomarker data utilised in current flavonoid research, a 
sensitive and specific GC-MS method was developed to determine flavonoids and 
phenolic acids in biological samples. The developed method has potential to measure 
115 flavonoid-related biomarkers in various biological samples, and is applied in later 
studies of this thesis.  
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A second systematic literature review identifies a paucity of research regarding food-
based anthocyanin (a subclass of flavonoids) consumption and cognitive outcomes. 
Various methodological limitations in published studies are highlighted, including a 
lack of information regarding dosage and dose-timings, age related variations in 
responses and small sample study sizes. The findings are utilised inform the 
development of acute and longer-term intervention studies to assess the impact of a 
flavonoid and anthocyanin-rich cherry juice supplementation on cognitive and 
physical outcomes.  
 
A pilot cross-over study assesses the acute effects on cognition, blood pressure and 
plasma biomarkers associated with consumption of a 300ml cherry juice, provided 
either as a single quantity or as 3x100ml doses administered over 2h. In young adults, 
older adults, and older adults with dementia similarly, results indicated that the acute 
impact of anthocyanin-rich cherry juice consumption on cognition was not supported, 
but a dose-timing administration effect may influence blood pressure outcomes. 
  
A longer-term intervention assesses whether daily consumption of anthocyanin-rich 
cherry juice changed cognition and blood pressure in older adults with dementia over 
12-weeks. The results indicate that anthocyanin-rich cherry juice consumption 
improve cognitive performance and significantly reduced blood pressure. This study 
provides the first evidence that a feasible serving of flavonoid-rich food may have 
beneficial consequences in older adults with Alzheimer’s type dementia 
 
Overall, this doctoral thesis provides a number of contributions to the literature. 
Primarily it demonstrates that the dietary flavonoid intake measurement strategies are 
lacking and the novel tools developed by this thesis improve upon current methods 
with potential application in future research. Additionally, the findings of the 
flavonoid intervention trials support the indication that flavonoid, and especially 
anthocyanin-rich food consumption, may be beneficial for cognitive and physical 
outcomes. 
 
 
PUBLICATIONS CONSTITUTING THIS THESIS 
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CHAPTER 1: INTRODUCTION 
 
This chapter examines the scientific literature relevant to this thesis, introducing 
concepts related to the measurement of flavonoid intake and a broad overview of the 
assessment of flavonoid consumption on health outcomes. The introduction provides 
a background to the thesis and exposes the gaps in current literature, and relates these 
to the empirical chapters of this thesis. The main research questions are introduced 
and the methodologies applied to address these are presented.  
  
 
27 
 
1.  
1.1 Flavonoids 
Plant based foods form an integral component of the human diet and their consumption 
is consistently linked to the maintenance of health and the prevention of a vast array 
of diseases (1, 2). In the past, the compounds believed to be responsible for the 
protective effects of a plant-based diet included carotenoids and other antioxidant 
vitamins (1). More recently, a growing body of literature illustrates that other 
phytochemicals, which are non-nutritive compounds, significantly contribute to the 
antioxidant activity of fruits and vegetables and are consequently attributed to the 
observed health benefits (3).   
 
These polyphenolic compounds, or polyphenols, encompass a huge range of 
compounds present in varying quantities in all plants and can be divided into the 
subclasses flavonoids, lignans, stilbenes and phenolic acids (4) (Figure 1-1). 
Flavonoids are further divided into six major classes: anthocyanins, flavanols, 
flavanones, flavones, flavonols and isoflavones (4) (Figure 1-1).  
 
 
Figure 1-1 Classification of polyphenolic compounds and examples of flavonoids 
 
Polyphenols
Flavonoids
Flavonols e.g. quercetin
Flavanones e.g. hesperetin
Flavones e.g. apigenin
Anthocyanins e.g. cyanidin
Flavan-3-ols
e.g. epicatechin 
e.g. proanthocyanin 
(polymeric flavanols)
Isoflavones e.g. daidzein
Stilbenes
Lignans
Phenolic Acids
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Flavonoids have been studied intensely with several hundred flavonoids identified in 
foods. Flavonoids are found in particularly high concentrations in fruits and 
vegetables, wine, tea, cocoa, and soy (5). The consumption of flavonoids is estimated 
to be much higher than other dietary antioxidants; for example, around 10 fold higher 
than vitamin C, and 100 times higher than both vitamin E and carotenoids (6). 
Flavonoids are secondary plant metabolites, indicating they are not directly involved 
with the growth of plants, but their role is related to the protection of plants from 
microbe and insect damage (2). As a component of the human diet, flavonoids 
contribute to the sensory characteristics of foods such as flavour, astringency and 
colour (7).  
 
1.2 Methods for measuring flavonoid intake 
To link flavonoid consumption with positive health outcomes, the first and most 
fundamental step is to accurately estimate dietary flavonoid intake. Despite the first 
estimations of flavonoid intake being reported on a population level more than a 
decade ago, the numerous methods currently employed have evident flaws (8). As 
dietary flavonoid intake is difficult to quantify, numerous methods have been 
developed for application in various settings. Methods include various techniques 
within the fields of dietary assessment and biomarker analysis, as will be described 
below and in further detail in Chapter 2.  
 
1.2.1 Methods of measuring flavonoid intake using dietary assessment 
The most common method of estimating flavonoid intake in a population relies on 
dietary assessment and informatics (the development of computerised food 
composition databases (FCDB)). Generally, usual dietary analysis is performed using 
either a 24 hour diet recall, diet history or food record, which is then cross-referenced 
with a flavonoid specific FCDB. There are very few flavonoid specific FCDBs that 
exist, with the two most commonly used being the USDA Database for the Flavonoid 
Content of Selected Foods (9) and Phenol Explorer Database on Polyphenol Content 
in Foods (10). Aside from the limitations associated with each dietary assessment 
method, there are several well documented problems associated with utilising food 
composition databases to assign flavonoid content to foods to estimate dietary intake. 
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These limitations include inadequate food lists, and the inability of FCDBs to account 
for the specific growth and processing conditions that influence foods and the high 
inter-individual variation in the bioavailability of flavonoids. These limitations are 
suggested to have contributed to the large variations in estimations of flavonoid intake 
(11). 
 
The limitations associated with current methods hinder the interpretation of 
observational research outcomes that associates dietary flavonoid intake and specific 
health outcomes. In light of Australia’s expanding and ageing population and the need 
for lifestyle recommendations to improve healthy ageing, these limitations must be 
rectified to create advances in this research area. Most notably, there is currently little 
information available on the dietary intake of flavonoids in older Australians and no 
recommendations have been developed to advise the best way to measure flavonoid 
intake in this cohort using dietary assessment methods (this will be discussed in more 
detail in chapter 3 of this thesis).  
 
1.2.2 Methods of measuring flavonoid intake using laboratory analysis 
Dietary flavonoid intake can also be determined by quantifying biomarkers of 
flavonoid intake, which include flavonoids and phenolic acids found in biological 
samples (12).  There are currently many methods of measuring flavonoid biomarkers 
in human biological samples. However, like dietary methodology, there is no 
standardised protocol of how to perform this analysis and researchers tend to develop 
and validate their own methods. Biomarkers of flavonoid intake are generally 
validated against dietary records (which capture either recent or habitual flavonoid 
intake) or after a dietary intervention study (13). A major limitation associated with 
accurately estimating flavonoid intake using biomarkers is that there are many 
hundreds of dietary flavonoids, which are rapidly and extensively metabolised into a 
wide range of metabolites (e.g. phenolic acids). There is currently no consensus 
regarding which of the intact flavonoid(s) or their in vivo phenolic acid metabolites 
are indicative of total dietary intake. Indeed, gaps in understanding of the exact uptake 
and metabolism of dietary flavonoids make it unclear as to which biological fluids 
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(plasma, urine or faecal water) to target for analysis of biomarkers. This concept will 
be addressed in more detail in chapter 4 of this thesis. 
 
Another major limitation of these methods relates to the fact that they are physically 
invasive in terms of collecting biological specimens, which may especially be 
problematic to collect older adults and vulnerable groups. Moreover, most of the 
biomarker analyses are expensive and quite often it is not possible to perform them as 
part of a large epidemiological study (14). Future research should focus on identifying 
specific biomarkers of flavonoid intake and confirm the best methods in which to 
quantify these biomarkers in biological specimens in order to inform population 
research. 
 
1.3 Dietary flavonoids and health outcomes 
A high consumption of total flavonoids and flavonoid subclasses has been consistently 
linked with a protection against chronic diseases associated with ageing (15, 16), 
including cardiovascular (17) and neurodegenerative diseases (18).  Biologically, 
flavonoids and their metabolites exert powerful antioxidant activities, influence 
vascular changes (17) and may guard areas of the brain against age-related decline 
(19, 20).  The majority of research into the biological aspect of flavonoids has been 
pre-clinical. However, some strong epidemiological research exists, linking habitual 
flavonoid intake to various improved health outcomes in older adults, specifically 
cognition (21), coronary (22) and ischemic heart disease (23). Experimental trials in 
humans are rarer, but preliminary studies highlight positive results.  
 
1.3.1 Dietary flavonoids and cardiovascular outcomes  
Cardiovascular diseases (CVD), including stroke and coronary heart disease, are a 
major cause of mortality in developed countries and are closely associated with 
modifiable lifestyle factors including diet (24). A diet high in flavonoids has been 
linked with a reduction in CVD mortality (24, 25), with a recent review indicating four 
out of eight studies reporting a significant inverse association between coronary heart 
disease mortality with at least one flavonoid subclass (24). The association between 
flavonoid intake and incident stroke is less clear with three out of seven studies 
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reporting an association with flavonoid intake (24). The inconsistencies in 
epidemiologic studies associating flavonoid intake with CVD outcomes may relate to 
the use of different dietary assessment methods and flavonoid composition databases, 
differences in the types of flavonoid subclasses studied and differences between the 
populations (26). 
 
The consumption of flavonoid-rich foods have been hypothesised to alter CVD risk 
factors including vascular function (27, 28) and blood pressure (29, 30), although the 
results are inconsistent. The mechanisms of action of flavonoids and cardiovascular 
outcomes are varied (25), with reviews indicating a multiplicity of effects (26). The 
antioxidant capacity of flavonoids has been postulated to reduce arterial stiffness 
through preventing the oxidation of LDL cholesterol (30). Another mechanism relates 
to a reduction in circulating free-radicals, reducing thrombogenesis and platelet 
aggregation in the body. The ability of flavonoids to modulate endothelial function, 
and thus influence blood pressure has also been investigated and relates to the 
modulation of nitric oxide bioavailability to the endothelium, resulting in 
endothelium-dependant vasodilation (27, 31, 32). Additional evidence suggests that 
flavonoid consumption may have the ability to prevent age-related vascular injury 
(33). It is possible that a culmination of all these effects may provide a protection 
against coronary heart disease and stroke.  
 
Limitations in the literature surrounding flavonoid consumption and vascular 
outcomes relate to the limited research in human controlled trials, the inconsistencies 
with intervention (diet, pure flavonoids etc.), a lack of knowledge relating to timing 
and dose-dependency of outcomes and inconsistencies in outcomes between different 
population groups (34) (discussed in further detail in chapters 6 and 7 of this thesis).  
 
1.3.2 Dietary flavonoids and cognition 
The consumption of dietary flavonoids has been associated with improved cognitive 
performance and a preservation of cognitive function with ageing (35-37), with the 
flavonoid sub-groups flavanols, anthocyanins and flavanones having shown the most 
beneficial effects in the area of neuroprotection (20). 
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Initially, the biological actions of flavonoids on the brain were attributed solely to their 
antioxidant actions, ability to scavenge free radicals and reduction of inflammation in 
the body. It was then demonstrated that the antioxidant activity of flavonoids could 
not fully account for their total bioactivity in the brain as their concentration in brain 
tissue is very low, and their ability to cross the blood-brain barrier was questioned 
(38). Therefore, the actions of flavonoids in the brain have been investigated further 
and a variety of mechanisms have been postulated alongside their antioxidant activity. 
These include an ability to protect vulnerable neurons, increase the number of, and the 
strength of the connections between neurons (20), and an enhancement existing 
neuronal function (via the modulation of signalling processes)(39). Additionally, 
flavonoids have been shown to stimulate blood flow to the brain and induce 
neurogenesis in the hippocampus, the area of the brain associated with memory (38). 
The culmination of these mechanisms has been theorised as the potential pathways by 
which flavonoids may influence memory, learning and cognition and prevent 
neurodegeneration. 
 
Limitations exist regarding the literature associating flavonoid intake with cognitive 
outcomes. Firstly, controlled intervention trials in humans are rare, with small samples 
sizes (40). Additionally, there is little consistency in the cognitive outcomes 
investigated across the literature, a wide range of intervention vehicles, doses and 
intervention durations investigated, which makes comparison and interpretation of 
study findings difficult (40) (discussed in further detail in chapters 6 and 7 of this 
thesis).  
 
1.3.3 Dietary flavonoids and dementia  
Neurodegenerative diseases is a term that describes a group of diseases that are 
irreversible and have debilitating symptoms including permanent memory 
impairment, continuous cognitive decline, and progressive behavioural disturbances 
(41). While cognitive impairment increases exponentially with age, it is not an 
inevitable consequence of ageing (42). Mild cognitive impairment and dementia 
related diseases are diagnosed when the level of impairment is greater than what is 
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associated with normal ageing (43). Dementia is the most common mental and 
behavioural disorder in Australia, accounting for 89% of cases in 2006 (44). In light 
of Australia’s ageing population, it is predicted that by 2050 spending on dementia is 
set to exceed any other health condition if no significant developments in the 
prevention or treatment of this disease are made (45). It is therefore necessary to 
identify strategies that prevent or delay the onset of cognitive impairment and the role 
of nutrition in neuroprotection is a promising area of research.  
 
Habitual consumption of flavonoid-rich foods and/or beverages has been associated 
with 50% reduction in the risk of developing a neurodegenerative disease (18) and a 
delay in the onset of Alzheimer’s disease (46). The proposed mechanisms by which 
flavonoids might delay the initiation of dementia and slow the progression of dementia 
have been summarised in a recent review (19). The review suggests that flavonoids 
have potential to inhibit neuronal apoptosis (cell death) which is generated by 
neurotoxic species by reducing oxidative stress and neuroinflammation in the brain, 
the latter of which is a characteristic of dementia progression (19). Dietary flavonoids 
have also shown the potential to disrupt amyloid β aggregation and may inhibit the 
production of amyloid β through the disruption of amyloid precursor protein 
processing (19). However, much of this research relies on pre-clinical evidence, which 
cannot easily be translated into the human experience. To date, there has been little 
experimental research that investigates the impact of flavonoid rich foods on cognitive 
and physical functioning, specifically in older adults with a neurodegenerative disease. 
This may be a result of the difficulties in recruiting and retaining participants with 
dementia to clinical trials, which tend to have restrictive inclusion criteria, be intrusive 
and require large investments of time for participants (47).  
The studies that have been conducted in healthy participants provide promising results 
in terms of cognitive benefits of flavonoids, for both acute and longer-term trials (48, 
49). It is therefore surprising that studies in have not been extended to include older 
adults with a neurodegenerative disease. To the best of our knowledge, there are no 
human studies investigating the impact of dietary flavonoids on cognitive outcomes in 
older adults with a dementia, despite some small trials in older adults with mild-
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cognitive impairment (50-52). A recent review (53) suggested that conclusions 
regarding the impact of dietary flavonoids on dementia cannot be made due to a lack 
of high quality research. It was recommended that future clinical trials be conducted, 
focussing on elucidating an effective dose to result in neuroprotective effects and the 
confirming bioavailability of flavonoids in population living with dementia (53) 
(addressed in further detail in chapters 6 and 7 of this thesis).   
 
1.4 Summary of evidence and gaps in the literature 
This overview of the literature has highlighted that there have been substantial recent 
advances in the measurement of dietary flavonoids and that preliminary studies 
support the impact of flavonoids on cognitive and physical outcomes. However, some 
major limitations of the current body of evidence are evident and there are a number 
of important questions still to be resolved surrounding dietary flavonoids.  
 
Firstly, the measurement of dietary flavonoids, both with dietary assessment tools and 
with biomarkers of intake is not well established. Synthesis of the literature 
surrounding the current use of dietary tools to measure flavonoid intake and biomarker 
methods is needed to inform future research. Additionally, better methods to measure 
flavonoid intake through dietary assessment tools and biomarkers of intake need to be 
developed in light of the findings. 
 
Secondly, the impact of flavonoid consumption on cognitive and physical outcomes 
needs be further investigated, with an emphasis on research in older adults and older 
adults with an existing neurodegenerative disease. While evidence exists for the 
potential beneficial effect of the consumption of flavonoids on a range of health 
outcomes, the body of evidence relating to flavonoid intake and improvements in 
cardiovascular and neurological health, especially for older adults with a 
neurodegenerative disease is sparse. There is a need to identify which cognitive 
domains are impacted by flavonoid intake and the most appropriate tools to measure 
the changes. The most notable gaps in the literature exist in relation to differences in 
short and long-term responses to flavonoid intake and dose-response relationships. 
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1.5 Aims and hypothesis 
In light of the gaps in the literature surrounding flavonoids two main research 
questions were proposed (Figure 1-2):  
 
1. What methods should be employed to measure flavonoid intake? 
2. How does the consumption of dietary flavonoids impact cognitive and physical 
outcomes? 
 
In order to effectively address these broad questions, six studies were developed 
(Figure 1-2).  
 
Study 1: A systematic literature review that evaluates the tools used to estimate dietary 
flavonoid intake. 
Study 2: Development and validation of a Food Frequency Questionnaire to determine 
dietary flavonoid intake. 
Study 3: Development of a method to determine the phenolic profile of human plasma 
using Gas Chromatography/Mass Spectrometry technique.  
Study 4: A systematic literature review that evaluates effect of anthocyanin-rich food 
intake on cognitive outcomes. 
Study 5: An acute crossover study to assess the impact of differing doses of 
anthocyanin-rich cherry juice on cognitive and physical outcomes, and plasma 
phenolic profile. 
Study 6: A randomised controlled trial to assess the longer-term impact of 
anthocyanin-rich cherry juice on cognition and physical outcomes in older adults, with 
mild to moderate dementia. 
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Main Research 
Questions
1. What methods should 
be employed to measure 
flavonoid intake
2. How does the 
consumption of dietary 
flavonoids impact 
cognitive  and physical 
outcomes?
A systematic literature review to 
evaluate tools used to measure 
flavonoid intake
A systematic literature review to 
evaluate literature associating 
anthocyanin intake and cognition
The acute impact of fruit 
flavonoid supplementation on 
cognitive and physical outcomes, 
in young adults, older adults and 
older adults with mild to 
moderate dementia.
The longer-term impact of fruit 
flavonoids on cognition and 
physical outcomes in older 
adults, with mild to moderate 
dementia.
Development of a gas 
chromatography/mass 
spectrometry technique to 
determine flavonoid related 
biomarkers in biological 
samples. 
Development and validation of a 
flavonoid specific food frequency 
questionnaire in older 
Australians.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Overview of the thesis studies in relation to the central thesis questions 
 
  
Measurement of dietary 
flavonoid intake 
Assessment of the impact of 
dietary flavonoids on cognitive 
and physical outcomes 
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1.6 Thesis structure and methodology  
In order to address the central research questions, several study designs need to be 
applied (Figure 1-2, Table 1-1). These approaches include various research 
methodologies, incorporating systematic literature reviews, dietary assessment 
methodologies, laboratory based methodologies and clinical trial study designs. The 
combination of research designs reflects the complexity of the central research 
questions. Each method is identified below, but significantly more detail pertaining to 
the methods of each study will be described in each chapter.  
 
Chapter 1 provides an introduction to the literature surrounding this thesis, 
introduces each chapter and the methodology used throughout.   
Chapter 2 is a systematic literature review that evaluates the tools used for 
estimating dietary flavonoid intake in current literature, to describe their application 
and relevance.  
Chapter 3 and 4 describe the development of flavonoid intake assessment 
methods, with chapter 3 outlining a secondary data analysis of the Blue Mountains 
Eye Study to inform the development and validation of a food frequency questionnaire 
for older Australians, and chapter 4 describing the development of a novel gas 
chromatography/mass spectrometry technique to determine plasma phenolic profile in 
humans for application in chapter 6. 
Chapter 5 is a systematic literature review that synthesises the literature 
relating to the impact of food-based anthocyanins on cognition, to inform the 
development of the studies comprising chapters 6 and 7.  
Chapter 6 and chapter 7 introduce and provide the results of the human 
intervention trials conducted to assess the impact of fruit flavonoids on acute and 
longer-term cognition, blood pressure and physical outcomes. 
Chapter 8 summarises the findings and generates recommendation for future 
research. 
 
Each individual study comprising this thesis has been published or submitted for 
publication, but will be presented in this thesis in a consistent and cohesive format 
(with published papers included in the Appendices). 
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Table 1-1 Overview of thesis studies and study design 
Thesis component 
Study number  
(chapter 
number) 
Study design utilised 
Measurement of dietary 
flavonoid intake 
1 (2) Systematic literature review 
2 (3) 
Secondary data analysis and 
dietary methodology 
validation study 
3 (4) 
Laboratory methods 
development (GC/MS) 
Assessment of the impact of 
flavonoids on cognition and 
physical outcomes 
4 (5) Systematic literature review 
5 (6) 
Randomised acute crossover 
study  
6 (7) 
Randomised controlled 
clinical trial 
 
 
1.7 Significance of research 
A review of the methodology used to measure flavonoid intake is important to evaluate 
the methods currently applied in flavonoid-related research and to provide 
recommendations for future research. With no gold standard method for measuring 
flavonoid intake, it is unclear which method for measuring or estimating dietary 
flavonoid intake is most useful in intervention and empirical studies. The systematic 
review provides an overview of the available strategies for measuring or estimating 
dietary flavonoid intake and may provide an important resource for researchers when 
developing future studies.  
 
The development of new methodologies, both to estimate the intake of dietary 
flavonoids through dietary assessment and to confirm the uptake and metabolism of 
dietary flavonoids in biological samples, contributes significantly to a research area 
with few valid tool options.   
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 The evaluation of current research that investigates the cognitive benefits 
associated with specific flavonoid rich foods is important to highlight the gaps in the 
literature and to provide recommendations for future research. 
 
Investigations into the impact of anthocyanin-rich foods on acute and longer-
term cognitive function and physical outcomes in specific population groups 
contributes original knowledge related to a body of literature surrounding the impact 
of flavonoids on cognition. 
 
As a whole, this doctoral thesis provides a well-rounded approach to address the 
most significant gaps in current literature surrounding the measurement of flavonoid 
intake and the impact of flavonoids on cognitive and physical outcomes, with an 
emphasis on older adults with a neurodegenerative disease. It contributes to the fields 
of basic science, nutrition, psychology and public health, with each study contributing 
a novel and innovative investigation, which together, advances our scientific 
knowledge about dietary flavonoids.   
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CHAPTER 2: EVALUATION OF TOOLS USED FOR ESTIMATING 
DIETARY FLAVONOID INTAKE: A SYSTEMATIC REVIEW 
 
In order to associate the impact of dietary flavonoids on health outcomes, accurate 
measures of dietary intake are fundamental. The gaps in knowledge surrounding how 
dietary flavonoid intake is measured, presented in the Introduction (Chapter 1) of this 
thesis, indicated the need for improved methods for measuring dietary flavonoid 
consumption. A systematic literature review was conducted to provide an evaluation 
of the various methods employed by current literature to measure flavonoid intake, 
and their associated limitations. The review presents findings showing the reliance of 
studies utilising flawed dietary assessment methods to measure dietary flavonoid 
intake. Additionally, the review concludes that despite several methods that measure 
biomarkers of flavonoid intake being developed and validated, few studies apply 
biomarkers as a measure of dietary flavonoid intake. 
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1 Faculty of Science, Medicine and Health, University of Wollongong 
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manuscript. All authors contributed to writing and editing the manuscript.  
 
To assist clarity of formatting, Tables 2-2, 2-3 and 2-4 are provided at the end of this 
chapter 
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2   
2.1 Introduction 
While the association between flavonoid intake and health outcomes is promising, 
more robust clinical data is needed. However, in order to associate flavonoid 
consumption with positive health outcomes, the first and most fundamental step is to 
accurately estimate dietary flavonoid intake. Despite the first estimations of flavonoid 
intake on a population level being reported more than a decade ago, the methods 
currently employed have evident flaws (1). Dietary flavonoid intake is difficult to 
quantify, and consequently numerous methods have been developed for application in 
various settings. With the absence of a gold standard approach, the methods utilised 
include various techniques within the fields of both dietary assessment and biomarker 
analyses.  
 
There are currently numerous methods used to measure dietary flavonoid intake. With 
no gold standard method for measuring flavonoid intake, it is unclear which method 
for measuring or estimating dietary flavonoid intake is most useful in intervention and 
empirical studies. The limitations associated with current methods hinder the 
interpretation of observational and experimental research related to dietary flavonoid 
intake and specific health outcomes. An evaluation and comparison of the tools to 
measure flavonoid intake in observational and experimental research is imperative to 
interpret current findings across the literature and to provide recommendations for 
methods to apply in future research. Flavonoids are unlike other known nutrients in 
foods, and therefore their complexity and variability needs to be carefully considered. 
Traditional methods of dietary assessment require a recall or documentation of food 
intake from a given time period in either a prospective or retrospective manner (2). To 
determine the nutrient composition of individual or group intakes, this dietary intake 
data is required to be converted to an estimated consumption of the nutrient of interest. 
This can be done two ways, either applying a flavonoid specific food composition 
database (FCDB) to the dietary intake data; or through the assessment of biomarkers 
of intake that can be detected in biological samples. 
 
 
47 
 
To improve methodological quality of future research, a clear understanding of 
appropriate methods for measuring flavonoid intake is required. The proposed 
systematic review aims to provide an overview of available strategies for measuring 
or estimating dietary flavonoid intake and to provide an important resource for 
researchers when developing future studies.  
 
The overall purpose of this review is to summarise and synthesise the evidence about 
the methods used in all published literature to measure or estimate dietary flavonoid 
intake in adults. The following question guided the literature search: 
“What method did researchers apply to determine intake of dietary flavonoids, 
using a dietary assessment or biomarker method?” 
 
2.2 Methods 
This review is registered with the International Prospective Register of Systematic 
Reviews (PROSPERO) under the registration number #CRD42014015607. 
 
2.2.1 Types of studies 
This review included randomised, non-randomised food-based trials, crossover food-
based trials, and analytical epidemiological study designs including prospective and 
retrospective cohort, case-control and cross-sectional studies. Studies were restricted 
to those published from January 2004 to November 2014 to ensure the literature was 
current and relevant. Only studies published in English language were considered for 
inclusion due to a lack of translation resources.  
  
2.2.2 Types of participants 
Adults aged 18 years or over. 
 
2.2.3 Types of data  
Dietary assessment methods (and the application of a flavonoid related FCDB) that 
were utilised to investigate flavonoid intake were examined. Additionally, biomarkers 
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including intact flavonoids or flavonoid metabolites, quantified in biological samples 
(urine, plasma and/or faecal water) which are used to measure intake of flavonoids in 
habitual diet or a flavonoid rich food were also reviewed  
 
Flavonoid intake is defined as: 
• Total flavonoid intake 
• Intake of a single or multiple flavonoid subclass including 
· Flavonols 
· Flavanols (flavan-3-ols) 
· Flavones 
· Flavanones 
· Anthocyanins (anthocyanidins) 
 
Estimation of isoflavone intake will be excluded from this analysis due to the specific 
biological activities of isoflavones and the fact that isoflavone intake is often excluded 
from studies that address total flavonoid intake. Additionally, the breadth of isoflavone 
research is large enough to justify a distinct systematic review of the methods used to 
estimate intake. 
 
1. Valid dietary assessment method employed, where applicable, which is cross-
referenced with food composition data for determining flavonoid content of dietary 
intake/food/food groups. Including: 
• 24-hour recall 
• food record/diary 
• food frequency questionnaire 
• diet history  
 
2. Biomarkers (intact flavonoids or associated metabolites) measured in 
biological samples using one or a combination of the following methods, where 
reported: 
• chromatography (high performance liquid; gas; column; thin layer; paper) 
• mass spectrometry; 
• nuclear-magnetic resonance spectroscopy; 
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• Folin–Ciocalteu assay 
 
Validation and application assessment studies were also included. The exclusion 
criteria were animal studies, food analytical experiment studies, studies related to 
essential oils, mechanistic studies (bioavailability, pharmacokinetics or mechanistic 
feeding studies) and reviews and meta-analyses. Studies were also excluded if ‘in 
house’ or unpublished FCBDs not available to researchers were utilised. Lastly, 
studies utilising non-specific biomarkers to measure flavonoid intake (i.e. antioxidant 
activity or markers of inflammation) were excluded (Table 2-1). 
 
2.2.4 Search Strategy 
The search aimed to find both published and unpublished studies through electronic 
databases, the World Wide Web and reference lists. Key terms were established:  
• Phenolic acid  
• Flavonoid* 
• Flavanol*  
• flavan-3-ol*  
• Anthocyanin*  
• Flavanone* 
• Flavonol*  
• Flavone* 
• Polyphenol*  
Table 2-1 Overall inclusion and exclusion criteria for screening 
  Include if: 
Language Article published in English language Yes 
Design Randomised or non-randomised food-based trials, or 
prospective or retrospective cohort or, case-control, cross-
sectional studies. 
Case reports, reviews, editorials, letter to the editor, 
qualitative research 
Yes 
 
 
No 
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Population Adults aged 18+ years 
Animal studies or studies including <18 years 
Yes 
No 
Content Studies examining total or specific dietary flavonoid intake 
through valid dietary assessment or biomarkers 
Pharmacokinetics/bioavailability studies of intake 
Yes 
 
No 
Access Full-text article accessible Yes 
 
 
A three-step search strategy was utilised in this review. The initial phase consisted of 
searches of the following databases using the key terms searching in titles and abstracts 
in the following databases: 
 
• Web of Science 
• Scopus 
 
A second stage includes searching for key terms in the following sites on 
www.googlescholar.com. A third stage of hand searching reference lists of articles 
retrieved to identify further studies of interest was conducted.  
 
2.2.5 Selection of studies  
One review author (YP) conducted the literature search in the specified scientific 
databases. Two review authors (KK and VG) independently assessed potential studies 
identified by the search strategy for inclusion. Resolution of any disagreements was 
mediated through discussion and as required, consultation with a third reviewer (YP) 
for consensus.  
 
Results of the search were collated in the reference manager, Endnote (EndNote X4 
for Windows, Thomson Reuters). Duplicate publications were excluded. Articles 
identified by database searches were assessed for relevance to the review based on the 
title and abstract (Table 2-1). For those meeting the inclusion criteria, the full text 
publication were retrieved and assessed for relevance to the review criteria.  
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2.2.6 Data extraction, management and synthesis 
Relevant data relating to flavonoid sub group, study design, tool used and where 
relevant, the key methodological conclusions of the authors was extracted from the 
studies into an Excel template, prepared for the purpose of this review. The studies 
were grouped by total flavonoid intake and each flavonoid sub-group, described and 
evaluated in accordance to their methodological similarities. The findings are 
presented both in a narrative synthesis, as well as in tables and figures. When 
information regarding any of the above was unclear, attempt was made to contact 
authors of the original publication to provide further details.  
 
2.3 Results 
A PRISMA flow chart outlining the results of the search strategy and selection process 
was developed (Figure 2-1). The search returned 833 articles, after duplicates were 
removed, with 58 other potential studies identified through hand-sorting of reference 
lists. After the abstracts were screened, 174 potential studies were identified. A further 
77 were excluded according to the inclusion/exclusion criteria, leaving 97 final papers 
in the review, with 76 estimating flavonoid intake using dietary assessment, and 20 
relating to flavonoid biomarker analysis (including 15 validation studies and 5 
application studies) (Figure 2-1). 
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2.3.1 Estimation of flavonoid intake from dietary assessment (Table 2-2) 
Details regarding the studies that estimate dietary flavonoid intake using dietary 
assessment are reported in Table 2-2. The study sample sizes ranged from 19 - 477,312 
adults. The studies were conducted in the USA (n=28), Europe (multiple centre 
Records identified through 
database searching (duplicates 
removed) 
(n =833) 
Additional records identified 
through other sources  
(n = 58) 
Total records identified  
(n = 891) 
Records screened 
(abstract) 
 (n = 891) 
Records excluded  
(n = 717) 
Full-text articles 
assessed for eligibility  
(n = 174) 
Full text articles 
excluded (n =77) 
Studies included in 
qualitative synthesis – 
Dietary assessment  
(n = 76) 
Studies included in qualitative 
synthesis - Biomarkers  
(n = 20) 
 Validation studies (n = 15) 
 Application studies (n  = 5) 
 
Figure 2-1 PRISMA flowchart of the search strategy 
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studies) (n=9), Finland (n=6), Spain (n=4), China (n=2), the Netherlands (n=2), UK 
(n=2), Scotland (n=2), Australia (n=2), Mexico (n=2) and elsewhere. Study designs 
included cohort studies (n=39), cross-sectional analysis (n=18), case-control studies 
(n=16), randomised controlled trials (n=2) and an analytical study design (n=1).  
 
Approximately a quarter of studies (n=19) were conducted with the primary aim of 
estimating flavonoid intake, or intake of flavonoid subclasses in populations using a 
dietary assessment tool. The majority of studies (n=57) estimated intakes to investigate 
the association of flavonoid consumption with health outcomes, including various 
cancers (n=29), cardiovascular diseases (n=14), diabetes (n=6), neuro-degenerative 
conditions (n=3) and others (n=5). The majority of studies utilised a FFQ to estimate 
dietary intake of flavonoids (n=57), while fewer estimated intake from 24 or 48h 
recalls (single or multiple) (n=12), diet history methods (n=5) and food records (n=2).   
 
The reference FCDBs utilised in the studies included data from one or a combination 
of the USDA flavonoid database (2003, 2007, 2011) (n=49), the Phenol Explorer 
database (n=11), other published data sources (n=21) and other databases (n=5) (Euro 
FIR-eBASIS, ‘functional food database’).  
 
Total flavonoid intake was reported by 58 studies (n=18 reported intake from a single 
or multiple subclass only). However, the culmination of subclasses and sum of 
individual flavonoids that contributed to this figure varied widely for each study, and 
differences mainly reflected the different FCDBs applied in each study (Table 2-2).   
 
Most studies provided detailed information pertaining to the individual flavonoids that 
contributed to each subclass (the sum of which resulted in a measure of total flavonoid 
intake). 24 studies provided insufficient detail on the individual flavonoids which 
contributed to each subclass (denoted with NS – Table 2-2).  
 
2.3.2 Estimation of flavonoid intake from biomarkers (Table 2-3) 
Five studies were identified that utilised a biomarker as a measure of flavonoid intake 
as outlined in Table 2-3. These studies were case-controls (n=4) and cross sectional 
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(n=1) in nature, with populations ranging from 589 – 24,226 adults. Three studies 
measured biomarkers in urine and the other studies assessed biomarkers in plasma 
(n=2). Two studies assessed tea related biomarkers (EGC, EC, EGCG and ECG) using 
HPLC, one study measured quercetin, kaempferol, two studies measured EC, EGC 
and related metabolites using HPLC ESI-MS, and one study measured total 
polyphenols in urine using the Folin-Cicocalteu assay. 
 
2.3.3 Biomarker validation studies (Table 2-4) 
Fifteen studies were identified that validated methods developed to measure 
biomarkers of flavonoid intake or the intake of flavonoid-rich foods (Table 2-4). The 
study sample sizes ranged from 19 – 786 adults, and were conducted in Norway (n=2), 
Denmark (n=4), Australia (n=1), Africa (n=1), France (n=2), Spain (n=1), Finland 
(n=1), China (n=1) and the UK (n=2). Twelve studies reported utilising Liquid 
Chromatography, two studies reported utilising Gas Chromatography, and one study 
utilised the Folin–Ciocalteu assay. Ten studies reported measuring intact flavonoids 
in either urine or plasma. Other studies measured metabolites of flavonoid intake, 
including phenolic acids (n=1) or a combination of both (n=3). Four studies 
investigated the validity of the biomarkers in relation to total dietary flavonoid intake 
(n=2), or the intake of specific flavonoid subclasses (n=2). Eleven studies validated 
the biomarkers against the intake of flavonoid rich foods, such as fruit and vegetable 
intake, tea consumption or the intake of specific foods (citrus and berries).  The 
reference methods were FFQs (n=7), food records (n=2), or controlled intervention 
diets (n=3), food recall (n=1), and two studies did not adequately report on the 
reference method utilised.  
 
2.4 Discussion 
This systematic literature review has presented and described the methods utilised by 
researchers to measure or estimate dietary flavonoid intake, and/or intake of flavonoid 
subclasses in studies, using a dietary assessment or biomarker method, published 
between 2004 and 2014. 
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The most common method of estimating flavonoid intake relied on dietary assessment 
of habitual food intake. Generally, usual dietary analysis was performed using a FFQ, 
a single or repeated 24-hour diet recall or a food record, which were cross-referenced 
with a flavonoid FCBD. This review highlighted that there are very few flavonoid 
specific FCBDs that exist globally and country-specific food composition data was 
rarely available. Aside from the limitations associated with each dietary assessment 
method (2), there are several well documented problems associated with utilising 
FCBDs to assign flavonoid content to selected foods, resulting in large variations in 
estimates of intake (3).  
 
Firstly, estimation of dietary flavonoid intake is only as comprehensive as the 
composition database utilised. If, for example, a composition database does not have 
an extensive list of foods and the flavonoid content of a food in an individual’s diet 
cannot be assigned or matched to its closest equivalent, then an individual’s intake 
will certainly be under-estimated. This is particularly challenging when analysing food 
intake data from a country that does not have a specific composition database for that 
population, potentially resulting in significant sources of flavonoids for the population 
not being captured. The primary databases utilised by studies identified in this review 
(USDA, Phenol Explorer and Euro FIR-eBASIS) provide extensive and precise 
information on the individual flavonoids in foods, with additional  detail provided on 
the variability of flavonoid contents in foods, as well as the values associated with 
processing circumstances. It is interesting to note that the utilisation of different 
databases may substantially influence the estimation of flavonoid intake in a study, as 
highlighted by a recent comparison between estimates of dietary flavonoid intake 
produced by the USDA and Phenol Explorer databases (4). However, this is not a well 
researched concept and needs further verification.     
 
Secondly, the flavonoid content of specific foods is highly variable and largely 
influenced by a foods growth and processing conditions (5). Disregarding the 
processes by which foods are manufactured and the impact on flavonoid levels leads 
to an over-estimation of flavonoid intake. A flavonoid FCBD is largely unable to 
account for this variability and can only provide an estimate for each food consumed 
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(5). Studies did not generally apply retention factors, or comment if any methods were 
applied to manage flavonoid degradation associated with cooking, for instance.  
 
Lastly, estimating dietary flavonoid intake through dietary assessment is unable to 
account for the high intra-individual variation associated with flavonoid metabolism 
and absorption, which is influenced by factors other than intake, such as bioavailability 
and genetic factors (6). Advances in informatics are crucial (5). Until the exact 
bioavailability of all flavonoids are understood and the individual variations in 
metabolism are accounted for, estimations of flavonoid intake and their correlation 
with health outcomes should be interpreted with caution. 
 
Despite the validation of several tools developed to specifically measure flavonoid 
intake (7, 8), it appears that these tools have not been applied in further research. The 
relative validity of these tools for the measurement of flavonoid intake can be partially 
attributed to the fact that they effectively measure what they are hypothesised to 
measure (i.e. estimated dietary flavonoid exposure). However, as true flavonoid intake 
is difficult to establish, their objective validation, for example against a gold standard 
assessment, remains questionable. This review highlighted that studies tended to 
estimate flavonoid intake from a dietary assessment method that was not specifically 
intended for the purpose of measuring flavonoid intake (e.g., a general FFQ designed 
to capture energy intake). This can lead to misestimating exposure assessment, as 
foods included in the surveys may not be comprehensive enough or specific enough 
to capture the unique dietary exposure to flavonoids in that population. A major 
limitation of FFQs in this sense is the practice of combining foods that are similar 
nutritionally (e.g. apples and pears) into one question (thus, saving time coding and 
entering data). However, as the flavonoid content of foods is very specific, this can 
lead to misrepresentation of flavonoid intakes. It can not always be possible to collect 
detailed dietary information due to the very large numbers of participants in large 
epidemiological studies. However, the ability of these FFQs to capture flavonoid 
intake and the intake of flavonoid subclasses must be questioned and considered when 
interpreting the results of large studies. 
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While dietary flavonoid intake can be determined by quantifying biomarkers which 
include intact flavonoids and their metabolites found in plasma, urine and faecal water, 
there is an obvious lack of validated biomarkers of dietary flavonoid intake. While 
several of the validation studies outlined by this review (Table 2-4) found good 
correlation between specific biomarkers and the intakes of tea, fruits and vegetables 
(collectively), there is a lack of research to highlight the ability of a single, or multiple 
biomarkers as a measure of total dietary flavonoid intake, or even intake of flavonoid 
subclasses. This may be attributed to the difficulty in identifying useful biomarkers of 
flavonoid intake. Many thousands of flavonoids have been identified and after 
consumption they are quickly and extensively metabolised into various metabolites 
(9). Consequently, there are thousands of potential biomarkers (this is 
comprehensively explained in chapter 4 of this thesis) and there is no consensus 
around which flavonoids or metabolites are indicative of total dietary intake or 
reflective of intake for a certain food and/or food group. While many methods of 
measuring flavonoid biomarkers in human biological samples exist, it appears there is 
no standardised protocol of how to perform this analysis. This factor limits the 
comparison of studies that have used different methods to measure certain biomarkers.  
 
The usefulness of urinary metabolites to measure polyphenol (including flavonoid 
intake) has been reviewed (10), and information pertaining to the bioavailability of 
certain biomarkers after intake of foods. However, the review did not include synthesis 
of studies that evaluated the ability of these biomarkers to measure dietary flavonoid 
intakes in population settings. Another review recently summarised biomarkers of 
fruit and vegetable intake applied in intervention studies (11). After reviewing 96 
studies, the authors concluded that studies generally measured an antioxidant nutrient 
(carotenoid or vitamin C) and highlighted that relatively fewer studies measured 
flavonoid specific biomarkers such as quercetin (a flavonol). Some studies tried to 
measure total flavonoid excretion in urine, but no studies measured flavonoid 
biomarkers in plasma or faecal water.  
 
Lastly, it is currently unknown which biological sample should be selected and some 
research suggests each may be indicative of different consumption patterns. Previous 
research has shown that urinary biomarkers of the flavonoid subclass of flavonoids 
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may be more reflective of short-term intake (12, 13). Additionally, biomarkers in 
fasting plasma or faecal water samples seem to be a suitable biomarker of short-term 
intake and a possible biomarker of the medium-term intake (12). However, biomarkers 
of long-term intake are not yet identified and may be unlikely due to the short half-
lives of dietary flavonoids. Lastly, most of the biomarker analyses are expensive and 
often cannot be performed as part of large epidemiological studies (14). Future 
research needs to focus on identifying specific biomarkers of flavonoid intake and 
confirm the best methods in which to quantify these biomarkers in biological 
specimens. 
 
2.4.1 Conclusion 
This review has highlighted the reliance of studies measuring dietary flavonoid intake 
using dietary assessment methods (FFQs), with only a few studies associating 
biomarkers of flavonoid intake with health outcomes (15, 16). This review has also 
highlighted the considerable limitations surrounding the estimation of dietary 
flavonoid intake, which are unlikely to be overcome in the near future. However, the 
recent rapid advances in the understanding of flavonoid metabolism and 
bioavailability is a promising sign for continuing future developments. Future research 
needs to apply flavonoid specific dietary assessment methods that can adequately 
measure total flavonoid intake and the intake of specific subclasses. Additionally, 
future research needs to focus on identifying suitable biomarkers of flavonoid intake 
for an objective measurement of flavonoid intake. Until such biomarkers are available, 
reliance on dietary assessment methods will remain despite their many limitations.  
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2.5 Tables 2-2 – 2-4 
Table 2-2 Dietary assessment of flavonoid intake in published literature 
Author Study 
design 
Method Flavonoid 
total 
Flavonoid Sub-classes  FCDB 
used 
Population & 
Setting 
Health 
outcome 
 Flavonol Flavan-3-ol Flavanone Flavone Anthocyanin Other   
Adebamo
wo et al., 
(24) 
Cohort FFQ, semi-
quantitative 
- quercetin, 
kaempferol, 
myricetin 
- - - - - Published 
data (25)   
private 
food 
compositio
n data 
90,630 
women, 
USA 
Cancer, 
breast 
Arem et 
al., (26) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS - 2007 
USDA 
flavonoid 
database, 
537 104 
adults, USA 
Cancer, 
pancreatic 
Bai et al., 
(27) 
Cross-
section
al 
24h recall Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
hesperetin, 
naringenin, 
eriodictyol 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin,  
petunidin 
proanthocya
nidins 
2011 
USDA 
flavonoid 
database 
17 900 
adults, USA 
- 
Bobe et 
al., (28) 
RCT FFQ, semi-
quantitative 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
hesperitin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
- 2007 
USDA 
flavonoid 
database 
1,859 adults, 
USA 
Cancer, 
colorectal 
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Bobe et 
al., (29) 
Cohort FFQ, 
quantitative 
Sum of 
sub-
classes 
 
kaempferol, 
myricetin,   
quercetin 
catechin,  
EC 
- luteolin, 
apigenin 
- - Published 
data (25, 
30-32) 
27,111 
adults, 
Finland 
Cancer, 
pancreatic 
Bosetti et 
al., (33) 
Case 
control 
FFQ Sum of 
sub-
classes 
quercetin, 
myricetin   
kaempferol 
EC, 
catechin 
hesperitin   
narigerin 
luteolin, 
apigenin 
cyanidin   
malvidin 
isoflavones 2003 
USDA 
flavonoid 
database 
5,157 adults, 
Italy 
Cancer, 
breast 
Butchart et 
al., (34) 
Cross-
section
al 
FFQ, semi-
quantitative 
- NS catechins NS NS - procyanidins a UK 
flavonoid 
database 
(35) 
1091 adults, 
UK 
Cognition 
Cassidy et 
al., (36) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
theaflavins,   
thearubigins 
2007 
USDA 
flavonoid 
database, 
EuroFIR 
eBASIS 
93 600 
women, 
USA 
Myocardia
l Infarction 
Cassidy et 
al., (37) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
theaflavins,   
thearubigins 
2007 
USDA 
flavonoid 
database, 
EuroFIR 
eBASIS 
87,242 
women, 
USA 
Hypertensi
on 
Cassidy et 
al., (38) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
theaflavins,   
thearubigins 
2007 
USDA 
flavonoid 
database, 
EuroFIR 
eBASIS 
69 622 
women, 
USA 
Stroke 
Chun et 
al., (39) 
Cross-
section
al 
24h recall 
(single) 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC, TF, 
TR 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
isoflavones 2003 
USDA 
flavonoid 
database 
8809 adults, 
USA 
- 
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peonidin, 
petunidin 
Chun et 
al., (40) 
Cross-
section
al 
24h recall 
(single) 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC, TR, 
TF 
 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
isoflavones 2003 
USDA 
flavonoid 
database 
8809 adults, 
USA 
- 
Cui et al., 
(41) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC, TR, 
TF 
 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
- 2007 
USDA 
flavonoid 
database 
1395 adults, 
USA 
Cancer, 
lung 
Cutler et 
al., (42) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones, 
proanthocya
nidins 
2003 
USDA 
flavonoid 
database 
34,708 
women, 
USA 
Cancer, 
lung, 
colorectal, 
breast, 
pancreatic 
and upper 
digestive 
cancer 
Dilis et al., 
(43) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG   
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
Proanthocya
nidins, TAC 
indexes, 
2007 
USDA 
flavonoid 
database 
28572 
adults, 
Greece 
- 
Djuric et 
al., (44) 
Case-
control 
FFQ, semi-
quantitative 
- quercetin - - - - - NS 2664 adults, 
USA 
Cancer, 
colorectal 
Dwyer et 
al., (45) 
RCT 24h recall 
(x3) 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
isoflavones 
 
2003 
USDA 
flavonoid 
database 
550 women, 
USA 
- 
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CG  TF, 
TDG, 
TFG 
petunidin, 
peonidin 
Fink et al., 
(46) 
Cohort FFQ Sum of 
sub-
classes 
NS NS NS NS NS isoflavones, 
lignans 
2003 
USDA 
flavonoid 
database 
1210 
women, 
USA 
Cancer, 
breast 
survival 
Fisher et 
al., (47) 
Analyti
cal 
study 
FFQ NS - - - - - proanthocya
nidin 
2003 
USDA 
flavonoid 
database 
19 older 
adults, USA 
Endothelia
l function 
Galvan-
Portillo et 
al., (48) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS - NS - - 2003 
USDA 
flavonoid 
database 
50 women, 
Mexico 
- 
Gates et 
al., (49) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
myricetin, 
kaempferol, 
quercetin 
- - Luteolin, 
apigenin 
-  Published 
(25) and 
unpublishe
d data 
66,940 
women, 
USA 
Cancer, 
ovarian 
Gates et 
al., (50) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
myricetin, 
kaempferol, 
quercetin 
- - Luteolin, 
apigenin 
- - 2007 
USDA 
flavonoid 
database 
2324 
women, 
USA 
Cancer, 
ovarian 
Geybels et 
al., (51) 
Case-
control 
FFQ Sum of 
sub-
classes 
myricetin, 
kaempferol, 
quercetin 
catechin, 
EC 
- - - - Published 
data (25, 
31, 52, 53) 
58,279 men, 
Netherlands 
Cancer, 
prostate 
González 
et al., (54) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS phenolic 
acids, 
lignans, 
stilbenes 
Phenol-
Explorer 
database 
159 older 
adults, Spain 
Lipid 
oxidative 
damage 
Grosso et 
al., (55) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones, 
phenolic 
acids, 
lignans, 
Phenol-
Explorer 
database 
10477 
adults, 
Poland 
- 
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stilbenes, 
alkylphenols
, tyrosols 
Hardcastel 
et al., (56) 
Cross-
section
al 
FFQ Sum of 
sub-
classes 
quercetin Catechin, 
EC 
Hesperitin, 
narigenin 
NS - isoflavones, 
proanthocya
nidins 
Published 
data (35) 
and 2003 
USDA 
flavonoid 
database 
3226 
women, 
Scotland 
Bone 
health 
Hernandez
-Ramirez 
et al., (57) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS - NS - phenolic 
acids, 
lignans, 
coumestans 
2003 
USDA 
flavonoid 
database 
735 adults, 
Mexico 
Cancer, 
gastric 
Hirvonen 
et al., (58) 
Cohort Self-
reported, 
modified diet 
history 
method 
- NS - - NS - - Published 
data (25, 
31, 32) 
25,041 men, 
Finland 
Intermitten
t 
claudicatio
n 
Hirvonen 
et al.,(59) 
Cohort Self-
reported, 
modified diet 
history 
method 
- NS - - NS - - Published 
data (25, 
31, 32) 
27,110 men, 
Finland 
Cancer 
Hughs et 
al., (60) 
Cohort FFQ, semi-
quantitative 
- myricetin, 
kaempferol, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  
- - - - Published 
data (25, 
31, 52, 53) 
4280 adults, 
Netherlands 
Stroke risk 
Ivey et al., 
(61) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
isoflavones 
2007 
USDA 
flavonoid 
database 
1063 older 
women, 
Australia 
Atheroscle
rotic 
vascular 
disease 
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TDG, 
TFG 
Jacques et 
al., (62) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
Quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG   
Eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
Cyanidin, 
delphinidin, 
nnalvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidin 
2007 
USDA 
flavonoid 
database 
2915 adults, 
USA 
Diabetes 
Knaze et 
al., (63) 
Cohort 24 recall - - catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
- - - proanthocya
nidin 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database 
36 037 
adults, 
Europe 
- 
Lagiou et 
al., (64) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones 2003 
USDA 
flavonoid 
database 
200 adults, 
Greece 
Peripheral 
arterial 
occlusive 
disease 
Lagiou et 
al., (65) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones 2003 
USDA 
flavonoid 
database 
899 adults, 
Greece 
Coronary 
heart 
diseases 
Laurin et 
al., (66) 
Cohort 24h recall NS - - - - - - Published 
data (31) 
2,459 men, 
Honolulu-
Asia 
Dementia 
Letenneur  
et al., (67) 
Cohort FFQ Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin 
- - luteolin, 
apigenin 
- - Published 
data (25) 
1064 older 
adults, 
France 
Cognitive 
decline 
Lin et al., 
(68) 
Cohort FFQ, semi-
quantitative 
- quercetin, 
kaempferol, 
myricetin 
- - luteolin, 
apigenin 
- - Published 
data (25, 
69, 70) 
66,360 
women, a, 
USA 
Coronary 
heart 
disease 
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McCullou
gh et al., 
(71) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin. 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
isoflavones 
2007 
USDA 
flavonoid 
database 
98469 
adults, USA 
Cardiovasc
ular 
disease 
mortality 
Mink et 
al., (72) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
ECG,EGC
G 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
isoflavones 
2003 
USDA 
flavonoid 
database 
34 489 
women, 
USA 
Cardiovasc
ular 
disease 
mortality 
Mullie et 
al., (73) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins, 
isoflavones 
2003 
USDA 
flavonoid 
database 
45 women, 
Belgium 
- 
Mursu et 
al., (74) 
Cohort 4-day FR Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
- 2003 
USDA 
flavonoid 
database 
and 
published 
literature 
(75) 
1380 men, 
Finland 
Carotid 
atheroscler
osis 
Musru et 
al., (76) 
Cohort 4-day FR Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isorhamnetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
- 2003 
USDA 
flavonoid 
database 
and 
2590 men, 
Finland 
Cancer 
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petunidin, 
peonidin 
published 
literature 
(75) 
Nettleton 
et al., (77) 
Cohort FFQ Sum of 
sub-
classes 
NS NS NS NS NS proanthocya
nidins, 
isoflavones 
2003 
USDA 
flavonoid 
database 
35816 
women, 
USA 
Diabetes 
(Type II) 
Nothlings 
et al., (78) 
Cohort FFQ, 
quantitative 
- quercetin, 
kaempferol,  
myricetin 
- - - - - Published 
literature 
(79) 
424 978 
adults,  
Europe 
Cancer, 
pancreatic 
Nothlings 
et al., (80) 
Cohort FFQ, semi-
quantitative 
- quercetin, 
kaempferol,  
myricetin 
- - - - - Published 
literature 
(79) 
183,518 
adults, USA 
Cancer, 
pancreatic 
Ock et al., 
(81) 
Cross-
section
al 
24h recall Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
EC, TR, 
TF 
 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
isoflavones 2003 
USDA 
flavonoid 
database 
8809 adults, 
USA 
- 
Otaki et 
al., (82) 
Cross-
section
al 
FFQ Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
fisetin 
EC, EGC, 
catechin 
Hesperitin, 
narigenin 
luteolin, 
apigenin 
- isoflavones Functional 
Food 
Factor 
database 
569 women, 
Japan 
- 
Ovaskaine
n et al., 
(83) 
Cross-
section
al 
48h recall - Isorhamnetin
, 
kaempherol, 
myricetin, 
and 
quercetin 
EC, 
catechin 
Eriodictyol, 
hesperetin, 
and 
naringenin. 
- cyanidin, 
delphinidin 
phenolic 
acids 
Published 
data (25, 
32) 
2007 adults, 
Finland 
- 
Perez 
Jimenez et 
al., (84) 
Cross-
section
al 
24h recall 
(x6) 
- NS NS - NS NS phenolic 
acids, 
lignans, 
stilbenes, 
minor 
Phenol-
Explorer 
database 
4942 adults, 
France 
- 
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polyphenols 
Rossi et 
al., (85) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS proanthocya
nidins, 
isoflavones 
2003 
USDA 
flavonoid 
database 
1362 
women, Italy 
Cancer, 
endometria
l 
Rossi et 
al., (86) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS proanthocya
nidins, 
isoflavones 
2003 
USDA 
flavonoid 
database 
978 adults, 
Italy 
Cancer, 
pancreatic 
Rossi et 
al., (87) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones 2003 
USDA 
flavonoid 
database 
3442 
women, Italy 
Cancer, 
ovarian 
Rossi et 
al., (88) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones 2003 
USDA 
flavonoid 
database 
6107 adults, 
Italy 
Cancer, 
colorectal 
Somerset 
et al., (14) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
Sum of sub-
classes 
isorhamne
tin, 
kaempfero
l, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, TFG 
eriodicty
ol, 
hespereti
n, 
naringeni
n 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
2007 
USDA 
flavonoid 
database 
60 adults, 
Australia 
- 
Simons et 
al., (89) 
Cohort FFQ, semi-
quantitative 
- myricetin, 
kaempferol, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  
- - - - Published 
data (25, 
31, 90) 
120852 
adults, 
Netherlands 
Cancer, 
colorectal 
Song et 
al., (91) 
Cross-
section
al 
FFQ, semi-
quantitative 
- myricetin, 
kaempferol, 
quercetin 
- - luteolin, 
apigenin 
- - Published 
data (25, 
31) 
38,018 
women, 
USA 
Diabetes 
(Type II) 
Tavani et 
al., (92) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones 2003 
USDA 
1442 adults, 
Italy 
Myocardia
l infarction 
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flavonoid 
database 
Theodorat
ou et al., 
(93) 
Case-
control 
FFQ, semi-
quantitative 
- quercetin Catechin, 
EC 
Hesperitin, 
narigenin 
NS - isoflavones, 
proanthocya
nidins 
Published 
data (35) 
2912 adults, 
Scotland 
Cancer, 
colorectal 
Wang et 
al., (94) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin 
- - Luteolin, 
apigenin 
- - Published 
data (25, 
31, 70) 
38,408 
women, 
USA 
Cancer 
Wang et 
al., (95) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones, 
proanthocya
nidins 
2007 
USDA 
flavonoid 
database 
43,268 men, 
USA 
Prostate 
cancer 
Wedick et 
al., (96) 
Cohort FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, and 
petunidin 
- 2007 
USDA 
flavonoid 
database 
200,894 
adults, USA 
Diabetes 
(Type II) 
Welch et 
al., (97) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
quercetin, 
kaempferol, 
myricetin, 
isohamnetin 
catechins, 
epicatachi
ns 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin. 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
petunidin, 
peonidin 
proanthocya
nidins 
2007 
USDA 
flavonoid 
database 
3160 
women, UK 
Bone 
mineral 
denisty 
Woo et al., 
(98) 
Case-
control 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS isoflavones Published 
data (99) 
668 adults, 
Korea 
Cancer, 
Gastric 
Zamora-
Ros et al., 
(100) 
Cohort FFQ or  Diet 
history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
lignans, 
procyanidins
, isoflavones 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
477,312 
adults, 
Europe 
Cancer, 
gastric 
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flavonoid 
database 
Zamora-
Ros et al., 
(101) 
Cross-
section
al 
Diet history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
procyanidins
, isoflavones 
2007 
USDA 
flavonoid 
database,  
UK Food 
Standards 
Agency 
40,683, 
Spain 
- 
Zamora-
Ros et 
al.,(102) 
Cohort FFQ or  Diet 
history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG  TF, 
TDG, 
TFG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
lignans, 
procyanidins
, isoflavones 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database 
334,850 
women, 
Europe 
Cancer, 
breast 
Zamora-
Ros et 
al.,(103) 
Cohort FFQ or  Diet 
history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG   TF, 
TDG, 
TFG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
lignans, 
procyanidins
, isoflavones 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database 
340,234 
adults, 
Europe 
Diabetes 
(Type II) 
Zamora-
Ros et al., 
(104) 
Cohort FFQ or  Diet 
history 
questionnaire 
- isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG 
- - - proanthocya
nidin 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database 
340,234 
adults, 
Europe 
Diabetes 
(Type II) 
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Zamora-
Ros et al., 
(105) 
Cohort Diet history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG   TF, 
TDG, 
TFG 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin, 
petunidin 
lignans, 
procyanidins
, isoflavones 
2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database, 
 
40,622 
adults, Spain 
Mortality 
Zamora-
Ros et al., 
(106) 
Cohort 24h recall Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin 
and 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG, GC, 
CG 
eriodictyol, 
hesperetin 
and 
naringenin 
apigenin 
and 
luteolin, 
cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin and 
petunidin 
isoflavones 2009 
Phenol-
Explorer 
database, 
2007 
USDA 
flavonoid 
database 
35 628 
adults, 
Europe 
- 
Zamora-
Ros et al., 
(107) 
Cohort 24h recall - isorhamnetin
, 
kaempferol, 
myricetin 
and 
quercetin 
- eriodictyol, 
hesperetin 
and 
naringenin 
apigenin 
and 
luteolin, 
- - 2007 
USDA 
flavonoid 
database 
36 037 
adults, 
Europe 
- 
Zamora-
Ros et al., 
(108) 
Cohort 24h recall - - - - - cyanidin, 
delphinidin, 
malvidin, 
pelargonidin, 
peonidin and 
petunidin 
- 2007 
USDA 
flavonoid 
database 
36 037 
adults, 
Europe 
- 
Zamora-
Ros et al., 
(109) 
Case-
control 
Diet history 
questionnaire 
Sum of 
sub-
classes 
isorhamnetin
, 
kaempferol, 
myricetin, 
quercetin 
catechin,  
EGC, EC, 
EGCG,   
ECG TF, 
eriodictyol, 
hesperetin, 
naringenin 
luteolin, 
apigenin 
cyanidin, 
delphinidin, 
malvidin, 
lignans, 
procyanidins
, isoflavones 
2009 
Phenol-
Explorer 
database, 
2007 
825 adults, 
Spain 
Cancer, 
colorectal 
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NS=details of individual flavonoids not specified, - = no data provided, FCDB = food composition database 
  
TDG, 
TFG 
pelargonidin, 
peonidin, 
petunidin 
USDA 
flavonoid 
database 
Zhang et 
al., (110) 
Cross-
section
al 
FFQ, semi-
quantitative 
- quercetin, 
myricetin, 
kaempferol, 
isorhamnetin 
- - luteolin, 
apigenin 
- - Published 
data (111) 
5,046 adults, 
China 
- 
Zhang et 
al., (112) 
Cross-
section
al 
FFQ, semi-
quantitative 
Sum of 
sub-
classes 
NS NS NS NS NS proanthocya
nidins 
2007 
USDA 
flavonoid 
database 
3317 adults, 
China 
Bone 
mineral 
density 
(-)-epigallocatechin (EGC), (-)-epicatechin (EC), (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), gallocatechin (GC), catechin3-gallate (CG) 
theaflavin (TF), theaflavin 3,3-digallate (TDG), theaflavin 3-gallate (TFG), thearubigin (TR) 
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Table 2-3 Studies identified that utilised a biomarker as a measure of flavonoid intake 
Author Study 
design 
Method Biological 
sample 
Biomarkers Health 
outcome 
Population & 
Setting 
Iwasaki et 
al., (22) 
Nested 
case-
control 
HPLC with 
colorimetric 
array detector 
Plasma EGC, EC, EGCG,   
ECG 
Cancer, 
breast 
24,226 women, 
Japan 
Luo et al., 
(23) 
Nested 
case-
control 
HPLC/ESI-MS 
 
Urine Quercetin, 
kaempferol, EC, 
EGC,  M4, M6, 40-
MeEGC 
 
Cancer, 
breast 
353 incident breast 
cancer cases, 701 
individually 
matched controls, 
Japan 
Medina-
Remón et al., 
(113) 
Cross-
sectional 
Folin-Ciocalteu 
assay 
Urine (spot) Total polyphenol Blood 
pressure 
589 adults, Spain 
Sasazuki et 
al., (114) 
Nested 
case-
control 
HPLC Plasma EGC, EC, EGCG,   
ECG 
Cancer, 
gastric 
494 gastric cancer 
cases, 494 
Controls, Japan 
Yuan et al., 
(115) 
Nested-
case-
control 
LC/ESI-MS, NMR Urine EGC, 40-MeEGC, 
EC, M4, M6 
Cancer, 
colorectal 
162 colorectal 
cancer cases, 806 
controls, China 
high-performance liquid chromatography (HPLC), liquid chromatography (LC), electrospray ionization (ESI), mass spectrometry (MS), nuclear magnetic resonance (NMR) 
(-)-epigallocatechin (EGC), (-)-epicatechin (EC), (-)-epigallocatechin 3-gallate (EGCG), (-)-epicatechin 3-gallate (ECG),  
5-(30, 40, 50-trihydroxyphenyl)-c-valerolactone (M4),  5-(30,40,-dihydroxyphenyl)-cvalerolactone (M6), 40-MeEGC, the methylated form of EGC,  
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Table 2-4 Validation of methods developed to measure biomarkers as markers of total flavonoid intake or intake of flavonoid rich foods 
Author Design Refere
nce 
metho
d 
Biomarker Method Biologic
al 
Sample 
Flavonoid sub-
classes or dietary 
intake estimated 
Population & 
Setting 
Sig. methodological conclusions 
Brantsæte
r et al., 
(116) 
Cross-
sectional 
FFQ hesperitin, naringenin, 
eriodictyol, phloretin, 
quercetin, kaempferol, 
isorhamnetin, 
tamarixetin 
apigenin 
LC/MS Urine Fruit, vegetables, 
tea intake 
119 pregnant 
women, West 
Africa 
FFQ estimate of fruit intake was 
significantly correlated with phloretin (r 
= 0.33), citrus fruit/juice with hesperetin 
(r= 0.44),  tea with kaempferol 
(r = 0.41) (P < 0.01 for all) 
Bredsdorf
f et al., 
(117) 
Nested 
case-
control 
study 
 
FFQ hesperetin, naringenin, 
quercetin, kaempferol, 
isorhamnetin, 
tamarixetin, genistein, 
daidzein, 
apigenin, phloretin 
HPLC-
MS 
Urine Individual 
flavonoids, sum 
sub-classes, sum 
total 
393 cases (acute 
coronary syndrome)   
393 non-cases, 
Denmark 
 
Correlations between urinary kaempferol 
excretion and intakes of tea 0.34 (P < 
0.0001), wine 0.17 (P < 0.0001),  
vegetables  0.08 (P = 0.020) 
Brevik et 
al., (118) 
Randomi
sed 
cross-
over 
study 
Contro
lled 
interve
ntion 
diet 
eriodictyol, naringenin, 
hesperetin; quercetin, 
kaempferol, 
isorhamnetin, 
tamarixetin, phloretin 
HPLC-
MS 
Urine Fruit, vegetable 
intake 
40 adults, Norway Increased intake of mixed fruits and 
vegetables from 2 to 5 servings/day 
significantly increased urinary excretion 
of eriodictyol, naringenin, hesperetin, 
quercetin, kaempferol, isorhamnetin, and 
tamarixetin. 
Cao et al., 
(119) 
Cross-
sectional 
study 
7-day 
food 
record
s 
quercetin, kaempferol, 
isorhamnetin, 
apigenin, luteolin 
HPLC Plasma 
(fasting) 
quercetin, 
kaempferol, 
isorhamnetin, 
apigenin, luteolin 
92 adults, China The mean 7 d intake of quercetin, 
kaempferol, isorhamnetin, apigenin, and 
luteolin was positively correlated to 
corresponding plasma concentrations, 
with correlation coefficients ranging 
from 0·33 to 0·51 (all P<0·05). 
Carlsen et 
al., (120) 
Cross-
sectional 
FFQ apigenin, eriodictyol, 
hesperidin, kaempferol, 
naringenin, phloretin, 
quercetin,  tamarixetin, 
isorhamnetin 
HPLC Urine 
(2x24h 
urine 
samples) 
Fruit, vegetables, 
juice intake 
85 adults, Norway Total urinary flavonoids showed good 
correlation with fruit, juice, and 
vegetable intake. The highest 
correlations were observed between the 
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intakes of fruit (including juice) with 
hesperidin and naringenin biomarkers. 
Hodgson 
et al., 
(121) 
Cross-
sectional 
Self 
report
ed tea 
intake 
(cups/
day) 
4-O-methylgallic acid 
(4OMGA), isoferulic 
acid 
GC-MS Urine 
(24h) 
Tea, coffee intake 
(# cups/day), no 
detail on data 
collection method 
455 adults, 
Australia 
4OMGA was related to usual (r 0·50, 
P<0·001) and current (r 0·57, P<0·001) 
tea intake,   isoferulic acid was related to 
usual (r 0·26, P=0·008) current (r 0·18, 
P<0·001) coffee intake. 
Huxley et 
al., (122) 
Randomi
sed-
controlle
d trial 
FFQ quercetin, kaempferol,   
isorhamnetin 
Not 
reported 
Plasma Fruit, vegetable 
intake 
690 adults, UK No change in total non fasting plasma 
flavonol concentrations between baseline 
and follow up in either the control or 
intervention group. Flavonol 
measurements may not predict total fruit, 
vegetable intake. 
Koli et al., 
(123) 
Randomi
sed, 
placebo-
controlle
d dietary 
intervent
ion trial. 
Contro
lled 
interve
ntion 
diet 
quercetin, p-coumaric 
acid, 3-
hydroxyphenylacetic 
acid, caffeic acid, 
protocatechuic acid, 
vanillic acid, 
homovanillic acid,   3-
(3-
hydroxyphenyl)propion
ic acid 
GC-MS,   
HPLC 
Plasma 
(fasting), 
Urine 
(24h) 
Berry intake 72 adults, Finl Plasma quercetin, p-coumaric acid, 3-
hydroxyphenylacetic acid, caffeic acid, 
protocatechuic acid, vanillic acid, 
homovanillic acid, 3-(3-
hydroxyphenyl)propionic acid increased 
significantly from the baseline in the 
berry group compared to the control 
group (p < 0.05). Urinary excretion of 
quercetin, p-coumaric acid,   3-
hydroxyphenylacetic acid increased 
significantly in the berry group compared 
to the control group (p < 0.05). All the 
biomarkers may reflect a diet containing 
moderate amounts of blue/ red berries. 
Krogholm 
et al., 
(124) 
Cross-
sectional 
24h 
recall 
quercetin, isorhamnetin, 
tamarixetin, 
kaempferol, hesperetin, 
naringenin, eriodictyol, 
daidzein, genistein,   
phloretin 
HPLC-
EI-MS 
Urine 
(24h) 
Fruit intake 103 adults, 
Denmark 
24 h urinary excretion of total flavonoids 
and the estimated intake of fruits were 
correlated (r0.31, P0.01). Intake of citrus 
fruits, citrus juices was correlated with 
total excretion of citrus specific 
flavonoids (r0.28, P0.01),   orange was 
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positively correlated with naringenin 
(r0.24, P0.01)   hesperetin (r0.24, P0.01). 
Phloretin was correlated with apple 
intake (r0.22, P0.01) and overall 
estimated intake of fruit (r0.22, P0.01). 
Krogholm 
et al., 
(125) 
Cross-
sectional 
FFQ quercetin, isorhamnetin, 
tamarixetin, 
kaempferol, hesperetin, 
naringenin, eriodictyol, 
phloretin   apigenin 
HPLC-
EI -MS 
Urine 
(spot, 
morning 
void) 
Fruit, vegetables, 
beverages 
191 adults, 
Denmark 
The intakes of fruit, juice, vegetables and 
tea reported in the FFQ were reflected by 
the flavonoid biomarker both in 
overnight and 24h urine samples. 
Validity coefficients for the flavonoid 
biomarker in overnight urine ranged 
from 0.39 to 0.49, while the 
corresponding validity coefficients for 
the biomarker in 24h urine ranged from 
0.43 to 0.66. 
Krogholm 
et al., 
(126) 
Randomi
sed, 
controlle
d 
crossove
r study 
Interv
ention 
diet 
flavonols quercetin, 
kaempferol, 
isorhamnetin, 
tamarixetin, the 
flavanones hesperetin   
naringenin,   the 
dihydrochalcone, 
phloretin 
HPLC-
EI-MS 
Urine 
(spot, 
morning 
void) vs 
Urine 
(24h) 
Fruit, vegetable 
intake 
12 men, Denmark The total excretion of flavonoids in 24-h 
urine samples increased linearly with 
increasing fruit   vegetable intakes (rs = 
0.86, P < 0.001). The total excretion of 
flavonoids in morning urine also 
increased, but the association was weaker 
(r = 0.59, P < 0.0001) 
Medina-
Remo´n et 
al., (113) 
Cross-
sectional 
FFQ Total polyphenol Folin-
Ciocalte
u assay 
vs FFQ 
Urine 
(spot) 
Total polyphenol 
intake 
589 adults, Spain The intake of 100 g of F&V (β=0.150;P 
< 0.001) had a greater contribution to 
TPE than 100 mL of coffee  
β=0.141;P=0.001),   the latter two foods 
contributed more than the consumption 
of 100 mL of wine (β=0.120;P=0.019). 
Mennen et 
al., (20) 
Cross-
sectional 
2-day 
FR 
chlorogenic acid, 
caffeic acid, m-
coumaric acid, gallic 
acid, 4-O-methylgallic 
acid, quercetin, 
HPLC–
EI–MS 
Urine 
(24h) vs  
urine 
(spot) 
Polyphenol rich 
food intake 
53 adults, France Spot urine: apple intake 
positively correlated to phloretin, 
grapefruit intake to naringenin, orange to 
hesperetin, citrus fruit consumption to 
both naringenin and hesperitin (r 
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isorhamnetin, 
kaempferol, hesperetin, 
naringenin, 
phloretin, enterolactone   
enterodiol, 
between 0·31 to 0·57) (P<0·05) 
 All fruits, juices  positively correlated to 
gallic acid, 4-O-methylgallic acid, 
isorhamnetin, kaempferol, hesperetin, 
naringenin, phloretin (r 0·24–0·44, 
P<0·05). Coffee consumption positively 
correlated to caffeic, chlorogenic acids (r 
0·29   0·63, P<0·05 respectively). Black 
tea, wine consumption were positively 
correlated with gallic, 4-O-methylgallic 
acids (r 0·37–0·54, P<0·001). The 
present results suggest that several 
polyphenols measured in a spot urine 
sample can be used as biomarkers of 
polyphenol-rich food intake. 
Pujos-
Guillot 
(127) 
Cohort 
study 
NS Flavanone glycosides LC-MS Urine 
(spot) 
Citrus intake 80 adults (40 low   
40 high citrus 
consumers), France 
Hesperetin 3′-O-glucuronide, naringenin 
7-O-glucuronide were identified as 
potential biomarkers of citrus intake, 
however the assessment was not 
sensitive enough to discriminate high 
low citrus consumers 
Ranka et 
al., (128) 
Cross-
sectional 
FFQ quercetin and 
naringenin 
HPLC Urine 
(24h) 
quercetin and 
naringenin intake 
49 adults, UK The correlation between FFQ estimated 
intake of quercetin and naringenin and 
levels excreted in the urine were r0.82 
(P<0.0001) and r0.25 (P=0.05), 
respectively. 
high-performance liquid chromatography (HPLC), liquid chromatography (LC), electrospray ionization (ESI), mass spectrometry (MS) 
food frequency questionnaire (FFQ), food record (FR), food composition database (FCDB) 
NS- not specified 
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CHAPTER 3: A SECONDARY DATA ANALYSIS CONDUCTED TO 
INFORM THE DEVELOPMENT AND VALIDATION OF A FOOD 
FREQUENCY QUESTIONNAIRE TO MEASURE FLAVONOID INTAKE 
IN OLDER AUSTRALIANS 
 
Accurate estimation of the impact of dietary flavonoids on health outcomes is 
dependent on the tools used to measure dietary intake. However, as previously 
described in Chapter 1 and 2, the current methods for measuring flavonoid intake are 
flawed and there is an absence of dietary assessment tools for older Australians. 
Therefore, this chapter describes two studies to address the measurement of dietary 
flavonoids in older Australians. The first is a secondary data analysis of the Blue 
Mountains Eye Study, conducted to describe the intake of flavonoids and flavonoid 
subclasses, and the main dietary sources of these, in older Australian adults. Secondly, 
this chapter outlines the utilisation of this data in the development and subsequent 
validation of a food frequency questionnaire designed to easily estimate flavonoid 
intake in older Australians.  
 
This chapter has been written and presented as two separate publications: 
Appendix C 
Kent, K, Charlton KE, Russell J, Mitchell P, Flood V, 2015. Estimation of 
flavonoid intake in older Australians: secondary data analysis of the Blue 
Mountains Eye Study. Journal of Nutrition in Gerontology and Geriatrics.  
http://dx.doi.org/10.1080/21551197.2015.1088917 
 
Kent, K, Charlton, KE, 2015. Validation of a food-frequency questionnaire to 
measure flavonoid intake in older adults. (In preparation) 
 
This data was also presented in: 
Caldwell* K., Charlton K., Flood V., and Russell, J., 2014. Development of a 
Quantitative Food Frequency Questionnaire to Measure Flavonoid Intake in 
Older Australians. 24 and 25 of November 2013, Adelaide, Australia. Making 
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Research Matter Conference Proceedings: The 13th National Conference of 
Emerging Researchers in Ageing (pp. 44-44).  
 
The Food Frequency Questionnaire developed and assessed in this chapter can be 
found in Appendix G.  
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PART 1: ESTIMATION OF FLAVONOID INTAKE IN OLDER 
AUSTRALIANS - SECONDARY DATA ANALYSIS OF THE BLUE 
MOUNTAINS EYE STUDY 
 
Katherine Kent1 
Karen E Charlton1  
Joanna Russell2 
Paul Mitchell3 
Victoria M Flood4 
 
1. Faculty of Science, Medicine and Health, University of Wollongong, 
Wollongong, Australia 
2. Faculty of Social Sciences, University of Wollongong, Wollongong, 
Australia 
3. Centre for Vision Research, University of Sydney, Sydney, Australia 
4. Faculty of Health Sciences, University of Sydney, Sydney, Australia and St 
Vincent’s Hospital, Sydney, Australia 
 
K.K. contributed to the design of the study, performed the analysis and prepared 
the manuscript; K.E.C. and J.R. provided advice on the study design and data 
analysis, and contributed to the preparation of the manuscript. P.W. and V.M.F. 
provided revision of the final manuscript.  
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3  
3.1 Introduction 
Information on consumption patterns of flavonoids is sparse, and only a few Australian 
estimations of flavonoid intake are available in the literature (1-3). Total flavonoid 
consumption (2), and the main sources of flavonoids (3), has been estimated in an 
Australian population using 24hr recall data from the 1995 National Nutrition Survey, 
in combination with the U.S. Department of Agriculture (USDA) flavonoid 
composition database (4). This analysis reported that the average adult intake of 
flavonoids was 454 mg day, with 70% of the intake attributed to black tea alone (3). 
The differing eating patterns of older Australians, compared with younger adults, were 
reflected in identification of different contributors of foods to total flavonoid intake.  
Notably, flavonoid contribution from tea and wine sources increased markedly with 
age (2). However, there are major limitations to the use of a 24hr recall for capturing 
the usual intake of flavonoids in a population. Some foods that are high in flavonoid 
content, such as seasonal fruits, may not be reflected and the high day-to-day 
variability in flavonoid intakes will introduce bias in estimation of habitual intakes. To 
this end, the National Nutrition Survey analysis provides an initial insight into the main 
sources of flavonoids and flavonoid subclasses in the Australian population, which 
differed from varied international estimates (5-9). In older adults few estimates of total 
flavonoid intake exist and a varied range of intake has been reported (8).  The 
Australian population-based estimation has a limited focus on older adults and thus 
provides insufficient evidence of estimated flavonoid intake in older Australians. 
Therefore, despite a large body of evidence that links flavonoid consumption with 
improved health outcomes in older adults, there is little published information on 
quantities, subtypes and food sources of flavonoids in this age group.  
 
The aim of this research was to describe dietary flavonoid intake in a sample of older 
Australians and identify the intake of flavonoids from various sub-classes (flavonols, 
flavan-3-ols, anthocyanins, flavones, and flavanones), using weighed food record 
(WFR) data obtained from a sub sample of older adults participating in the Blue 
Mountains Eye Study (BMES). 
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3.2 Methods  
The BMES is a longitudinal, population-based cohort study of eye diseases and other 
chronic health outcomes in residents aged 49 years and over in a defined area, west of 
Sydney, Australia (16). The BMES is unique in that it collected detailed dietary 
information specifically in older Australian adults. To the best of our knowledge, this 
study provides the most comprehensive dietary information from older Australians to 
date. The original cohort (n=3654) was enrolled at baseline (1992-1994) and were 
followed up at 5 year intervals (1997-1999; 2002-2004; 2007-2009) (16). The dietary 
intake data utilized in this study was collected in 1994, and comprised three separate 
4-day WFRs, that is twelve days in total, collected four months apart in a randomly 
selected sub-sample of the BMES cohort (n = 79), and thus reflected intake over a 12 
month period, in different seasons (17-19). This dietary data was collected to assess 
the validity and reproducibility of a self-administered food frequency questionnaire 
developed to measure dietary patterns in the larger cohort (17). Of the 150 individuals 
that agreed to participate in the validation study, a total of 79 participants adequately 
completed three WFR over eight months(17). The sub-sample comprised 45 females 
(57%) and 34 males (43%) with a mean age of 70.1 years (age range was 60y to 80+y) 
(17) and a mean BMI of 21.27 (±3.3). WFR data was analysed using Microsoft Access 
(2010). The proportion of men and women who participated in the WFR study and the 
baseline BMES cohort were similar. By design, those who participated in the WFR 
validation study were older than those in the BMES cohort study (70.1 years to 65.4 
years, p<0.0001). An older sample was selected to conduct the validation study as 
research interests were in age-related diseases uncommon in younger people and 
researchers wanted to ensure a valid instrument for subjects likely to become incident 
cases (17). The data was manually cross-referenced with the USDA Database for the 
Flavonoid Content of Selected Foods (Release 3.1) (10) to assign each food reported 
a total flavonoid value and a value for each flavonoid subclass: flavonols, flavan-3-
ols, anthocyanins, flavones, flavanones. The isoflavone content of foods is not reported 
in the USDA flavonoid database (it is reported in a separate database). This point, 
coupled with the fact that isoflavone consumption in Australia is very low (14) 
(isoflavones are largely provided by soy foods), isoflavone intake was not assessed. 
 
  
 
94 
 
Data was exported from Microsoft Access to SPSS statistical program (V17.0: 2006, 
SPSS, Inc., Chicago, II, USA) for analysis. The mean and range of flavonoid intake 
per 4-day food record was calculated and intake of flavonoids and flavonoid subclasses 
per person, per day was estimated. Differences between males and females were 
analyzed using a one-way ANOVA. Differences between the 4day WFRs taken across 
three different time points were assessed using a one-way ANOVA. A p value ≤0.05 
was considered to indicate statistical significance. The coefficient of variation was 
calculated for total flavonoid intake to analyze the degree of inter-individual variation 
between WFRs, and was reported as a percentage. The intra-individual variation was 
calculated to assess the potential variability within each individual’s score at each 
WFR. The proportion that each flavonoid subclass contributed to overall flavonoid 
intake was determined by calculating the total reported amount (mg) of each subclass 
divided by the total amount (mg) of flavonoids reported (described as percentage).  
Rich and commonly consumed dietary flavonoid sources were identified and ranked 
in relation to their contribution to overall flavonoid intake in the cohort, by calculating 
the total reported amount (mg) of a flavonoid subclass present in each food (as per the 
USDA database) divided by the total amount (mg) of flavonoids reported in each 
subclass (described as percentage). 
 
3.3 Results  
Mean, standard deviation and range of intake for total flavonoids and for each 
flavonoid subclass, per person each day was calculated (Table 3-1).  
There were significant differences between males (9130.3±3197.8 kilojoules/day) and 
females (7427.5±4699.1 kilojoules/day) for total energy intake (p=0.0005). However, 
there were no significant differences between males and females for total flavonoids 
(p=0.068) or for flavonoid subclasses; flavonol (p=0.621), flavone (p=0.364), 
flavanone (p=0.431), flavan-3-ol (p=0.055) and anthocyanin (p=0.081). The total 
percentage contribution of each flavonoid subclass to total flavonoid intake according 
to BMES WFR data is shown in Figure 3-1. 
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Table 3-1 Mean Intake of Total Flavonoids and Flavonoid Subclasses per Person, per 
Day According to Weighed Food Records* 
 
 
n 
Flavonoid 
(total) 
mg /day 
Flavonol 
mg /day 
Flavone 
mg 
/day 
Flavanone 
mg /day 
Flavan3ol 
mg /day 
Anthocyanin 
mg /day 
Total 
 
 
79 
683.2±506.7 
(7.3–5060.9) 
28.7±20.4 
(0.4–204.4) 
1.9±2.9 
(0–26.8) 
21.2±25.4 
(0–147.8) 
629.4±494.1 
(0-4906.3) 
7.0±9.2 
(0-69.4) 
Male 
 
 
34 
616.9±435.4 
(7.3-2038.2) 
27.9±22.1 
(0.375-
204.3) 
1.7±2.4 
(0-16.1) 
22.6±26.9 
(0-147.8) 
561.3±419.3 
(0-1921.3) 
8.1±1.0 
(0-49.1) 
Female 
 
 
45 
732.6±550.1 
(38.7-5060.9) 
29.2±19.1 
(2.6-181.6) 
2.1±3.1 
(0-26.2) 
20.1±24.3 
(0-131.9) 
680.2±538.9 
(7.56-
4906.3) 
6.1±8.4 
(0-69.4) 
*Data are expressed as mean±SD (range: min - max).  
 
One way ANOVA assessed the difference in total flavonoid intake and intake of 
flavonoid subclasses between the three separate 4-day WFRs and showed no 
significant differences in total intake or intake of any subclass between each of the 
collection periods. The inter-individual variation between WFRs showed a similarly 
large variation for WFR1 (55%), WFR2 (53%) and WFR3 (57%).  The coefficient of 
variation, which assessed the intra-individual variation in flavonoid intake across the 
three separate 4-day WFRS, showed a mean variation of 28.6% (range 0.9%-122.9%, 
median 22.2%).  
 
The total number of reported foods in the collated BMES WFR data was 895 foods 
and flavonoid content was assigned to 171 of these foods. The sources of total 
flavonoids that contributed the most to each food group as reported in the BMES WFR 
data, were calculated (Table 3-2). The top five foods that contributed to the flavan-3-
ols, flavonols, flavones, flavanones and anthocyanin subclasses of flavonoids are 
shown in Table 3-3. 
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Figure 3-1 Percentage contribution of flavonoid subclasses to total flavonoid intake. 
 
Flavonol, 5.15%
Flavone, 0.15%
Flavanone, 
1.90%
Flavan3ol, 
88.10%
Anthocyanin, 
0.046
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Table 3-2 Top 10 Flavonoid Containing Foods Ranked in Order of Contribution to Total Consumption 
 Fruit Vegetables Beverages Alcohol* Other foods 
 
Food (mean 
serve, g) 
% 
Food (mean 
serve, g) 
% 
Food (mean 
serve, g) 
% 
Food (mean 
serve, g) 
% 
Food (mean 
serve, g) 
% 
1 Orange (129.0) 1.37 Onion (63.5) 0.34 Black tea (237.6) 89.1 
Wine, Red 
(128.0) 
0.44 Parsley (13.94) 0.18 
2 Banana (100.7) 0.86 
Tomato, raw 
(59.5) 
0.19 
Green tea 
(307.4) 
1.3 
Wine, White 
(140.9) 
0.06 
Marmalade 
(19.4) 
0.08 
3 
Apple , Raw 
(112.0) 
0.66 
Green Bean 
(187.84) 
0.12 
Orange Juice 
(127.9) 
1.1 Beer (151.2) 0.04 
Milo Powder 
(12.4) 
0.03 
4 
Apple, Stewed 
(110.7) 
0.12 Potato (104.8) 0.09 
Grapefruit Juice 
(137.1) 
0.09 Sherry (73.1) 0.02 
Chocolate, Dark 
(18.3) 
0.019 
5 Mandarin (93.5) 0.12 Spinach (66.5) 0.05 
Apple Juice 
(148.6) 
0.06 
Champagne 
(271.1) 
0.002 Almond (24.8) 0.011 
6 Peach (125.3) 0.12 
Brussels Sprout 
(67.6) 
0.04 Coffee (188.9) 0.06   Pecan (34.0) 0.08 
7 
Strawberry 
(99.4) 
0.09 
Pumpkin 
(66.21) 
0.04 
Lemon Juice 
(24.6) 
0.04   Date (36.4) 0.007 
8 
Grape, black 
(160.9) 
0.08 Radish (47.7) 0.04 
Milk, chocolate 
(256.5) 
0.02   
Cocoa powder 
(4.31) 
0.065 
9 
Grapefruit 
(79.3) 
0.06 Celery (53.5) 0.04 
Tomato Juice 
(235.6) 
0.006   
Jam, Berry 
(24.75) 
0.004 
10 Plum (121.1) 0.06 Lettuce (42.1) 0.03 
Grape Juice 
(102.55) 
0.001   Ginger (10.1) 0.004 
% = percentage contribution to overall flavonoid intake according to 12 days of WFRs (n=79) from participants in the Blue 
Mountains Eye Study; * Alcohol only had five contributing beverages.
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Table 3-3 The Five Main Dietary Sources of Each Flavonoid Subclass Based on 
Weighed Food Records 
Flavonoid  
Subclass 
Food 
% contribution  
to subclass 
Flavan-3-ols Tea, Black 94.55 
 Tea, Green 3.52 
 Apple 0.40 
 Banana 0.39 
 Wine, red 0.155 
   
Flavonols Tea, Black 68.59 
 Onion 7.73 
 Apple 3.39 
 Tea, Green 2.78 
 Beans 2.76 
   
Flavones Parsley 98.52 
 Tomato 0.69 
 Celery 0.27 
 Pumpkin 0.23 
 Watercress 0.13 
   
Flavanones Oranges 44.47 
 Orange Juice 36.78 
 Mandarin 4.07 
 Tomato 3.06 
 Grapefruit Juice 2.80 
   
Anthocyanins Blueberry 29.56 
 Banana 22.81 
 Radish 9.14 
 Wine, red 8.19 
 Cabbage, red 7.71 
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3.4 Discussion  
The BMES WFR data was derived from 12 days of weighed food records in 79 people, 
equating to 948 person-days analysed.  The mean intake of total flavonoids 
(683mg/day) was significantly higher than previous estimations (454mg/day) (2) for 
the total Australian population. However, it is similar to the estimation of flavonoid 
intake (693mg/day) for the 65+ year old age group within the study from the 
Australian population estimates (2). The proportional intake of each flavonoid 
subclass in our data (Figure 3-1) compares closely with the Australian nationally 
representative 1995 National Nutrition Survey (NNS) data that was based on a 24hr 
recall method (3). Flavan-3-ols contributed the majority of flavonoid intake (92%), 
followed by flavonols (4%), flavanones (3%) and flavones (<1%). The difference in 
total flavonoid intake estimated between the studies may reflect the difference in 
dietary assessment methods and the size of the study population, however, the 
agreement seen between the comparative age group may confirm a higher flavonoid 
intake in this age range.  
 
The major food sources of flavonoids identified by the current analysis were black tea 
(89.1%), oranges and orange juice (1.37% and 1.3% respectively), green tea (1.3%) 
and bananas (0.87%). The strength of this data relates to the 12 days of dietary data 
being collected over 12 months, to reduce the impact of seasonality of food 
consumption and consequently flavonoid intake. However, it is interesting to note that 
no difference was seen in total flavonoid intake or intake of any flavonoid subclass 
between the three separate 4-day WFR, when comparing the group intakes as a whole. 
This is likely to be attributed to the habitual nature of tea consumption, which is fairly 
stable throughout the year. However, the high intra-individual variation, where on 
average there is a variation of nearly 29% in flavonoid intake between the 3 separate 
4-day WFRs, is quite significant. Therefore, the impact of seasonality for the group as 
a whole may be low, but the extent to which a particular individual may fluctuate is 
quite substantial. This should be a consideration in future studies investigating dietary 
flavonoid intake, whereby collecting dietary data in different seasons may not 
significantly influence flavonoid intake estimates on the population level, but the 
importance of individual variation should be considered. 
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The food sources identified are similar to the foods reported in the Australian NNS95 
population based analysis (3). In another Australian study (1), similar food sources 
were reported to contribute to flavonoid subclasses in a group of healthy, young 
women. Major sources of flavonols were reported to be tea, apples and onions, while 
major sources of flavones were parsley and celery, and significant sources of 
flavanones were citrus fruits, including oranges and grapefruit. Additionally, tea was 
shown to be the main contributor to total flavonoid intake (1), a finding confirmed by 
our study.  
 
International comparisons identify large variations in estimates of flavonoid intakes 
of older adults, with one US study reporting adults aged ≥51 years to consume only 
191mg/day, as estimated from two 24h diet recalls (15). A Finnish study of males aged 
48, 54 or 60 reported a similarly low estimate of 139mg/day, based on a 4-day food 
record (16). However, the trend showing higher intake of dietary flavonoids in older 
adults compared with other age groups is similar across all the national and 
international estimates. The low flavonoid intake estimates may be attributable to 
different dietary assessment methods and may also be potentially linked to the 
application of more limited flavonoid reference databases, leading to an under-
reporting of total flavonoid intake.  
 
While there was no significant difference between genders for total flavonoid intake 
or intake of any flavonoid subclasses, a difference in total energy intake was noted. 
This indicates that the major contributors to flavonoid intake may be minor 
contributors to total energy intake. This is highlighted by the influence of black and 
green tea, which account for more than 90% of total flavonoid intake and are low in 
kilojoules. Future research could adjust for energy intake to assess whether there are 
differences in flavonoid intake between genders after accounting for differences in 
energy intake.    
 
Despite providing sound dietary data, there are several limitations identified with 
utilizing the BMES WFR data to estimate flavonoid intake in older Australians. 
Firstly, this data was collected in the mid-1990s and the diets of older adults may have 
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evolved or changed over time to present. There is, however, a notable lack of 
population-based studies in older Australian adults that has collected dietary 
information with this level of precision since that time. A 10-year follow up of the 
BMES cohort showed overall fruit and vegetable consumption had not significantly 
changed from baseline (17). Changes that were found in dietary patterns over time 
generally related to fat (MUFA, PUFA, and SFA) and total sugar (not CHO) intake. 
These macronutrients are not present in large quantities in flavonoid-rich foods. 
Despite little change in fruit and vegetable intake over time in cohort survivors, 
applicability of the study findings may be limited by the changing food supply, 
limiting the generalizability of this data to the current population for specific food 
groups. However, further research is required to confirm these assumptions. While the 
BMES study population was generally representative of the older Australian 
population, they had slightly a higher socioeconomic status and a slightly higher level 
of post-school qualifications than the general population (18). Additionally, people 
who agree to complete 12 days of WFRs are also more likely to be highly motivated 
about recording the details of their diet (18), and could also therefore tend to have 
higher quality diets with an increased nutrient density, compared to the general 
population. Lastly, this secondary data analysis relied on the WFR data which had 
previously been transcribed into Diet 1.3 software (19). This software was not 
designed to incorporate phytochemical information and consequently there are 
limitations associated with our ability to manually assign flavonoid values to foods. 
One major example of this is green tea, which is combined with other herbal teas in 
the food composition databases. Despite perhaps having similar nutritional properties 
in terms of nutrients, the phytochemical properties of different herbal teas are 
extremely varied (20). 
 
Another major limitation relates to utilisation of the USDA database to determine the 
flavonoid content of selected foods as a reference database. The flavonoid content of 
foods in the database may not reflect that of Australian produce, as flavonoid content 
is heavily influenced by growth and processing conditions and the USDA recognizes 
this variability (4). Another well-established limitation relates to the inability of a 
reference database to account for storage and cooking methods (4). Future research 
should attempt to account for this through the application of retention factors for some 
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food preparation techniques, including boiling. However, retention factor applications 
in this instance were not warranted, as full disclosure of food treatment and cooking 
was not available due to limitations associated with secondary data analysis. 
Additionally, bioavailability of flavonoids is not taken into account, despite showing 
extreme individual variability (21). Once retention factors for all foods are perfected 
and the metabolism of flavonoids is adequately understood, they should be primary 
considerations in estimating bioavailability and therefore the bioactivity of flavonoids. 
It is also important to highlight that the USDA database attributed a delphinidin value 
for bananas of 7.39 mg/100 g, which may incorrectly reflect banana proanthocyanidin 
degradation during content analysis (22). However, all values that were presented in 
the USDA database were accepted as it was outside the scope of this analysis to 
question a critically evaluated and widely used database; however, this limitation 
means anthocyanin intake may be overestimated in this cohort. 
 
A further limitation of this study relates to the measurement of flavonoids alone, as 
many other classes of polyphenolic compounds hold similar biological properties. 
Total flavonoid intake and the intake of total flavonoid subclasses only were measured 
instead of specific flavonoids, in order for the results to have a more general 
application in broad nutrition research. Additionally, it is likely that specific 
flavonoids within a subclass have similar bioactivities.  
 
3.4.1 Conclusion 
Accurate estimation of flavonoid intake in populations is an important methodological 
consideration for studies that investigate the health impact of these food-derived 
bioactive compounds. Our analysis provides an assessment of usual intakes of 
flavonoids that may be useful for planning intervention studies in which dose-response 
outcomes are of interest.  
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3  
3.1 Introduction 
Currently, the consumption patterns of flavonoids in older adults have not been adequately 
assessed, and only a few Australian estimations are available in the literature (1, 2). The 
dietary assessment instruments currently used to measure flavonoid intake have 
limitations in their ability to accurately assess habitual intake, which hinders investigation 
of the association of the health benefits of flavonoids in epidemiologic studies (3). 
Inconsistent methodologies have been used to quantify flavonoid intake and few survey 
tools have been validated for this purpose (4). The collection of dietary information using 
food recall or food record (FR) methods has been employed most frequently when 
determining intake of flavonoids, and is cross-referenced with flavonoid-specific food 
composition databases. However, the burden of these methods can be large on both 
participants and researchers. 
 
Previously published food frequency questionnaires (FFQ) that have been developed to 
measure flavonoids have focused on specific flavonoids or flavonoid subclasses, rather 
than a comprehensive range to reflect total dietary intake. Hakim et al. (5) validated a FFQ 
that assessed intake of tea and tea polyphenols against a standard FFQ and 4-day FRs. In 
a more focused study, Hakim et al. (6) measured D-limonene contents in a range of citrus 
juices as the basis for the assessment of the intake of this flavonoid. Although accurate, if 
these types of instruments were expanded to provide information on the full range of 
flavonoids, their time burden on the respondent and researcher would be excessive. 
Research has also utilised post-hoc analysis of pre-existing FFQs that were not developed 
or validated for the purpose of measuring flavonoid intake (7, 8). This method has 
demonstrated large limitations in accurately assessing flavonoid consumption, because of 
grouping foods that may have similar nutritional profiles (pears and apples) and appear 
sensible to the respondent to consider together when reporting their intake, but which have 
vastly different flavonoid contents.  
 
Recent Australian research has validated a flavonoid specific FFQ in young adults, against 
3 day FRs (9). Additionally, total flavonoid consumption (1), and the main sources of 
flavonoids (4), have been estimated in an Australian population using 24hr recall data 
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from the National Nutrition Survey, 1995. The different eating patterns of older 
Australians was reflected in different dietary sources of flavonoids compared to younger 
adults, whereby contributions from tea and wine flavonoids increased markedly with age 
(1). Given the differences in total flavonoid intake, as well as the different major dietary 
sources of flavonoids in the diets of young and older adults (1), it is important to develop 
and validate a FFQ to measure the intake in older adults specifically. Despite a large body 
of evidence that links flavonoid consumption with improved health outcomes in older 
adults (10), there is little published information on habitual intake of food sources of 
flavonoids in this age group. A flavonoid specific FFQ, that includes a list of both 
flavonoid rich and the most commonly consumed food items that contribute to total intake, 
would be a useful contribution to research that investigates flavonoid consumption in 
older Australian cohorts, for the purpose of exposing diet-health associations, as well as 
to inform the development of dietary guidelines. The advantages of a FFQ over dietary 
recall and diary methods to assess long term intake patterns of nutrients, and to a lesser 
extent, foods and food groups, is well established (11). A FFQ is a cheaper and markedly 
less burdensome method for measuring dietary exposure to dietary attributes (12).  
 
A focused retrospective analysis of dietary flavonoid intake older adults was necessary to 
inform the development of a novel dietary assessment tool (2). We recently estimated the 
mean intake of total flavonoids, and the major dietary sources thereof, in an older 
Australian population using twelve days of weighed FRs (2), collected as a part of the 
Blue Mountains Eye Study (13). These findings (14) were utilised to develop a FFQ for 
use in older adults, the validation and reproducibility of which is the objective of this 
study. Validity, in this context, is the degree to which the FFQ measures specific dietary 
attributes, and the validation process involves appraisal of the FFQ against a reference 
method to determine their agreement in measuring the same dietary attributes (15). The 
reproducibility of an FFQ relates to the ability of the tool to accurately and equally 
measure the same dietary attributes on more than one occasion (15).  
 
The aim of this study was to assess the validity and reproducibility of a FFQ developed to 
measure total flavonoid intake, and flavonoid subclasses, in older adults against a 4-day 
FR.  
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3.2 Methods 
3.2.1 Development of the FFQ 
A FFQ was developed to quantitatively assess individual intake of dietary flavonoids over 
12 months and is structurally based on the National Health and Nutrition Examination 
Survey (NHANES) FFQ (16). All points of recommendation as outlined by Cade et al., 
(11) were addressed in the development of the instrument.  
As reported elsewhere (2), 12 days of weighed FR data from the Blue Mountains Eye 
Study (BMES) were used as the main basis for the development of the FFQ. To ensure all 
rich sources of flavonoids and top contributors to flavonoid intake were captured; foods 
were selected for inclusion in the FFQ if they met the following criteria: 
1. Any food with >30mg/100g total flavonoids and/or >30mg/average portion size. 
2. Any flavonoid containing food in the top 25% of all foods. 
3. A top 25% contributor in each flavonoid subclasses according to the average 
portion size (g) of that food. 
Several additional inclusions from the USDA database of flavonoid containing foods were 
selected on the basis of the definition of a flavonoid rich food, >30mg/100g edible weight, 
and if they were available in Australia and could form part of usual cuisine. Additionally, 
any foods highlighted as top contributors of flavonoid intake by previous Australian 
literature (1, 4) were also included. Of the total 96 foods included in the FFQ, 73 foods 
were identified from the BMES WFR data. An additional 23 foods were included from 
rich sources identified from the USDA flavonoid database (Table 3-1) and from other 
current literature sources (Table 3-2). 
The USDA database for the flavonoid content of selected foods was selected as the 
reference database for this study, as it is one of the most complete sources of flavonoid 
content data. The lack of an equivalent Australian database for the assessment of flavonoid 
intake from dietary records necessitated the use of an international one.  While other 
databases, including PhenolExplorer and EURO-FIR-eBasis. As the USDA database was 
adequately comprehensive (i.e. all included foods were able to be assigned flavonoid 
content), no other flavonoid databases were consulted.  
 
Table 3-1 Rich flavonoid sources (>30mg/100g) identified from the USDA database (3.1) 
(12). 
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Food source Flavonoid 
content/100g 
Dried Parsley 215.46 
Dill 55.15 
Thyme 45.25 
Capers (canned) 259.19 
Mint 30.92 
Coriander 52.9 
Lime 43.0 
Eggplant 85.69 
Blackcurrant juice 45.27 
Red onion (raw) 39.21 
Rocket 66.19 
Oregano 311.73 
 
Table 3-2 Flavonoid sources identified from Australian literature sources (2, 5). 
Food source Flavonoid 
content/100g 
Cherries 30.21 
Lemon 53.38 
Silverbeet (chard) 1.75 
Endive 10.1 
Beans (broad) 0.9 
Spring onion 30.6 
Mango 2.0 
Rhubarb 2.35 
Olives (green) 0.56 
Olives (black) 4.93 
Kale 92.98 
 
Grouping of food items was decided a priori to the analysis, with items being coded into 
the food categories of beverages, alcohol, fruit, vegetables, herbs and other foods. With 
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the aim of accurately quantifying flavonoid intake, serving sizes derived from the BMES 
WFR data were used (2). Median portion size (g) and the inter-quartile range informed 
the basis for four portion size options, specific to each food. A time period of 12 months 
was selected to ensure that habitual intake and the influence of seasonal dietary change 
was captured in the FFQ. 
 
3.2.2 Subjects 
A total of 42 community dwelling older adults aged 60 years and over from the Illawarra 
region of NSW, Australia, were recruited to the study between June and September 2014. 
Generally healthy older adults were recruited via advertising material distributed at local 
community groups. The study excluded individuals with major food intolerances or a 
condition that impacts usual diet (e.g. Cohn’s disease). Ethics approval was obtained from 
the University of Wollongong Human Research Ethics Committee and all subjects 
provided written informed consent. To determine an adequate sample size, a previous 
study (17) which assessed the validity of an FFQ against multiple 24h recalls, minimum 
of approximately 42 subjects were required to obtain a correlation coefficient of 0.377. 
 
Participants attended two identical interviews, held one month apart, and based on their 
preference for either a home visit or attendance at the university testing facility (Illawarra 
Health and Medical Research Institute). A single interviewer (KK) conducted the 
interview, at which weight (kg) and height (m) was measured and body mass index (BMI; 
weight (kg) / height (m) 2) was calculated. Resting blood pressure (BP) and heart rate (HR) 
was measured while seated, in triplicate and averaged using an Omron HEM7200 Deluxe 
Automatic Monitor. Personal and demographic information was collected including age, 
smoking and drinking habits, and education level.  
 
3.2.3 FFQ Analysis 
The self-administered FFQ, completed by the participant at home on the day before the 
interview, was screened during the interview for errors and missing data. Any questions 
about the foods contributing to the FFQ were clarified. The paper-based FFQ data was 
entered into a template created for this purpose in Microsoft Excel (Microsoft version 
14.1.2). The template was developed using nutritional information for each food or 
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beverage, for each serving size option in the FFQ, from the Foodworks dietary analysis 
package (Xyris software, version 5, 2007, Highgate Hill, QLD, Australia) and USDA 
database for the flavonoid content of selected foods (18). Foods reported were converted 
to daily intake frequencies as follows: 6+ per day= 7.5; 4-5 per day = 4.5; 2-3 per day = 
2.5; 1 per day = 1; 5 - 6 per week; 0.8; 3-4 per week = 0.5; 1-2 per week = 0.2; 2 - 3 per 
month = 0.09; 1 per month or less = 0.04; Never = 0.  
 
3.2.4 Dietary Assessment 
Participants were briefly trained by a nutritionist (KK) and instructed to complete a 4-day 
FR on any four consecutive days between the two interview dates, including 3 week days 
and 1 weekend day. Participants were instructed to record in detail all the foods and drinks 
they consumed during that period and to estimate the portion sizes using cup measures, 
weights or other household measurements. Dietary data from the 4-day FR was screened 
during the final interview and analysed using the Foodworks dietary analysis package 
(Xyris software, version 5, 2007, Highgate Hill, QLD, Australia). As dietary data relating 
to flavonoid content of foods is not integrated into the Xyris software, the food items were 
manually cross-referenced with the USDA database for the flavonoid content of selected 
foods (18) to estimate flavonoid consumption.  
 
3.2.5 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS) V15.0.0 (SPSS Inc., Chicago IL, USA). Descriptive statistics were performed on 
demographic data. For each participant, mean (±SD) flavonoid intake, intake of each 
flavonoid subclass from FFQ1, FFQ2 and 4-day FR was calculated. From this the mean 
(±SD) intake per person/per day for each method was determined. Major dietary sources 
of flavonoids and each flavonoid subclass were determined. Mean daily flavonoid intakes 
for the FFQ1, FFQ2 and 4-day FR were assessed for normality using histograms and the 
Shapiro Wilk test for normality. Data was not normally distributed for FFQ1, FFQ2 and 
4-day FR.  
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3.2.6 Validity 
A combination of tests was applied to assess several different facets of validity, which 
may therefore provide a superior assessment of validity than a single measure (19). A 
Wilcoxon signed rank sum test was used to compare flavonoid and flavonoid subclass 
intakes obtained from the two methods (FFQ1 and 4-day FR). Spearman correlation 
coefficients were calculated between the two dietary assessment methods (i.e. FFQ1 and 
FR) for total flavonoid intake and each dietary flavonoid subclass to test the strength of a 
relationship between two variables.  
The FFQ1 and 4-day FR were assessed for level of agreement using Bland-Altman plots 
(20), where the difference between the FFQ1 and 4-day FR (FFQ1 - 4-day FR) was plotted 
against the mean of the FFQ1 and 4-day FR (FFQ1 + 4-day FR)/2. Limits of agreement 
(the mean difference±1.96SD) for the difference between the two measures were 
calculated to evaluate if they were acceptable. A regression line was fitted in the graph to 
detect proportional differences and to indicate the direction and magnitude of the bias.  
Lastly, the Cohen's kappa (κ) test determined the FFQ’s ability to rank individuals into 
quartiles of intake (FFQ1 vs 4-day FR) for total flavonoid intake and flavonoid subclasses 
(21, 22), whereby values ≤ 0 as indicating no agreement and 0.01–0.20 as none to slight, 
0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as 
almost perfect agreement. 
 
3.2.7 Reproducibility 
A combination of tests was applied to assess reliability (19). The mean percentage 
difference between FFQ1 and FFQ2 for total flavonoid intake and intake of flavonoid 
subclasses was calculated. Wilcoxon signed rank sum test was used to compare flavonoid 
and flavonoid subclass intakes obtained from the FFQ1 and FFQ2. The association 
between FFQ1 and FFQ2 was assessed using the Spearman correlation for total flavonoid 
intake and each flavonoid subclass. Bland-Altman graphs were drawn for the difference 
between FFQs (FFQ1 - FFQ2) plotted against the mean of the FFQs ((FFQ1 + FFQ2)/2). 
Limits of agreement (the mean difference±1.96SD) for the difference between the two 
measures were calculated to evaluate if they were acceptable and to indicate the direction 
and magnitude of the bias. A regression line was fitted in the graph to detect proportional 
differences. The Cohen's kappa (κ) was determined to assess the FFQ’s reliability to 
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ranking individuals into quartiles of intake (FFQ1 vs FFQ2) (21, 22), whereby values ≤ 0 
as indicating no agreement and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41–0.60 
as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement. 
 
3.3 Results 
The developed flavonoid FFQ (Appendix G) includes 93 questions, pertaining to 9 non-
alcoholic beverages, 5 alcoholic beverages, 25 fruit, 33 vegetables, 8 herbs, 13 other foods 
(dried fruit, nuts, fruit spreads), and an additional 3 summary questions about usual 
alcohol intake, and fruit and vegetable consumption. The characteristics of the study 
participants are presented in Table 3-3. 
 
 Table 3-3 Summary statistics of subject characteristics (n=42). 
Gender 
Male  14 (33.3%) 
Female 28 (66.7%) 
Age (y) Mean±SD 75.3 ± 8.6 
BMI (kg/m2) Mean±SD 27.7 ± 4.3 
Primary Language 
English 40 (95.2%) 
Other 2 (5.8%) 
Smoking status 
Non-smoker 28 (66.7%) 
Current smoker 1 (2.4%) 
Ex-smoker 13 (30.9%) 
Supplement Use 
Any supplement 24 (57.2 %) 
No supplement 14 (42.8%) 
Education (highest level 
completed) 
Tertiary 27 (64.3%) 
Secondary (complete) 15 (35.7%) 
Secondary (incomplete) 0 
Primary 0 
Blood Pressure 
Systolic Mean±SD 138.1 ± 18.4 
Diastolic Mean±SD 83.74 ± 9.3 
Heart rate: Mean±SD 67.2 ± 10.6 
 
The mean intake, standard deviation and range of total flavonoid intake and intake of each 
flavonoid subclass (mg/day) for each method were determined (Table 3-4). For both the 
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FFQ (1 and 2) and the 4-day FR, a large variability in dietary flavonoid intake and intake 
of flavonoid subclasses is described (Table 3-4). The percentage contribution that each 
food made to total flavonoid intake and intake of each flavonoid subclass was calculated 
for each person (FFQ1) and averaged to indicate the major (top 10) foods contributing to 
intake in the total group (Table 3-5). 
 
Table 3-4 Description of mean flavonoid intake (mg/day) according to the FFQ1, FFQ1 
and 4-day FR (n=42) 
 (mg/day) Mean 
Std. 
Deviation 
Minimum Maximum 
% 
contribution 
FFQ 
1 
 
 
 
 
Total Flavonoids 1050.4717 725.52905 80.02 3253.48  
Anthocyanins 103.3685 104.66311 11.45 368.27 9.84 
Flavan-3-ols 829.5545 690.60154 32.27 2953.08 78.96 
Flavanones 42.4992 28.47302 2.39 105.35 4.04 
Flavones 6.5072 8.03556 .27 37.74 0.61 
Flavonols 68.5423 34.99465 19.68 147.20 6.52 
FFQ 
2 
 
 
 
 
Total Flavonoids 1047.0211 724.85865 140.14 2488.98  
Anthocyanins 103.4143 99.03593 14.75 367.82 9.88 
Flavan-3-ols 829.7809 686.56737 60.92 2312.23 79.25 
Flavanones 40.4190 29.37282 4.87 103.56 3.86 
Flavones 7.3939 9.20604 .46 37.70 0.71 
Flavonols 66.0130 32.80539 16.44 131.84 6.30 
4-day 
FR 
 
 
 
Total Flavonoids 847.5078 534.75680 22.08 2490.47  
Anthocyanins 38.8653 58.98484 .00 224.65 4.59 
Flavan-3-ols 754.6830 502.21665 6.93 2366.47 89.05 
Flavanones 18.5490 20.92953 .00 69.78 2.19 
Flavones 3.7307 5.24328 .00 27.40 0.44 
Flavonols 32.7868 18.88830 1.16 99.38 3.87 
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Table 3-5 Top 10 foods contributing to total flavonoid and flavonoid subclass intake ranked in order of contribution to total 
consumption according to the developed FFQ. 
  Flavonoid Total Anthocyanin Flavan-3-ol Flavanone Flavone Flavonol 
 Food % Food % Food % Food % Food % Food % 
1 Tea, black 56.97 Wine, red 31.13 Tea, black 75.22 Orange juice 40.86 Parsley 35.50 Tea, black 29.03 
2 Wine, red 7.63 
Grapes, 
red 
13.29 Tea, green 7.42 Mandarin 19.18 Wine, red 17.06 
Onion, 
brown 
9.79 
3 Tea, green 6.05 Cherry 10.28 Broccoli 4.80 Oranges 17.59 Pumpkin 11.08 Beans 8.93 
4 Orange 3.33 Blueberry 7.94 Apple, red 2.48 Wine, red 6.75 
Grapes, 
red 
7.35 Peas 5.04 
5 Broccoli 2.57 Banana 7.04 Peach 1.46 Wine, white 3.64 Tea, green 4.22 Onion, red 4.44 
6 
Grapes, 
red 
2.08 Pear 5.96 Wine, red 1.42 
Brussels 
sprout 
3.59 Celery 4.02 Wine, red 4.26 
7 Mandarin 2.07 Strawberry 5.53 Banana  1.06 Grapefruit 2.46 Spinach 2.30 Tea, green 3.81 
8 Cherry 1.95 Apple red 3.78 Nectarine 1.02 Lemon, flesh 2.26 Orange 2.28 Apple 3.37 
9 Apple, red 1.86 Plum 2.72 Cherry 0.94 Tomato 1.63 Kiwi fruit 1.93 Kale 2.66 
10 Banana  1.10 Peach 1.47 
Grapes, 
green 
0.65 Lemon juice 0.67 
Rock 
melon 
1.83 Spinach 2.60 
  
116 
 
3.3.1 Validity 
Wilcoxon signed rank sum test showed significant differences in total flavonoid 
(p<0.001), anthocyanin (p<0.001), flavanone (p<0.001) and flavonol (p<0.001) intakes as 
measured by the FFQ1 and 4-day FR, and no significant difference for flavone and flavan-
3-ol measurements (Table 3-6). The strength of the relationship as tested by Spearman’s 
correlation coefficients between the FFQ1 and 4-day FR are shown in Table 3-6.  
 
The Bland-Altman plot of the bias (average of the differences between methods) against 
the mean value for the two methods is shown in Figure 3-1. Visually, this demonstrates 
that the bias and limits of agreement are large for total flavonoid intake (+202.96), and 
intake of anthocyanins (+64.5), flavan-3-ols (+74.85), flavanones (+ 23.9) and flavonols 
(+35.75). The bias is small, with narrow limits of agreement for flavone intake (+2.77). 
These results indicate that the FFQ1 and 4-day FR are systematically producing different 
results. Interpretation of the systematic bias shows that the FFQ is overestimating 
flavonoid intake (and intake of flavonoid subclasses) in comparison to the 4-day FR. The 
linear regression analysis indicates a strong positive correlation for total flavonoid intake, 
and intake of anthocyanins, flavan3ols and flavonols, whereby the greater an individual 
estimates their flavonoid intake, the greater the systematic bias (or overestimation by the 
FFQ). This relationship is lesser for flavone and flavanone intakes, as shown visually in 
Figure 3-1.  
 
The Cohen's kappa (κ) indicates that there was substantial agreement (21) between the 
FFQ1 and 4-day FR for total flavonoid intake (κ =0.619, p<0.001), moderate agreement 
for flavan-3-ol intake (κ=0.492, p<0.001) and flavonol intake (κ =0.619, p<0.001); fair 
agreement for flavone intake (κ=0.238, p=0.008); slight agreement for anthocyanin intake 
(κ=0.142, p=0.111); and poor agreement for flavanone intake (κ=0.048, p=0.587). 
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Table 3-6 Comparison of the total flavonoid intake and intake of flavonoid subclasses 
(mg/day) for FFQ-1 vs FR (validity) and FFQ-1 vs FFQ-2 (reliability) 
(mg/day) 
Wilcoxon 
signed 
rank sum 
test 
Sig. (p-
value) 
Spearman’s Correlation 
Coefficient 
Sig.  
(p-value) 
FFQ-1 - 
vs  
4-day FR  
 
Total flavonoids <0.001 0.93 <0.001 
Anthocyanins 
<0.001 
0.32 0.042 
Flavan-3-ols 
0.413 
0.87 <0.001 
Flavanones 
<0.001 
-0.17 0.27 
Flavones 0.004 0.18 0.25 
Flavonols <0.001 0.75 <0.001 
FFQ-1 vs 
FFQ -2 
 
Total flavonoids 0.912 0.91 <0.001 
Anthocyanins 
0.955 
0.92 <0.001 
Flavan-3-ols 
0.957 
0.92 <0.001 
Flavanones 
0.350 
0.73 <0.001 
Flavones 0.119 0.85 <0.001 
Flavonols 0.328 0.90 <0.001 
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(a) 
 
 
(b) 
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(c) 
 
(d) 
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(e) 
 
(f) 
 
Figure 3-1 Bland Altman plots (difference in intake (mg/day) (FFQ1 – 4-day FR) against the mean intake of flavonoids and subclasses 
(mg/day) [FFQ1+4-day FR)/2]) showing the relative validity of the FFQ 1 vs the 4-day FR for total (a) flavonoids, (b) anthocyanin, (c) 
flavan-3-ol, (d) flavanone, (e) flavone and (f) flavonol intake. 
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3.3.2 Reproducibility 
The mean percentage difference between FFQ1 vs FFQ2 showed small variations for 
total flavonoid intake (6.74%), and intake of anthocyanins (13.75%), flavan-3-ols 
(14.07%), flavanones (10.73%), flavonols (-1.11%), with slightly higher variation for 
flavones (22.34%). 
 
Wilcoxon signed rank sum test showed no significant differences in the measurement 
of total flavonoid or any flavonoid subclass intakes (mg/day) between the FFQ1 and 
FFQ2 (Table 3-5). Total flavonoid intake showed excellent reliability (>0.9) and each 
flavonoid subclass showed between acceptable (>0.7) and excellent reliability (Table 
3-5). The Bland Altman plots visually showed small, non-significant bias (Figure 3-
2) and wide limits of agreement. Linear trends in the bias are not evident between 
FFQ1 and FFQ2 (Figure 3-2).  
 
The Cohen's kappa (κ) indicated substantial agreement (21) between the FFQ1 and 
FFQ2 for total flavonoid intake (κ =0.619, p<0.001), anthocyanin intake (κ=0.651, 
p<0.001), flavan-3-ol intake (κ=0.746, p<0.001), flavone intake (κ=0.714, p<0.001) 
and flavonol intake (κ =0.619, p<0.001), and moderate agreement (21) for flavanone 
intake (κ=0.492, p<0.001). 
 
 
  
  
122 
 
 
(a) 
 
(b) 
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(c) 
 
(d) 
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(e) 
 
(f) 
Figure 3-2 Bland Altman plots (difference in intake (mg/day) (FFQ1 – FFQ2) against the mean intake of flavonoids and subclasses 
(mg/day) [FFQ1+FFQ2)/2]) showing the relative validity of the FFQ 1 vs the FFQ2 for total (a) flavonoids, (b) anthocyanin, (c) flavan-
3-ol, (d) flavanone, (e) flavone and (f) flavonol intake. 
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3.4 Discussion 
A novel flavonoid-specific FFQ was developed for use in older Australians by applying a 
systematic approach using data obtained from 12 days of weighed FRs and the most appropriate 
flavonoid composition data (18). Total flavonoid intake as measured by the FFQ (1050mg/day) 
was significantly higher than that reported in other Australian studies (1, 4, 23), including the 
analysis of the cohort of older adults who were used to inform the development of this tool (14) 
(683mg/day). The 4-day FR similarly measured flavonoid intake (847mg/day) and intake of 
flavonoid subclasses as being higher than previous Australian estimations, however the 
percentage contributions of each flavonoid subclass to total flavonoid intake are closely related 
to previously reported estimates for the total Australian population (1). An overestimation of 
flavonoid intake was similarly reported in a validation study of an FFQ developed to measure 
flavonoid intake in younger Australian adults (9), and appears to be a typical finding when 
validating a FFQ against FRs (24). Nevertheless, the major sources of total flavonoids as 
estimated by the FFQ are black tea (57.0%), red wine (7.6%) and green tea (6.0%), which has 
previously been described as significant flavonoid sources in this age group (1). Inclusion of 
both the most commonly consumed flavonoid-containing foods; in addition to the richest 
dietary sources according to the food composition database in the FFQ provided a sound basis 
that enabled the most accurate estimation of habitual intake of all flavonoids. For example, 
although consumed sporadically and in small amounts, parsley provided the major source of 
flavone intake. Previous dietary questionnaires that have not incorporated both considerations 
(10, 25, 26) and have shown limitations in the assessment of total flavonoid intake.   
 
Despite the FFQ1 and 4-day FR being strongly correlated, except for flavanone and flavone 
intake, there were significant differences in estimation of the total flavonoid intake and intake 
of flavonoid subclasses (except for flavan-3-ols) between the two measures. This is a result of 
the FFQ consistently measuring flavonoid intake to be higher than the 4-day FR analyses. This 
finding was confirmed by the Bland-Altman analysis, which indicates a case of proportional 
error (strong positive correlation) (Figure 3-1). As correlation quantifies the degree to which 
two variables are related, but does not automatically imply that there is good agreement 
between the two methods (20), this finding is not uncommon. The agreement between the FFQ 
and the 4-day FR to assign an individual to quartiles of intake suggests that the FFQ is an 
excellent method for total flavonoid intake, but exhibits differing levels of agreement for 
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individual subclasses of flavonoid, particularly flavanone intake which are commonly found in 
citrus related foods. The misclassification for the flavonoid subclasses may also relate to the 
influence of seasonal foods being under-reported in the 4-day FR in comparison to the FFQ. 
This is of particular relevance for anthocyanins and flavanones that showed the poorest 
agreement between methods. Berries and cherries (summer fruits) and mandarins (winter fruit) 
are highly seasonal fruits that are available for short periods of time in Australia, but are rich 
in anthocyanins and flavanones, respectively. The period of reporting for the FFQ was 
consumption of fruits and vegetables over the previous 12 months, whereas the 4 day-FR 
measured intake over a short period between June and September which corresponds to winter 
and early spring in Australia. Thus, the FFQ could be expected to over-estimate the flavonoid 
intake related to seasonal fruit consumption. Alternatively the 4-day FR, which was considered 
to be robust reference method in our study, could be considered inadequate at estimating overall 
habitual flavonoid intake. These considerations are important when deciding on the purpose of 
the instrument, whether to measure absolute intakes in order to assess acute changes as would 
be needed in a short term intervention study or clinical trial, or whether the instrument is 
required for ranking individuals according to usual intake, as is required in epidemiological 
studies (12). Our study has demonstrated the latter, as is the desirable strength of a FFQ and 
highlights its potential application for use in large cohort studies. 
 
Our findings are consistent with a Flemish study in which an 86-item FFQ was validated 
against a 4-day non-consecutive food diary in dietitians (27). That FFQ was similarly able to 
assign subjects to correct quartiles of flavonoid intake and to identify high flavonoid containing 
foods and regular sources of flavonoid intake, but was less suitable for estimating total intake 
(mg/day). The FFQ also showed only weak or no correlation to the 4-day food diary in relation 
to specific flavonoid subclasses, for example, anthocyanins (27). In that study, the poor 
correlation was related to the sporadic consumption of high flavonoid-containing foods, such 
as red wine, that were not captured in the 4-day food diary; a result which appears to be 
replicated in our study.  
 
Using various statistical tests, the novel FFQ developed by this study showed an excellent level 
of reproducibility. The repeated FFQs were highly correlated, displayed a small percentage 
disagreement (21), and showed no difference between measured total intakes of flavonoids or 
their subclasses. These findings were confirmed in the Bland-Altman analyses that visually 
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indicated a low level of bias and the Cohen's kappa (κ) results that indicated moderate (κ = 
0.41– 0.60) to substantial agreement (κ = 0.61–0.80) (21) between the two time points. The 
FFQs were administered one month apart; therefore it is unlikely that any seasonal variation in 
diet would have impacted its reproducibility.  
 
There are limitations to this study, which partially relate to the general limitations associated 
with using a FFQ to measure dietary components. While FFQs are a cheap and relatively simple 
to apply, they are associated with large measurement error due to inaccuracies in estimating 
frequencies and food serving sizes (12). Longer FFQs have shown to overestimate fruit and 
vegetable intake (12), which could have been a contributor to measurement error in this study. 
Another potential source of bias in validation studies of this nature is that, because the FFQ 
was unable to make provision for information on the cooking processes associated with each 
food, a ‘raw food’ value was attributed for each food which may have over-inflated intake 
values. However, in the case of the 4-day FR method cooking-related flavonoid losses were 
able to be accounted for as cooking methods were advised. Future work should attempt to 
address the amount of cooked vs fresh food consumption that is associated with of each food 
item. The potential to add a retention factor to the raw food values and address the degradation 
associated with cooking should be investigated in the further refinement of this instrument. 
Future research should also consider the influence of the reference food composition database 
used, and the impact that it may have on the estimated flavonoid intake. A recent study by 
Witowska et al., (28) showed that utilizing the Phenol Explorer database and the USDA 
database resulted in different polyphenol estimations in Polish adults. However, until there is 
an Australian specific, comprehensive flavonoid reference database, then the relative validity 
of applying one database versus another (i.e. USDA vs Phenol Explorer) is questionable.  
 
To improve the validity of a FFQ, design issues including the length, closed vs open-ended 
responses, seasonality, time-frame and portion sizes can be manipulated (12). Future research 
may focus on adjusting the time-frame of the recall if short-term intake is required over habitual 
consumption. Additionally, a shorter version of the FFQ could be trialled, excluding foods that 
did not significantly contribute to flavonoid intake in our study (e.g. herbs). The usefulness of 
this FFQ over other general FFQs, such as the Block, Willett, and National Cancer Institute 
FFQ (16), should be a consideration for future research. However, due to the highly specific 
flavonoid content of foods, grouping of food items that are similar nutritionally (e.g. citrus 
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fruits) into a single question (12), which is the case for many pre-existing FFQs (16), is not 
recommended. Lastly, as diet is highly influenced by season, future studies may consider 
confirming these findings in all seasons across a year. 
 
3.4.1 Conclusion 
A novel FFQ developed to estimate flavonoid intake for use in older Australians has been 
shown to demonstrate fair validity against a 4 day FR method and substantial reproducibility. 
The FFQ could allow for an easier estimation of flavonoid intake and intake of flavonoid 
subclasses in older adults, especially when ranking individuals according to total flavonoid 
intake in epidemiological research. Future studies may attempt to validate this tool against 
repeated FRs collected across several seasons, in order to assess the instrument’s ability to 
more accurately capture seasonal food intake, and potentially improve the validity of the tool 
for measuring flavonoid subclasses.  
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CHAPTER 4: DEVELOPMENT OF A GAS CHROMATOGRPHY/MASS 
SPECTROMETRY TECHNIQUE TO DETERMINE PHENOLIC ACID 
BIOMARKERS OF FLAVONOID INTAKE AND METABOLISM 
 
This chapter describes the potential for phenolic acid metabolites as biomarkers of flavonoid 
intake. This chapter demonstrates the candidate’s knowledge about the analytical techniques 
of Gas Chromatography (GC) and Mass Spectrometry (MS). It the describes the process 
undertaken to develop and establish a GC-MS technique to measure phenolic acids in human 
plasma at the University of Wollongong, in the Illawarra Health and Medical Research Institute 
under the supervision of Dr. Andrew Jenner (Senior Research Fellow). This method is applied 
in Chapter 6 of this thesis: ‘Developing methodology to assess the acute dose-dependent effects 
of flavonoids in cherry juice on cognition and blood pressure: a pilot cross-over study.’ 
 
KK carried out experimental work and wrote the manuscript. Dr A Jenner devised and 
supervised the experimental work. Dr A. Jenner is an experienced GC/MS scientist, who 
trained KK in GC/MS methodology, carried out the GC/MS maintenance and designed the 
GC/MS programs. Undergraduate students, Linnea Svenson and Vijay Kuppurajan also 
contributed to the experimental work related to the method development. 
 
  
  
133 
 
4    
Background  
4.1 Flavonoid Absorption and Metabolism 
Flavonoids encompass a wide group of compounds that form a subclass of polyphenols and 
comprise 15 carbons, with two aromatic rings bound together by three carbon atoms (denoted 
as A, B and C) that form an oxygenated heterocycle (Figure 4-1). Common flavonoids and 
their chemical structure are shown in Table 4-1. 
 
 
Figure 4-1 Generic flavonoid structure (1) 
 
Until relatively recently, very little was understood regarding flavonoid bioavailability, 
absorption and metabolism. However, with evidence from human studies linking flavonoid 
intake to improved health outcomes, there has been a rapid increase in our knowledge 
surrounding their metabolism and bioactive effects (2). The bioavailability of specific 
flavonoids that are abundant in the human diet has been well established and reviewed (3). 
Manach et al., 2005 (3) reviewed 97 studies to conclude that polyphenols (including 
flavonoids) markedly differ to one another in relation to their bioavailability and intestinal 
metabolism. Additionally, intra-individual variation significantly impacts their uptake and 
biological effects (4).  
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Table 4-1 Chemical structure of common dietary flavonoids 
Flavonoid group Example Chemical Structure 
Flavones Apigenin 
 
 
Flavanones Hesperetin 
 
 
Flavan-3-ols Catechin 
 
Anthocyanins Cyanidin 
 
 
Isoflavones Genistein 
 
Flavonols Quercetin 
 
 
Flavonoids are subjected to extensive metabolism following ingestion. Flavonoid metabolism 
may begin in the oral cavity, with hydrolysis of flavonoid glucosides occurring when they make 
contact with saliva, which possesses strong hydrolic activity (5). In the upper GI tract, evidence 
suggests that only a small proportion of dietary flavonoids are directly absorbed and become 
available to tissues and cells (1-2%). Some flavonoids may be absorbed through the gut and 
once absorbed, they are transported to the liver where they are conjugated, commonly by 
methylation, sulphation and glucuronidation (6). Secretion via the biliary route will expose the 
conjugated compounds to the gut flora and are therefore subjected to reabsorption in the colon 
(6). A significantly greater proportion of dietary flavonoids are passed through the intestine to 
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the colon, where an abundance of colonic microflora metabolise them into a variety of phenolic 
acids and other metabolites (3).  
 
The structures of phenolic acids are related to derivatives of either benzoic or cinnamic acids 
(Figure 4-2), with some common phenolic acid metabolites and their structure is shown in 
Table 4-2. Although the basic skeleton remains the same, the numbers and positions of the 
hydroxyl groups on the aromatic ring produces is responsible for the many different phenolic 
acids (1). Phenolic acids are consumed through their presence in all plant-based foods, in 
addition to their endogenous production via the metabolism of flavonoids. 
 
a)            b)  
Figure 4-2 a) Benzoic Acid Chemical Structure b) Cinnamic Acid Chemical Structure 
(adapted from (1)) 
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Table 4-2 Common phenolic acid metabolites according to Benzoic or Cinnamic Acid 
derivatives 
Benzoic Acid 
Derivatives  
Structure Cinnamic Acid 
Derivatives 
Structure 
Vanillin  
 
Ferulic Acid 
 
Gallic Acid 
 
p-Coumaric 
Acid 
 
Syringic Acid 
 
Caffeic Acid 
 
 
 
It has only been fairly recently that the biological actions of flavonoid metabolites, including 
phenolic acids, has been investigated, meaning their relative contributions to the health benefits 
of a flavonoid rich diet are largely unknown. However, the association of phenolic acids and 
health outcomes has been made, and is largely underpinned by their antioxidant, anti-
inflammatory and anti-proliferative activities (1, 7). Given the vast difference in 
bioavailabilities between flavonoids and phenolic acids, it has been hypothesised that phenolic 
acids may therefore be responsible for the observed health effects of flavonoid consumption. 
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4.2 Biomarker analysis 
Biomarkers are important in the study of the effects of diet on health outcomes. It is usually 
defined as any biochemical measure of events occurring in a biological system following 
dietary exposure to a particular compound (8). 
 
Dietary flavonoid intake can be determined by quantifying biomarkers which include intact 
flavonoids and their derivatives (e.g. phenolic acids) found in plasma, urine and faecal water 
(9).  Many methods of measuring flavonoid biomarkers in human biological samples exist, 
with no standardised protocol of how to perform this analysis. Consequently researchers must 
develop and validate their own methods, limiting the ability to compare studies that have used 
different methods to measure certain biomarkers. As there many thousands of flavonoids 
identified, that are quickly and extensively metabolised into various metabolites, there are 
thousands of potential biomarkers (10). To date, there is no consensus around which flavonoids 
or metabolites are indicative of total dietary intake. 
 
In addition, it is currently unknown which biological sample (plasma, urine or faecal water) 
should be selected and some research suggests each maybe indicative of different consumption 
patterns.  Previous research shows urinary biomarkers may be more reflective of short-term 
intake (11).  The flavonoid content in fasting plasma or faecal water samples seems to be a 
suitable biomarker of short-term intake and a possible biomarker of the medium-term intake 
(11). However, biomarkers of long-term intake are not yet identified and may be unlikely due 
to the short half-lives of dietary flavonoids in vivo. Most of the biomarker analyses are 
expensive and quite often it is not possible to perform them as part of a large epidemiological 
study (12). 
 
4.2.1 Flavonoids as biomarkers 
Measurement of intact flavonoids (generally in a glucuronidated form) provides a potential 
biomarker to assess the intake and biological activities of flavonoid rich foods and can be 
measured in urine and plasma. There is little indication of the expected concentrations of 
flavonoids in biological samples, with examples from current literature highlighted in table 4-
3. Unfortunately, there are few expected flavonoid concentrations in plasma published in the 
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literature. With such a small and variable percentage of flavonoids consumed reaching the 
circulatory system intact (Table 4-3), they may be difficult to measure.  
 
Table 4-3 Concentrations of a selection of flavonoids in human plasma (fasting) 
 
Phenolic compounds 
Plasma 
concentration (nM) 
Mean±SD  
Radtke et al., 2002 (11) 
 
Quercetin 22.87±16.61 
Kaempferol  10.65±7.89 
Naringenin  8.15±15.43 
Hesperetin  22.16±44.85 
Cao et al., 2010 (13) Quercetin 80.23±81.73 
Kaempferol 57.86±60.88 
Isorhamnetin 39.94±45.01 
Apigenin  10.62±12.26 
Luteolin 99.9±97.65 
 
4.2.2 Phenolic acid metabolites as biomarkers 
Phenolic acids can also be measured as metabolic biomarkers of flavonoid intake and can be 
quantified in plasma (14), urine (14) and faecal water (15). Table 4-4 shows the concentrations 
of some phenolic acids in human plasma, measured using a GC-MS technique.  
 
Due to the complexity of plant-based foods, which contain many hundreds of compounds, the 
best metabolite for each flavonoid or flavonoid containing food, and which is indicative of 
dietary intake or reflects the bioactive effects, remains unknown (3, 10). Thus, a ‘metabolite 
profiling’ approach, in which researcher’s measure multiple biomarkers related to flavonoid 
intake, may be a superior method a single biomarker (flavonoid or phenolic acid) to improve 
the specificity of dietary exposure to a compound or food (4, 14).  
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Table 4-4 Concentrations of a selection of phenolic compounds in human plasma 
Phenolic compounds 
Plasma concentration (nM) 
Mean±SEM (range) 
4 ethyl phenol 1749 ± 233 (387, 8713) 
phenyl acetic acid 49411 ± 2559(13160, 97114) 
Catechol 1306 ± 631 (93, 30835) 
3-phenylpropionic acid 682.20±117.19 (192.78, 5504.99) 
t-cinnamic acid 173.20±22.31 (0.00, 640.21) 
3-hydroxyphenylacetic acid 356.51±82.64 (0.00, 2401.27) 
4-hydroxybenzoic acid 2511.89±101.00(1403.93, 4211.34) 
4-methoxyphenylpropionic acid 545.40±77.54 (0.00, 1922.35) 
4-hydroxy 3-methoxybenzoic acid (vanillic acid) 262.83±15.18 (98.72, 465.94) 
2-hydroxycinnamic acid (o-coumaric acid) 590.99±127.40 (0.00, 3417.39) 
3,4-dihydroxybenzoic acid 227.51±18.75 (73.10, 430.01) 
3,4-dihydroxyphenylacetic acid 7.89±2.09 (0.00, 49.68) 
3,4,5-trihydroxybenzoic acid (gallic acid) 5.05±1.73 (0.00, 58.35) 
4-hydroxy 3-methoxycinnamic acid (ferulic acid) 40.12±6.85 (0.00, 193.38) 
3,4-dihydroxycinnamic acid (caffeic acid) 1707.24±595.77 (71.87, 18887.12) 
Values via Dr A Jenner. Personal Communication, 14 April 2011 
 
The rapid and systematic measurement of phenolic acids and flavonoids in biological samples 
is challenging, due to their inherent structural diversity and low concentrations in biological 
samples. A recent review highlighted the numerous and various was in which researchers have 
quantified phenolic acids and flavonoids in samples (both biological and plant-based) (1). They 
concluded that the analytical methods selected by researcher depend on a variety of factors 
including the availability of tools and techniques, the sensitivity needed and the complexity of 
the biological matrix (1, 9). Therefore, generally a combination of a chromatography technique 
with sensitive detection method is utilised.   
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4.3 Gas Chromatography-Mass Spectrometry 
4.3.1 Gas Chromatography  
Various types of chromatography can be used in biomarker analysis (9, 16). The methodology 
related to Gas Chromatography (GC) will be discussed in more detail. A GC system consists 
of carrier gas, an injector, a column (with a stationary phase) and a detector (16) (Figure 4-3). 
 
Figure 4-3 Gas Chromatography system diagram (17) 
 
4.3.1.1 Sample preparation 
Generally, an analyte may have to undergo derivatization to become more suitable for GC 
analysis through making compounds more volatile or less polar, improving thermal stability 
and introducing a marker on the compound that can be detected (18). The derivatization 
reaction commonly occurs by alkylation, silylation, and acylation of polar functional groups.   
 
4.3.1.2 Injection 
The injection of a sample into the GC column involves rapid vaporisation of a liquid sample 
(0.2 – 3µL) and subsequent mixing with a carrier gas, before injection via an inlet into the GC 
column (17). The inlet is heated (to up to 400º Celsius) to ensure that the entire sample 
evaporates quickly and mixes with the carrier gas. Carrier gases (mobile phase) are usually 
very pure (<99.99%) sources of helium, hydrogen, nitrogen or argon, which carry the sample 
through a GC column where it is separated into individual components.  
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4.3.1.3 Column separation 
The column (comprising tubing and a stationary phase) sits in a temperature controlled oven 
that is able to separate compounds based on their solubility and boiling point. As the sample 
reaches the column, it will cool and condense, moving in a tight band around the GC column 
(20). The analytes that are lighter and have lower boiling points will move more quickly around 
the column towards the detector. The oven temperature is pre-determined to rise in a tightly 
controlled temperature program, which is established to manipulate the speed at which 
compounds will be fed through the column, to enhance separation of the compounds of interest 
(20).  
 
4.3.1.4 Detection 
After the separation of the analytes that are eluted from the column, they are individually 
measured in a detector that converts a chemical or physical property into an electrical signal 
(21). A PC based data system is used to process the signal from the GC to determine peak 
areas: peak heights and widths and retention times. The chromatogram, which is the graphical 
representation of the sample elution, is displayed. The height of the peak or the area under the 
peak is used to determine the amount of the compound in the original mixture. Each peak is 
displayed by the exact time it leaves the column and passes to the detector (retention time).The 
retention time provides a qualitative measure of the compound, which can determine the 
presence of a certain compound, by comparing the sample peak times with known reference 
standard peaks times. Analysis of the peak area or peak height quantitates the amount of the 
sample component. Standard amounts of the compounds can be used as a reference to make a 
calibration curve to produce quantitative results for each calibration peak. Comparison of the 
peaks produced by a sample to the calibration curve indicates the amount of the compound of 
interest in the sample mix. 
 
4.4 Mass spectrometry 
Mass spectrometry (MS) is an analytical quantification technique designed to identify 
molecules by measuring their mass-to-charge ratio (m/z). MS is highly regarded as a sensitive 
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and quick analytical method, with a particular strength in application for biochemical 
compound analysis (22). The principle of this technique is to ionize the molecules and create 
smaller fragments, which can then be identified by molecular mass (21). The three essential 
components of a mass spectrometer are the ion source, which converts the molecules into ions; 
a mass analyser, which sorts the ions depending on their mass and charge and finally; a detector 
that quantifies the amount of each ion (21) (Figure 4-4). 
 
 
Figure 4-4 Schematic diagram of a Mass Spectrometer (23) 
 
4.4.1.1 Triple Quadrupole Mass Spectrometer 
In a triple quadrupole mass analyser is a tandem mass spectrometer consisting of two 
quadrupole mass analysed with a collision chamber between them. Essentially, the triple 
quadrupole mass spectrometers operate under the same pretence as the single quadrupole mass 
analyser. However, a triple quadrupole mass analyser has the advantage of being more sensitive 
and is able to detect smaller low energy low molecule reactions, which is useful when small 
molecules are being analysed.  
 
4.4.1.2 Ionisation 
Ionisation is the first step in MS analysis, which acts to produce gas-phase ions of the 
compound of interest. In the ionisation source, the sample molecule is bombarded with a high-
energy electron beam to form a radical cation (also called a parent/precursor ion). The process 
leaves the molecule with an excess of energy, leading to instability and fragmentation of the 
molecule into various pieces (product ions). Fragmentation provides a unique 'fingerprint' for 
that molecular structure, resulting in ion fragments with a certain mass and charge (m/z). Many 
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impacts occur simultaneously, generating numerous different ions and fragments for each 
compound. 
4.4.1.3 Mass Filtration/Mass Analyser 
The positive ions which are formed in the ioniser, are accelerated down a curved tube (deflected 
by a magnet) into the mass analyser where they are separated in space, and are then identified 
based on their mass/charge ratio (21). Lighter ions will be deflected to a greater extent than 
heavier ions and a ‘mass spectrum’ is created by the different mass ions that are detected.  
 
4.4.1.4 Detection 
After the ions are separated they enter a detector and a ‘mass spectrum’ is produced. The x-
axis represents the m/z ratios. The y-axis represents the signal intensity (abundance) for each 
of the fragments detected during the scan. A computer database of mass spectra can be used to 
match compounds in an unknown sample. 
 
4.4.2 Benefits of combining GC with MS for measuring phenolic acids in biological samples 
The combined GC-MS procedure is very useful when dealing with a sample that is a mixture 
of two or more different compounds, as the various compounds are separated from one another 
before being subjected individually to MS analysis. Combining GC and MS have great 
advantages when analysing biological metabolites due to its high sensitivity and specificity. 
High specificity (24) is desirable in an analytical method to accurately positively identify the 
presence of a particular substance. A high sensitivity is necessary in assessments where the 
biological concentrations are low, and only a small amount of biological is sample needed for 
a reliable quantitative analysis (22). Additionally, there are extensive compound databases and 
experimental protocol available to researchers developing this technique (22). Less favourable 
attributes of GC-MS includes the need to derivatize samples to improve their volatility and 
thermal stability before injection, which is labour-intensive and may produce derivatives that 
will obstruct the quantification (9, 25).  
 
While many analytical investigations into phenolic acids and flavonoids have been reported 
(9), there is no gold standard method for their separation and quantification in biological 
samples, leaving researchers to develop their own techniques.  
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4.5 Aim 
The aim of this work was to develop a sensitive method for analysing various phenolic acids 
and flavonoids in biological samples using a standardised method with a GC-MS triple 
quadrupole mass analyser.  
The objectives of the study were to: 
1. Develop a library of spectra (database) to provide a reference for the identification of 
compounds in future analysis; 
2. Optimise the programs for the GC and MS portions of the analysis for the separation 
and detection of phenolic acids and flavonoids. 
 
4.6 Methods 
4.6.1 Materials 
The instrument used was an Aligent 7000 GC/MS-Triple Quad, stationed at University of 
Wollongong, Australia. The separation was carried out on 30 m long capillary column with a 
diameter of 0.25 mm. The stationary phase was made up of a 0.25µM thick 5% phenyl 
methylpolysiloxane film and 1 µl was injected through a splitless inlet. Helium was used as 
carrier gas with a flow rate at 1.2 ml/min. Positive chemical ionisation (PCI) was used and the 
reagent gas in the ionisation chamber was methane. Argon gas was used in the collision 
chamber in the mass analyser. 
 
4.6.2 Preparation of standards for database 
To create an in-house library of spectra, injections of pure standards need to be processed for 
reference. For an adequate database, all patterns of the retention times of compounds and the 
mass spectrum of the pure standard need to be recorded.  
 
Reference compounds of flavonoids and phenolic acids (full list in Table 4-5) were dissolved 
in an appropriate medium (acetonitrile, methanol or isopropanol) and made up to a 
concentration of 25mM. Seven internal standards were used for quantification (d5-benzoic 
acid; phenyl-d7 acetic acid; 3-phenyl-d9 propionic acid; t-cinnamic acid (phenyl-d7); 2-OH,6-
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MeO benzoic acid; 2,4,5-triMeO cinnamic acid and 6-methylflavone) and were prepared in the 
same way. Internal standards are added in a constant amount to the samples, the blank and the 
calibration standards and are used to account for the loss of analyte during processing.  
 
Each compound was added to individual vials and dried off in a heater, before adding 10 µl of 
acetonitrile and 30 µl of derivatizing agent N,O-bis-(trimethylsilyl)-trifluoroacetamide 
(BSTFA). The samples were incubated for five hours before injecting to the GC-MS. 
Assessment of retention times was conducted and the mass spectrum for each compound was 
determined. As a compound's spectrum is very reliable and reproducible, the instrument can 
search the database and identify each compound in the sample, based on similarities within the 
database.  
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4.7 Results 
4.7.1 Assessment of retention times 
The first step in this process is o optimise the separation of the compounds using GC. A mixture 
of all compounds was made and analysed with various temperature programs designed to 
improve the separation of compounds, so each compound elutes at a different time. Trial-and-
error was used to optimise the separation. The initial temperature programs tested were based 
on the method Jenner, Rafter and Halliwell (2005) (15), with some adjustments, resulting in 
retention times (in minutes) as per Table 4-5.  An example of the output for the elution from 
the GC for Cinnamic Acid at 8.6minutes is shown in Figure 4-5. 
 
 
Figure 4-5 Elution time for Cinnamic Acid (8.6m) 
 
  
  
147 
 
Table 4-5 The 115 reference compounds, retention times and selected transitions comprising 
the in-house database 
Compound 
Retention Time 
(m) 
Transition 
4-ethyl phenol 3.47 194.1 -> 179.1 
benzoic acid - d5 3.55 184.1 -> 110.1 
benzoic acid 3.57 179.1 -> 105.1 
catechol (1,4-diOH benzene) 3.78 254.2 -> 239.2 
phenyl acetic acid - d7 4.2 200.1 -> 172.1 
phenyl acetic acid 4.26 193.1 -> 165.1 
1,3,5-triMeO benzene 5.9 168.1 -> 139.1 
3-phenylpropionic acid - d9 6.1 231.2 -> 112.1 
3-phenylpropionic acid 6.2 222.2 -> 104.1 
4 ethyl benzoic acid 6.95 207.1 -> 133.1 
2 MeO benzoic acid 7.05 209.1 -> 135.0 
3,4-diMeO phenol 7.1 226.1 -> 221.0 
1,2-diOH, 3-MeO benzene 7.15 284.1 -> 269.0 
1,4-diOH, 3-MeO benzene (3-MeO catechol) 7.2 284.1 -> 269.0 
3-MeO benzoic acid 7.3 209.1 -> 135.0 
2-MeO phenyl acetic acid 7.73 238.1 -> 179.1 
3,5-diMeO benzene 7.85 226.1 -> 211.0 
2-OH benzoic acid 7.9 209.1 -> 165.1 
4-MeO benzoic acid 8 209.1 -> 165.1 
2-MeO phenyl acetic acid 8.3 238.1 -> 194.1 
4-OH, 3-MeO benzaldehyde (vanillin) 8.49 224.1 -> 209.1 
t-cinnamic -d7 8.55 212.1 -> 168.1 
t-cinnamic acid 8.6 205.1 -> 161.1 
4-MeO phenyl acetic acid 8.63 238.1 -> 194.1 
pyrogallol (1,2,4 tri-OH benzene) 8.7 239.1 -> 211.1 
3-OH benzoic acid 9.1 267.1 -> 223.1 
2,3-diMeO benzoic acid 9.6 239.1 -> 224.1 
2-MeO phenylpropionic acid 9.75 252.1 -> 134.1 
2-OH phenylacetic acid 9.8 296.1 -> 252.1 
3-OH phenyl acetic acid 9.9 296.1 -> 252.1 
3,4-diOH benzaldehyde 9.95 282.1 -> 267.1 
4-OH benzoic acid - d4 10.32 271.1 -> 227.1 
4-OH benzoic acid 10.38 267.1 -> 223.1 
3-MeO phenylpropionic acid 10.46 252.1 -> 134.1 
2,6-diMeO benzoic acid 10.48 254.1 -> 239.1 
4-OH phenyl acetic acid 10.58 296.1 -> 252.1 
4-OH phenyl-2-propionic acid 10.7 310.1 -> 193.1 
1,3,5-triOH benzene (phloroglucinol) 10.87 342.1 -> 327.1 
4-MeO phenylpropionic acid 10.92 252.1 -> 134.1 
2,5-diMeO benzoic acid 11.1 254.1 -> 224.1 
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2-OH,6-MeO benzoic acid (IS1) 11.75 297.1 -> 249.1 
3,5-diMeO benzoic acid 11.85 254.1 -> 239.1 
2,OH,5-MeO benzoic acid 11.9 297.1 -> 249.1 
3,4-diMeO benzoic acid 12.1 239.1 -> 195.1 
3,4-diMeO phenylacetic acid 12.2 268.1 -> 268.1 
3-OH phenylpropionic acid 12.35 310.1 -> 192.1 
2,3-diOH benzoic acid 12.8 355.1 -> 249.1 
3,4,5-triMeO benzoic acid 13 284.2 -> 269.1 
1,3,5 triMeO benzoic acid 13.1 284.2 -> 269.1 
3-OH,4-MeO benzoic acid (isovanillic acid) 13.15 312.1 -> 297.1 
2,6-diOH benzoic acid 13.17 355.1 -> 249.1 
4-OH phenyl propionic acid 13.2 310.1 -> 192.1 
4-OH,3-MeO benzoic acid (vanillic acid) 13.3 282.1 -> 267.1 
2,3,4-triMeO benzoic acid 13.31 284.1 -> 269.1 
(H) homovanillic acid-d3 13.32 270.1 -> 179.1 
4-OH,3-MeO phenylacetic acid (homovanillic 
acid) 
13.34 267.1 -> 179.1 
2,5-diOH benzoic acid 13.45 355.1 -> 297.1 
2-OH cinnamic acid (o-coumaric acid) 13.98 293.2 -> 147.1 
3-MeO cinnamic acid 14.05 235.1 -> 191.1 
3,5-diOH benzoic acid 14.25 370.1 -> 355.1 
3,4-diOH benzoic acid 14.32 370.1 -> 193.1 
2,4-diOH benzoic acid 14.35 355.1 -> 281.1 
4-MeO cinnamic acid 14.36 235.1 -> 191.1 
3,4-diOH phenylacetic acid 14.45 369.1 -> 179.1 
4,5-O-diMe gallic acid 14.5 312.1 -> 297.1 
Shikimic acid 14.6 357.1 -> 147.1 
3,4,5-triMeO phenylacetic acid 14.7 298.1 -> 239.1 
3,4-O-diMe gallic acid 14.9 312.1 -> 297.1 
3-OH cinnamic acid 15 308.2 -> 293.2 
2,4,5-triMeO benzoic acid 15.08 284.2 -> 269.1 
4-OH,3-MeO phenylpropionic acid 15.16 310.1 -> 192.1 
4-O-Me gallic acid 15.2 370.1 -> 355.1 
3,5-O-diMe gallic acid (syringic acid) 15.4 312.1 -> 297.1 
2,3,4-triOH benzoic acid 15.65 443.1 -> 281.1 
4-OH cinnamic acid (p-coumaric acid) 15.76 293.1 -> 249.1 
3-O-methyl gallic acid 15.84 400.1 -> 223.1 
3,4-diOH phenyl propionic acid 15.85 412.1 -> 412.1 
3,4,5-triMeO cinnamic acid 15.9 310.1 -> 295.1 
3,4,5-triMeO phenylpropionic acid 15.95 312.1 -> 194.1 
3,4,5-triOH benzoic acid (gallic acid) 16.03 458.1 -> 281.1 
(H) 3,4-diMeO cinnamic acid-13C3 16.4 283.1 -> 268.1 
3,4-diMeO cinnamic acid 16.45 280.1 -> 265.1 
3,5-diMeO cinnamic acid 16.5 280.1 -> 265.1 
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4-OH,3-MeO cinnamic acid (ferulic acid) 16.85 308.1 -> 293.1 
3-OH,4-MeO cinnamic acid (Isoferulic acid) 16.95 308.1 -> 293.1 
3,4-diOH cinnamic acid (caffeic acid) 17.26 396.1 -> 219.1 
2,4,5-triMeO cinnamic acid (IS2) 17.5 310.1 -> 279.1 
3,5-diMeO, 4-OH cinnamic acid 17.7 368.1 -> 338.1 
flavanone 18.4 222.0 -> 194.0 
diethyl stilbestrol 18.5 412.2 -> 383.2 
6-methylflavone 19.1 236.1 -> 208.1 
Resveratrol 20.1 444.2 -> 355.2 
Phloretin 20.2 342.2 -> 327.2 
Formononetin 20.6 340.2 -> 267.1 
Epicatechin 20.9 650.2 -> 355.2 
Naringenin 20.95 560.2 -> 545.2 
Catechin 21.05 650.2 -> 355.2 
Biochanin A 21.06 413.2 -> 398.2 
Genistein-d4 21.38 475.1 -> 403.1 
Hesperetin 21.4 575.1 -> 545.1 
Genistein 21.41 471.2 -> 399.1 
Daidzin 21.55 398.1 -> 383.1 
Taxifolin 21.57 649.1 -> 368.1 
Eriodictyol 21.59 560.2 -> 369.0 
Kaempferol 22.25 559.2 -> 487.2 
Chlorogenic acid 22.3 345.1 -> 255.1 
Apigenin 22.7 471.1 -> 399.1 
Quercitin 23.08 647.2 -> 575.2 
Isorhamnetin 23.15 589.2 -> 559.2 
Diosmetin 23.5 501.2 -> 471.2 
Myricetin 23.5 647.2 -> 575.2 
Luteolin 23.75 559.1 -> 399.1 
Diosmetin 23.5 500.5 -> 471.0 
Myricetin 23.5 734.5 -> 647.0 
Luteolin 23.75 574.5 -> 559.0 
 
The final temperature program is described in Table 4-6. The sample was injected at an initial 
oven temperature of 100ºCelcius and held for 1.5 minutes. The ramp rate was then raised at 
various increments until the oven reached 262ºCelcius, where it was held for 4minutes, and 
then raised again to reach 290ºCelcius and held for 3 minutes to achieve adequate separation 
of the compounds.  
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Table 4-6 Final temperature program utilised to achieve adequate separation of compounds 
Ramp rate Next Temp Hold 
Actual Run 
Time 
(ºCelcius/min) (ºCelcius) (min) (min) 
  100 1.5 1.5 
10 140 0 5.5 
15 150 0 6.17 
2 160 0 11.17 
15 215 0 14.84 
20 262 4 21.19 
10 290 3 26.99 
 
4.7.2 Precursor ion identification 
After separation by GC, the molecules are eluted into the MS. The MS first operates by 
selecting precursor ions of a specific mass, to separate the ions from the chemical background. 
To identify the most appropriate precursor ion of the compounds, the mass analyser was set in 
an all-scan mode without any collision energy. For each of the compounds, the precursor ion 
was identified in the spectrum. An example of this scan output is in Figure 4-6, for Cinnamic 
Acid at 8.6m.  
 
From the obtained spectrum for each compound, four ions were selected to be used in further 
collision experiments to identify appropriate product ions for each precursor ion. The criteria 
for selecting ions were to be abundant and of high mass. For example, the ions selected for 
cinnamic acid were m/z 220, 205,161 and 145 (Figure 4-6).  
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Figure 4-6 Mass spectrum for Cinnamic Acid at 8.6m 
  
 
4.7.3 Collision energy experiments 
The precursor ions are then induced to further dissociate through collision energy experiments 
(Figure 4-7), with all compounds and their four respective ions being analysed in separate 
experiments with four different collision energies (2, 6, 15 or 30 eV). This experiment is used 
to evaluate the best product ion generated from each identified precursor ion for each 
compound.  The most appropriate collision energy generates a fragment that is smaller than the 
precursor ion, but still of reasonably high mass and abundance. This result is called a 
‘transition’, which is written as precursor ion mass-> product ion mass, with each compound 
providing a unique ion spectrum.  
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Figure 4-7 Collision energy experiment output for Cinnamic acid; the ions in each collision 
experiment are 220, 205, 161, 145 at CE 2, 6, 15 and 30 eV. 
 
After the initial collision energy experiments, a multiple reaction monitoring (MRM) 
experiment  is conducted to assess the most suitable collision energy from nine different 
collision energies (2.5, 5, 7.5, 10, 15, 20, 25, 30, 40 eV) for each selected transition. The 
collision energy which produces the greatest signal detected is selected as the most appropriate. 
An example of Cinnamic Acid is shown in Table 4-7.  
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The most appropriate transition and corresponding collision energy to be utilised is selected 
for each compound and is recorded for application in future analysis. The most appropriate 
transition for each compound analysed was selected and is displayed in table 4-5. 
 
Table 4-7 MRM experiment output for all Cinnamic Acid transitions 
Transition  
(precursor ion -> product ion) 
Collision Energy Signal 
205.0 -> 161.2 4 1300000 
205.0 -> 145.1 14 5200000 
205.0 -> 131.1 14 13000000 
205.0 -> 103.1 32 11000000 
220.0 -> 205.1 4 3000000 
220.0 -> 192.1 0 450000 
220.0 -> 161.2 14 1300000 
220.0 -> 135.2 4 1300000 
220.0 -> 103.2 36 1100000 
220.0 -> 75.2 24 380000 
220.0 -> 73.2 24 90000 
161.0 -> 145.1 4 7600000 
161.0 -> 135.2 14 200000 
161.0 -> 159.2 4 1300000 
161.0 -> 105.1 32 710000 
161.0 -> 59.2 16 3700000 
145.1 -> 119.1 18 1400000 
145.1 -> 129.1 36 340000 
145.1 -> 105.1 24 720000 
145.1 -> 93.1 32 700000 
 
Finally, calibration curves were analysed using a blank matrix sample to determine whether 
the compounds added to the analysis were present. Calibrations curves for all compounds were 
obtained, with most producing good linearity, and some showing mixed linearity.  
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4.8 Discussion 
The chapter initially describes the potential of measuring flavonoids and phenolic acids in 
biological samples as biomarkers of flavonoid intake, and the characteristics of GC-MS as a 
method to measure flavonoid intake are explained and evaluated. Additionally, this chapter 
describes the development of a GC/MS technique for the detection of 115 phenolic acids and 
flavonoids in biological samples via the construction of an in-house database of spectra and 
optimisation of the GC and MS methods. This method has been applied to measure some 
specific phenolic acids in human plasma to confirm the consumption and uptake of potential 
bioactive compounds in an anthocyanin-rich cherry juice, described in chapter 6 of this thesis, 
and the details of its application are reported in chapter 6.  
 
A  GC-MS method for the determination of phenolic acids and flavonoids in biological samples 
provides a sensitive and specific technique (24) and is a superior method for the separation of 
compounds (24). A sensitive and specific tool for the measurement of phenolic acids and 
flavonoids in biological samples is important, as the compounds are structurally similar and 
are present at micromolar to sub-micromolar levels (24).  
 
The ability of a GC-MS method to measure biomarkers to provide an accurate indication of 
total dietary flavonoid exposure or quantify the intake of specific subclasses requires further 
investigation. However, the potential of biomarkers to indicate dietary intake of specific foods, 
such as tea (26), is more frequently studied, and more thoroughly understood. 
 
Given the limitations that surround dietary measurement of flavonoids, it is important to 
develop methods to investigate the impact of flavonoids on health through measurement of 
intact flavonoids or related metabolites (to be used in conjunction or as stand-alone measures).  
The development of dietary biomarkers as an objective measure of food intake or exposure to 
bioactive molecules (4) is of significance for dietary studies, and in particular are useful when 
little data exists surrounding bioactive molecules and their metabolism (4).  
 
Traditionally, a single biomarker is selected to measure dietary exposure to a food component. 
For example, vitamin C is often used as a measure of fruit consumption (4).  However, early 
metabolomics studies have indicated that the use of a combination of several biomarkers may 
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improve the specificity of dietary exposure measurements (4), and could be applied when 
investigating the intake of single compounds, foods or potentially even dietary patterns.  
 
4.8.1 Conclusion 
The limited knowledge regarding which biomarker(s) are indicative of total dietary flavonoid 
intake, or which biomarkers should be measured to provide a relevant indication of the 
bioactive components of a particular food, a comprehensive method that can quickly and 
reliably measure multiple biomarkers of intake would be valuable in human trials.  In this 
instance, the developed method has the potential to measure up to 115 possible biomarkers, 
which has a large applicability for exploratory ‘metabolomics’ related studies.  
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CHAPTER 5: FOOD-BASED ANTHOCYANIN INTAKE AND COGNITION IN 
HUMAN INTERVENTION TRIALS: A SYSTEMATIC REVIEW 
 
Pre-clinical evidence suggests anthocyanins, a subclass of dietary flavonoids, that provide the 
purple and red pigmentation in plant-based foods, may beneficially impact cognitive outcomes. 
A systematic review was conducted to summarise and synthesise the published literature on 
food-based anthocyanin consumption and cognitive outcomes in human intervention trials. 
Four studies were included in this review, comprising acute trials (n=2) and longer-term (n=2) 
interventions which assessed multiple cognitive outcomes in children, adults and older adults 
with cognitive impairment. Three out of 4 studies reported improvements in either a single, or 
multiple cognitive outcomes after anthocyanin-rich food consumption. Due to methodological 
limitations and the large clinical and methodological diversity of the studies, pooling of data 
was not feasible. The impact of food-based anthocyanin consumption on both acute and long-
term cognition appears promising. However, adequately powered studies that include sensitive 
cognitive tasks are needed to confirm these findings and allow translation of research into 
dietary messages. 
 
This manuscript has been updated and submitted for publication (Appendix G) : 
Kent, K, Charlton, K, Netzel, M, Fanning K 2015. The impact of food-based 
anthocyanin consumption on cognition in human intervention trials: a systematic 
review. (Journal of human nutrition and dietetics) 
 
KK designed and conducted the review, and prepared the manuscript. KC, MN and KF 
provided critical revisions of the manuscript. 
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5  
5.1 Introduction 
The rapidly aging population has led to a major projected increase in the prevalence of neuro-
degenerative diseases such as dementia (1), and resulted in intense research interest regarding 
the role of diet in neuro-protection. Dietary approaches are highly regarded as safe and effective 
methods for the prevention of cognitive disorders and the maintenance of cognitive function. 
The consumption of dietary flavonoids has been shown to both enhance cognitive function (2) 
and prevent age-related cognitive decline in older adults (3). The neuroprotective effects of 
flavonoids have been well-documented (4-8), but most of the research has focused on animal 
models, limiting translation to humans who utilise more complex cognitive domains, such as 
executive functioning. Due to their strong antioxidant potential (9), it has been hypothesised 
that flavonoids limit neurodegeneration by reducing neuroinflammation and protecting cellular 
architecture in the brain (10). Flavonoids may also contribute to improved cognitive function 
by increasing the number and strength of neuronal signals (11), through increased brain blood 
flow (7) and an ability to initiate neurogenesis (5) in areas of the brain that are associated with 
learning and memory. A large proportion of this research has specifically highlighted the 
benefits of anthocyanin-rich foods (12-15). 
 
Anthocyanins are a subclass of dietary flavonoids (different from proanthocyanidins, which 
are polymers of flavanols), which provide the purple, red and blue pigmentation in plant based 
foods (16). Typical food sources of anthocyanins are fruits such as apples, grapes, plums; 
berries including strawberries, blueberries and blackberries; vegetables such as red cabbage, 
red onion, eggplant, and beverages including red wine and grape juice (17). Approximately 
640 individual anthocyanins have been identified to date(18), however anthocyanins naturally 
occur most ubiquitously in six common agylcones (pelargonidin, cyanidin, delphinidin, 
peonidin, petunidin, malvidin) in various glycosylated and acylated forms (18).  Anthocyanins 
are unique among flavonoids due to their ability to reversibly change their structures in 
response to changing pH values, from the stable red to orange coloured flavylium cation at pH 
<2 to the colourless and less stable carbinol and chalcone forms at higher or neutral pH (18-
20). This unique feature may impact their stability and binding ability (e.g. to enzymes) 
throughout the gut which has a dramatically changing pH environment (“acid” stomach to 
“neutral” intestine).  
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The metabolism, absorption and bioavailability of anthocyanins is unique to other flavonoids 
and has been well documented (21). Briefly, food based anthocyanins are consumed and are 
either quickly absorbed as intact molecules via the stomach, or after extensive metabolism in 
the small and large intestine or the colon, to enter the circulation as metabolites such as phenolic 
acids (21). In previous animal and human studies, only very low amounts of intact (non-
metabolised) anthocyanin glycosides could be detected in plasma and urine after ingestion of 
pure anthocyanin compounds and/or anthocyanin-rich food and beverages (15 animal and 17 
human bioavailability studies were comprehensively reviewed by Pojer et al., 2013(19)). 
However, recent human studies have clearly demonstrated that dietary anthocyanins undergo 
intensive metabolism after consumption and that those metabolites are the main transport forms 
in vivo (22-25). For example thirty-two anthocyanin-derived metabolites could be detected in 
urine, serum and faeces of eight healthy volunteers after the consumption of 500 mg of 13C-
labelled cyanidin-3-glucoside(23). In another study published by Ludwig et al. (22)17 
metabolites were quantified in urine collected from nine volunteers after the consumption of 
300 g blended raspberries(22). Previously, bioavailability of  anthocyanins was considered to 
be  very low (urinary recoveries <2% of intake in most studies) but is now estimated as being 
at least  15% if   detectable in vivo metabolites are also taken into account(22).  
 
The main biological activity of anthocyanins in vivo was thought to be their antioxidant 
capacity and protection against lipid peroxidation (26). However, recent studies have identified 
more complex molecular effects of anthocyanins on signalling pathways in cells that may play 
a significant role in their protection against chronic diseases (19, 26, 27). Modulation of 
neuronal functions by anthocyanin-rich food has been reported in several animal studies (cited 
and reviewed by Pojer et al., 2013(19)). It is suggested that these neuroprotective effects (e.g. 
improved memory, learning, cognitive and motor functions) by anthocyanins (and/or their in 
vivo metabolites) are mediated by their ability to cross the blood-brain barrier and act to 
inhibit/supress interleukin-1b (IL-1b), tumor necrosis factor-alpha (TNF-α), and nuclear factor 
kappa B (NF-κB) (19). Furthermore, modulatory effects of anthocyanins on important 
structural and synaptic plasticity markers have also been reported. 
 
A body of evidence about the benefits of anthocyanin consumption in human health, including 
protective effects against age-related neurodegeneration and cognitive decline, has been 
accumulating over the past few years (16, 19). Animal studies have provided evidence that 
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anthocyanin-rich food consumption can improve several cognitive functions, including long-
term memory (28), spatial-working memory (29), object-recognition memory (30). In addition, 
improvements in motor performance (i.e. balance and coordination) have been documented 
after an anthocyanin-rich blueberry supplemented diet in an animal model (14). Intact (non-
metabolised) anthocyanins  were  been detected in the brains of rats as soon as ten  minutes 
after their consumption, and these concentrations were found to be correlated with 
improvements in learning and memory tasks (13). Of particular interest is that supplementation 
of the diet with anthocyanin-rich fruits, such as blueberries and strawberries, has been shown 
to not only maintain, but also reverse, age-related cognitive decline in animal models (11, 31, 
32).  
 
A large epidemiological study of 16,010 older women enrolled in the Nurses Health Study 
reported significant associations between anthocyanin-rich blueberry and strawberry 
consumption and maintenance of cognitive function (a composite score of 6 cognitive tests, 
including various measures of memory) over 4 years (33). It was reported that those who 
consumed the highest amount of berries had delayed cognitive aging by up to 2.5 years, 
compared to those who ate the least (33). Despite their known health benefits, anthocyanins 
are often overlooked in human intervention trials that investigate the impact of overall 
flavonoid intake on cognitive outcomes (34). In a 2009 systematic review of human 
intervention trials assessing the impact of flavonoids on cognitive outcomes (34), no studies 
related to anthocyanins were included. 
 
There has been an  increasing interest in other areas of anthocyanin research, with  a 15-fold 
rise in the number of published papers between 1990 and 2013 having the word “anthocyanin” 
in their title and abstract (35) Important advances in an increased understanding of the 
bioavailability and metabolism of anthocyanins (e.g. biotransformation by the gut microbiota), 
coupled with a greater focus on the role of plant foods in brain health (e.g. neuroprotective 
activities), warrant a targeted review to summarise the evidence to date of human trials on 
anthocyanins and cognitive function.  
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5.2 Objective 
The aim of this systematic review is to summarise and synthesise the published literature on 
food-based anthocyanin consumption and cognitive outcomes in human trials. The objectives 
of the review are to: 
a) Examine the effects of food-based anthocyanin consumption on cognition and; 
b) Highlight the gaps in the literature and address the implications for future studies 
 
5.3 Methods 
A systematic review of the literature was performed using the following strategy. 
5.3.1 Types of studies 
Studies were considered for inclusion in this review if they:  
 had an experimental design (randomised or non-randomised controlled trials; cross-
over trials)  
 examined humans (any age, gender); 
 administered an anthocyanin-containing food or beverage (amount of anthocyanin 
objectively measured); 
 measured change in cognitive function using a single, or multiple valid and reliable 
tool/s; 
 included a control group; 
 had full text available. 
 
Only studies written in the English language were considered due to a lack of translational 
resources, but studies from any country were eligible if they met the rest of the inclusion 
criteria.  
5.3.2 Search terms 
The following search terms were developed: 
 Anthocyan* and/or 
 Flavonoid* and 
 Cognit* and/or 
 Memory 
The * indicates a truncation, to ensure all variations of the search terms were included.  
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5.3.3 Databases 
A three stage search was conducted. Firstly, a search of the following databases (abstract, title 
and keywords) was performed using the search terms using the Boolean terms AND/OR as 
appropriate (Table 5-1): 
 Scopus (1960 – Sept 2015) 
 Medline (1960 – Sept 2015) 
 CINAHL (1960 – Sept 2015) 
 Psychology and Behavioural Sciences Collection (1960 – Sept 2015) 
 PsychInfo (1860 – Sept 2015) 
 Web of Science (1965- Sept 2015) 
Note: the differing search years relate to the database availability 
 
The second stage consisted of a hand search of the reference list of identified studies. A third 
search consisted of an internet search to identify any studies published outside the realms of 
the available databases. This website searched was google scholar (www 
scholar.google.com.au) using the aforementioned key words (1960-Septermber 2015). The 
records were managed in EndNote X4 software. 
 
5.4 Results 
The search (Table 5-1) returned 1,684 articles, and one other potential study was identified 
through hand-sorting of reference lists. After duplicates were removed and the titles screened, 
32 potential studies were identified. After screening abstracts a further 25 were excluded (Table 
5-2) and after reading the full text articles of 7 studies, a further three were excluded (Table 5-
2) according to the inclusion/exclusion criteria, leaving four final papers in the review (Figure 
5-1). 
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Figure 5-1 PRISMA flowchart for the search and study selection process of included and 
excluded studies 
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Table 5-1 Search strategy results 
  Terms 
# 
Results 
PsychInfo 
1 
anthocyan*.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
38 
2 
flavonoid*.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
285 
3 
memory.mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
182671 
4 
cognit*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
445379 
5 1 or 2 315 
6 3 or 4 556903 
7 5 and 6 87 
Medline, CINAHL, Psychology and 
Behavioral Sciences Collection 
S3 (memory OR cognit*) AND (S1 AND S2) 639 
S2 memory OR cognit* 663,419 
S1 anthocyan* OR flavonoid* 54,144 
Web of science 
3 
#2 AND #1 
61 
Indexes=SCI-EXPANDED, SSCI Timespan=All years 
2 
(TI=(cognit*) OR TI=(memory)) AND LANGUAGE: (English) 
20,397 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC 
Timespan=All years 
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1 
(TI=(anthocyan*) OR TI=(flavonoid*)) AND LANGUAGE: (English) 
298,592 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC 
Timespan=All years 
Scopus  
( ( TITLE-ABS-EY ( anthocyan* ) OR TITLE-ABS-KEY ( flavonoid* ) ) ) AND 
( ( TITLE-ABS-KEY ( cognit* ) OR TITLE-ABS-KEY ( memory ) ) ) 
897 
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Table 5-2 Excluded studies 
  Study reference Reason 
Excluded after 
abstract reviewed 
1 (36) No measure of cognition 
2 (37) No measure of anthocyanin in apples 
3 (38) Animal study 
4 (39) Not primary research 
5 (40) Not primary research 
6 (41) Animal study 
7 (42) Conference abstract 
8 (43) Animal study and non-food based 
9 (44) Conference abstract and study design 
10 (45) Review, not anthocyanin specific 
11 (46) Conference abstract 
12 (47) Editorial 
13 (48) Review of blueberries, not focussed on cognition 
14 (49) Full text cannot be found 
15 (50) Animal study 
16 (51) Pomegranate extract in pill form 
17 (52) Narrative review focussed on animal studies (small section 
on Krikorian papers identified) 
18 (53) Animal study 
19 (54) Review of grape products, not focussed on cognition 
20 (55) Review of animal studies 
21 (56) Animal study 
22 (57) Intervention not flavonoid related 
23 (58) Review, cognitive outcomes not addresses 
24 (59) Review, not food vehicle 
25 (60) Animal study, black soy contains no anthocyanin 
Excluded after full 
text retrieved 
26 (61) No measure of anthocyanin in juice 
27 (62) No measure of anthocyanin in juice 
28 (63) No measure of anthocyanin in juice 
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5.4.1 Description of studies 
Four studies were deemed eligible for the review (64-67). For this review, statistical pooling 
of the data was not possible due to the large clinical and methodological diversity (variability 
in the participants, interventions, study design and outcomes studied) leading to a lack of 
homogeneity of the studies, therefore the findings are presented in a narrative form. The 
characteristics of each study are described in Table 5-3 and relevant information summarised 
in Table 5-3. The publication dates ranged from 2010-2015. Of the four included studies, two 
were randomised, double blind, placebo controlled studies (64, 65) that assessed chronic daily 
consumption of anthocyanin-rich juices on cognitive outcomes, and one was a randomised (67) 
and the other a non-randomised (66) placebo-controlled crossover trial that assessed the acute 
impact of anthocyanin rich juices on cognitive outcomes. Two studies investigated older adults 
with mild-cognitive impairment (MCI) (64, 65), one study was conducted in young, healthy 
adults (67) while another was undertaken in children aged 8-10y (66). The studies were 
undertaken in New Zealand (67), the USA (64, 65) and the UK (66).  
 
5.4.2 Description of the interventions 
In all four studies, the vehicle for anthocyanin administration was a beverage. Two studies 
utilised a pre-formulated juice (64, 65) and placebo control, one study (67) utilised a juice 
processed from fresh fruit (150g fruit yielded ~140ml juice) and a powdered fruit extract made 
up with water, and one study (66) blended fresh fruit into a smoothie. Two studies based the 
beverage serving size on the body weight of each participant (64, 65) providing between 6ml 
– 9ml of juice/kg body weight of juice (providing between 428mg-598mg anthocyanin/day 
divided over three servings). One study (67) altered the serving sizes of the juice to consistently 
deliver 525±5 mg of polyphenols per 60 kg of bodyweight per participant. One study (68) 
administered a standard serving size to each participant (143mg anthocyanin/serve), regardless 
of body size.  
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Table 5-3 Included studies 
Author Participants Design Intervention Dose Cognitive tests Results 
Krikorian 
et al., 
2012 (64) 
Krikorian et 
al., 2012 (64) 
21 older 
adults, 68y+, 
mild 
cognitive 
impairment 
(clinical 
dementia 
rating scale) 
Randomised 
double-blind 
placebo controlled 
trial 
16 weeks, daily 
consumption of 
concord grape 
juice (n=10) vs 
placebo (n=11) 
(colour, taste, 
calorie & sugar 
matched) 
Anthocyanins: 425mg/L 
(spectrophotometry). 
Serving size calculated to 
be between 6 & 9ml/kg 
body weight over 3 
servings/day 
Baseline & 16 weeks: 
California Verbal 
Learning Test II (verbal 
learning & memory), 
Geriatric depression scale 
(mood), Sub-group (4 per 
group) fMRI brain 
imaging 
Krikorian 
et al., 
2010 (65) 
Krikorian et 
al., 2010 (65) 
9 older adults 
(5 men, mean 
age 76.2±5.2) 
mild 
cognitive 
impairment 
(clinical 
dementia 
rating) 
Randomised, 
double blind, 
placebo controlled 
trial 
12 weeks, daily 
consumption of 
blueberry juice 
(n=9) vs placebo 
(n=7) (not 
matched, control 
group from 
another study 
(62)).  
Anthocyanins: 877mg 
cyaninidin 3-glucoside 
equiv/L (HPLC). Serving 
size between 6 & 9ml/kg 
body weight over 3 
servings/day 
Baseline & 12 weeks: 
California Verbal 
Learning Test (verbal 
learning & memory), 
Verbal paired associate 
learning test (memory) 
Watson et 
al., 2015 
(67) 
36 young 
adults (mean 
age 24.8y ± 
3.9) 
Acute 
randomised 
double-blind 
placebo 
controlled 
crossover 
study 
3 juices on 
different 
occasions: 
placebo juice, 
blackcurrant 
extract or 
blackcurrant juice  
Placebo juice: 
0mg/kg 
anthocyanin; 
Blackcurrant 
extract: 7.7mg/kg 
anthocyanin; 
Blackcurrant fruit 
7 repetitions over 70m post 
intervention: digital 
vigilance (attention), 
Stroop (attention, 
inhibition), rapid visual 
information processing 
(RVIP, attention & 
Sig. improvement in 
RVIP accuracy after 
supplementation with 
anthocyanin-enriched 
blackcurrant extract vs 
control (p= 0.011). Sig. 
improvement in reaction 
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juice: 8.0mg/kg 
anthocyanin. 
Serving size 
10ml/kg body 
weight 
working memory), Bond-
Lader visual analogue 
(mood) 
time on some repetitions 
(1, 4, 7) on digit vigilance 
task vs baseline for the 
cold-pressed blackcurrant 
fruit juice (overall effect 
p=0.044). No sig. effect 
on mood 
Whyte et 
al., 2015 
(66) 
16 children 
(10 male, 
mean age 
9.17y ± 0.6) 
Acute cross-
over placebo 
controlled 
trial 
Intervention: 200g 
fresh blueberries, 
100mL milk & 8g 
sucrose. Control 
(sugar & vit C 
matched): 0.02g 
vit C powder, 
8.22g sucrose, 
9.76g glucose & 
9.94g fructose & 
100mL milk 
Intervention: 143 
mg anthocyanins 
(method not 
described) 
Baseline and 2h post 
intervention: 
Go-No Go (response 
inhibition), Stroop (verbal 
reaction & interference), 
RAVLT(verbal learning & 
memory), Object Location 
Task (spatial memory & 
discrimination), & a Visual 
N-back (visual attention & 
short term memory) 
Sig. improvement in 
delayed recall of RAVLT 
(word learning & 
retention) for intervention 
group (p=0.038). No sig. 
improvement for other 
tasks 
 
  
172 
 
5.4.3 Outcome assessment 
Cognitive outcomes were measured using valid tools in all studies. Two studies measured acute 
change in cognition (66, 67) while the other two studies measured longer term change in 
cognition over 12 to 16 weeks (64, 65).  
 
5.4.4 Longer term anthocyanin supplementation and cognition 
The longer-term studies both evaluated verbal learning and memory in older adults with MCI 
(64, 65) using the California Verbal Learning Test, one study measured change in explicit 
episodic memory using Paired Associate Learning Test (65) and one study assessed change in 
mood using the Geriatric Depression Scale (64). One study (64) measured cognition 
objectively, using fMRI brain imaging, which indicates stimulation and activity in specific 
regions of the brain.  
 
Krikorian et al., (64) reported that after 16 weeks supplementation with concord grape juice, 
there was no between-group difference for performance on the CVLT learning task, but there 
was a reduction in interference on the CVLT memory task compared to baseline (p=0.04). 
There was a NS effect on mood. Analysis of the fMRI brain analysis indicated that there was 
greater activation in the anterior and posterior regions of the brain for the intervention group 
only (64). In another study, the same research team of Krikorian et al., (65) reported significant 
improvements on the verbal paired associate learning task (p=0.009) after 12 weeks of 
supplementation with blueberry juice. However, both of these studies had small sample sizes 
of only n = 10  in the Concord grape juice intervention arm (64) and n = 9 in the blueberry 
juice intervention arm (65).  
 
5.4.5 Acute anthocyanin supplementation and cognition 
The two acute feeding studies evaluated change in acute cognition using the Digital Vigilance 
test (a measure of attention) (67), the rapid visual information processing test (attention and 
working memory) (67), the Go-NoGo test (response inhibition) (66), Rey Auditory Verbal 
Learning Task (RAVLT) (verbal learning, memory) (66), an objective location task (spatial 
memory) (66) and a visual-n back test (attention and short term memory) (66). Both studies 
used the Stroop test to measure attention and inhibition (66, 67).  
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Watson et al., (67) compared three conditions (placebo vs powdered blackcurrant extract with 
7.7mg anthocyanins/kg vs blackcurrant juice with 8mg/kg, based on body weight) on acute 
cognition in 36 young adults by administering tasks seven  consecutive times during a period 
of 65 minutes after consumption of the beverages. The authors reported significant 
improvements in accuracy as measured by the Rapid Visual Information Processing test 
(p=0.011) when participants consumed the blackcurrant extract vs placebo, and improvements 
in reaction time for some repetitions (1, 4 and 7) on the digital vigilance task compared to 
baseline tests (p=0.044) for blackcurrant juice or extract vs placebo. No change in mood or 
other tasks was recorded.  
 
Whyte et al., (66) assessed acute change in cognition after consumption of 200g fresh 
blueberries (143 mg anthocyanins) provided in a milk-based smoothie  in 16 children. There 
was a significant improvement in the delayed recall portion of the RAVLT task after 
consumption of the blueberry smoothie (p=0.038), but no improvements seen for any other 
task. 
 
5.5 Discussion 
The aim of this systematic review was to assess the effects of anthocyanins consumed from 
food, not supplements, on domains of cognitive function, as well as highlight gaps in the 
literature and address the applicability of the available evidence for development of future 
study designs. Despite over a decade of pre-clinical evidence supporting the association of 
anthocyanin intake on cognitive outcomes (69), there remains a lack of experimental studies 
conducted in humans. The four studies included in the review reported positive benefits of 
anthocyanin consumption on some aspects of cognition; however the interpretation of the 
studies is limited by small sample sizes and inconsistent methodologies.  
 
There remains a lack of consensus regarding which cognitive domain is impacted by flavonoid 
(including anthocyanin) intake. This limits choice of best instruments and methods to employ 
in studies that investigate potential change in cognitive function (34). The four identified 
studies used a wide range of tools to address multiple cognitive domains. This inconsistency 
limits comparability between studies and prevents the study findings from being synthesized. 
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This limitation has been recognised, as pointed out in a recent methodological review paper 
(70). The review concluded that future research should be guided by positive findings from 
previous similar research and that it may be best to continue to include a battery of sensitive 
and specific tools that address multiple cognitive domains, until there is better understanding 
of specific brain functions that are influenced by these bioactive components in foods.  
 
The length of the intervention needed to demonstrate outcomes in both acute and chronic trials 
is also poorly understood. The results of the studies by Krikorian and colleagues (64, 65) 
indicate that an intervention of 12 weeks is long enough for cognitive improvements to be 
observed, and that extending study to 16 weeks may not improve the strength of the association. 
The timing related to the acute impact of food-based anthocyanins on cognition is hampered 
by the limited knowledge related to their metabolism and the exact intrinsic effects of 
anthocyanin-rich foods. Understanding to date of anthocyanin metabolism (71) suggests that a 
small proportion of anthocyanins are absorbed within 1-2h of consumption and that the 
remainder pass through to the colon (at 5-6h post consumption), where they are extensively 
metabolised by colonic microflora into metabolites with many potential bioactivities. It is not 
yet clear whether the intact anthocyanins or their metabolites, or both, are responsible for the 
beneficial effects of an anthocyanin-rich diet (72). The two acute studies reviewed in this paper 
did not extend their trial times to encompass the secondary uptake of anthocyanin-related 
metabolites in the colon, and thus may have missed an important later interaction that these 
compounds have on cognition. 
 
Another outcome from our systematic literature review is that biomarker data for anthocyanin 
uptake is largely unavailable. Only one study (67) conducted an objective analysis of biological 
specimens to determine the uptake and metabolism of the anthocyanin present in the 
intervention foods. This fundamental data needed to confirm the bioavailability of 
anthocyanins from different foods and to determine which of the bioactive components are 
specifically associated with the observed health benefits. Current information suggests that the 
level of absorption of flavonoids, and especially anthocyanins, is very low (73) which makes 
them difficult to detect in plasma and urine samples. Identification of the full complement of 
phenolic acid metabolites produced from the breakdown of anthocyanins has not yet been 
made.  
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Different age groups may respond differently to anthocyanin intake. The studies included in 
this review investigated groups ranging in age from children (8-10y) to older adults (>68y) 
with mild-cognitive impairment. Disease states that affect brain function, including vascular 
and non-vascular dementia, as well as Alzheimer’s disease may also result in different 
measureable outcomes in these groups (74), as shown by the limited impact of antioxidant 
clinical trials in this group(74). Therefore, it is important to clearly define patient groups and 
the differences in the effect between children, and young and older adult’s needs to be 
investigated.  
 
The provision of anthocyanins through a juice/beverage vehicle was not well explained in all 
of the studies. It can be speculated that the provision of a pre-formulated juice is an ideal way 
to control the variation of anthocyanins in the fresh-fruit equivalent, which can be heavily 
influenced by growth conditions and can differ between seasons. Provision of a juice also 
reduces the impact of fruit seasonality on intervention timing. However, the impact of food 
processing can substantially alter the anthocyanin content of foods, especially with regard to 
heating or cooking.  For example heating of dark anthocyanin-rich blood plums during jam 
making resulted in losses of up to 70% of their total anthocyanin content (75). Additionally, 
some studies administered relatively large doses of anthocyanin-rich beverages (up to over 
600ml), presumably to maximise the potential of the bioactive anthocyanins. The division of 
the anthocyanin-rich food over 3 servings per day in the longer-term trials (64, 65) may have 
diminished their bioactivity. The provision of smaller doses may not have provided a sufficient 
concentration of anthocyanin to exert a physiological effect, compared to an increased 
bioactivity if a larger serve is consumed at once. However the dose-response mechanisms for 
the impact of anthocyanin-rich food on cognition have not been well investigated. There is a 
trade-off in clinical trial methodology between reflecting usual intake of anthocyanin-rich 
foods, as spread throughout the day, and ensuring a sufficiently high dose is provided (in a 
single serving) to observe outcomes. Future trials are needed to further elucidate the dose-
dependent responses associated with consumption of anthocyanin-rich foods. 
  
Background diet was considered by only one of the intervention studies(76), whereby 
recommendations were provided on which foods to avoid the evening prior to testing day. Diet 
was controlled on the day of the intervention in the longer acute trials (76, 77), but was not 
controlled in the longer-term trials. Controlling the background diet, or at least monitoring it, 
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is an important consideration in flavonoid trials (78) in order to isolate the effect of the 
intervention. Provision  of low flavonoid and/or washout diets before and during trials may be 
an effective way to reduce the impact of habitual diet on intervention outcomes, although 
monitoring habitual diet throughout the period of longer term interventions may also be useful 
to identify potential dietary confounders (78). However, the ideal protocol for standardising 
with the  background diet, including the length of run-in periods in flavonoid trials has not been 
investigated and identified, although a minimum of 3 days has been suggested (78).  
 
Berries, particularly blueberries and blackberries, have received the most interest in studies 
investigating the health impacts of anthocyanin-rich foods. Many other anthocyanin-rich 
sources have been overlooked, including vegetables such as red onions and cabbage. The 
potential for these foods to influence cognition needs to be confirmed, as the large dependence 
in research on berries limits the translation of the outcomes to nutritional advice for the 
population. The consumption of large amounts of berries is not always feasible, as berries are 
often expensive, seasonal (not available year-round) and can spoil quickly. The use of freeze-
dried fruits to overcome these barriers may be a possibility, providing that  the anthocyanin 
content of the fresh fruit equivalent is not spoiled. Freeze-dried fruit may be a nutritionally 
more preferable way in which to consume anthocyanins, compared to encapsulated 
anthocyanins or anthocyanins added to other processed foods. This is because anthocyanin 
pigments present within natural foods are unlikely to be working independently, as plants 
typically contain a complex mixture of phytochemicals that have synergistic bioactivities (79). 
Some studies have found that anthocyanin bioactivity may be increased when they are 
consumed within a mixture of polyphenols, for example as they would naturally occur within 
a complex food matrix (80). This emphasises the importance of investigating whole food 
sources of anthocyanins, rather than isolated and encapsulated anthocyanins when studying 
health related outcomes. 
 
The implication of study design (ie a cross-over design versus parallel groups) is important 
when considering flavonoid trials. Due to the high intra-individual variability in the metabolism 
of flavonoids (81), a cross-over design whereby each individual serves as their own control, is 
arguably more appropriate, especially in trials with small sample sizes.  
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The studies identified in this systematic review that were conducted by Krikorian et al.,(64, 65) 
have been criticised for using the placebo control results from one study, as the placebo control 
in the other(82). It may have been preferable to analyse this data three-arm study. Lamport et 
al., (82) has suggested that this method may reduce the significance of the results (loss of power 
from increased number of comparisons). Another limitation of these studies is the differences 
in mean age between the placebo and the control groups (5 years), which may be associated 
with the difference in cognitive performance.  
 
Three studies were excluded on the basis of not having a measure of anthocyanin in the 
intervention juice (61-63). Hendrickson et al., 2008 (63) measured total phenolic content, but 
did not report anthocyanin content specifically. Despite previous research showing that both 
cranberry (83) and grape juice (64) contain anthocyanins, without an objective measure of their 
anthocyanin content the extent to which their bioactivities relate to the anthocyanin content 
cannot be speculated. These studies showed that in older adults (n=5), daily concord grape 
juice consumed (4-6ml/kg body weight divided over 3 servings per day) over 12 weeks was 
associated with significant improvements (p=0.04) in verbal learning and memory on the 
California Verbal Learning Test. In young adults (n=35), grape juice (10ml/kg body weight) 
had no impact on acute cognition (implicit memory as measured by a word fragment 
completion task) and cranberry juice consumption (~470ml consumed twice per day) had no 
significant impact on cognitive outcomes.  
 
5.5.1 Conclusion 
The impact of food-based anthocyanin consumption on both acute and long-term cognition 
appears promising. However, adequately powered studies that include sensitive cognitive tasks 
are needed to confirm these findings and allow translation of research into dietary messages.  
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CHAPTER 6: FLAVONOID RICH CHERRY JUICE ACUTELY REDUCES 
BLOOD PRESSURE, BUT NOT COGNITION IN YOUNG ADULTS, OLDER 
ADULTS AND DEMENTIA PATIENTS: A PILOT CROSSOVER STUDY 
 
This chapter describes a pilot cross-over study that was conducted to assess the acute effects 
on cognitive function, blood pressure and plasma biomarkers associated with consumption of 
a 300 ml flavonoid-rich fruit juice, provided either as a single quantity or as 3x100ml doses 
administered over 2h. Young adults (n=6), older adults (n=5), and older adults with dementia 
(n=5) received in random order either a single 300ml dose or 3x100ml doses of high-flavonoid 
cherry juice at 0, 1 and 2h. Blood pressure and plasma levels of phenolic metabolites were 
measured at 0, 2 and 6h. A battery of cognitive tests was administered at baseline and 6h. 
Regardless of dose, cherry juice did not impact acute cognitive function. The single 300ml dose 
of juice significantly reduced heart-rate (p=0.024) and diastolic blood pressure (p=0.016), with 
a trend for reduced systolic blood pressure (p=0.066) after two hours. The 3x100ml doses did 
not result in blood pressure reductions and no group effect was evident in either dose. Plasma 
phenolic metabolites increased at 2 and 6 hours, however changes were higher after the single 
300ml dose. The methodology used in this acute pilot study contributes to study design for 
food-based trials of cognition. Flavonoids delivered in cherry juice did not acutely improve 
cognition; however a single 300ml quantity of juice reduced blood pressure in all groups 
similarly. The data suggests that dose-interval administration may be an important factor when 
administering the intervention, as a minimum threshold of uptake may need to be reached in 
order to induce acute bioactive effects.  
 
This chapter has been published in two separate manuscripts, but will be presented here as a 
cohesive chapter. 
Appendix A 
Caldwell* K, Charlton KE, Roodenrys S, Jenner A. 2015. Anthocyanin-rich cherry 
juice does not improve acute cognitive performance on RAVLT. Nutritional 
Neuroscience. DOI: 10.1179/1476830515Y.0000000005 
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Kent, K, Charlton, KE, Jenner, A, Roodenrys, S, 2015, Acute reduction in blood pressure 
following consumption of anthocyanin-rich cherry juice may be dose-interval dependant: 
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6  
6.1 Introduction 
A growing body of evidence suggests that consumption of flavonoids, a group of polyphenols 
synthesised by plants is associated with enhanced cognitive function (1) and protection against 
neurodegenerative diseases (2). Dementia is a common mental and behavioural disorder in 
Australia and limited successful treatment options highlights the need for alternative practices 
to improve cognitive outcomes. Reviews of pre-clinical evidence have shown that flavonoids 
act to suppress neuroinflammation, improve cerebrovascular blood flow inducing angiogenesis 
and neurogenesis, as well as improve synaptic plasticity and scavenging neurotoxins and pro-
inflammatory species in the brain (3, 4). Intense interest relates to class of flavonoids known 
as anthocyanins, that are concentrated in purple and red fruits (5). Anthocyanins have been 
shown to improve cognitive function (6-10), with various anthocyanin derivatives providing 
among the greatest antioxidant and free radical scavenging activity of all flavonoids (11). 
Sweet cherries are a rich source of anthocyanins and to a lesser degree contain flavan-3-ols, 
flavonols (12, 13) and phenolic acids (14) but have been overlooked in investigations of the 
cognitive effects of flavonoid and anthocyanin-rich foods.  
 
6.1.1 Anthocyanins and acute cognition 
While large scale epidemiological research has provided evidence that anthocyanin 
consumption is associated with improved cognition (15, 16) and slower cognitive decline (15) 
the ability of these bioactive compounds found in fruit and other foods to modulate acute 
cognition has yet to be fully examined. In the context of large-scale trials investigating the 
long-term cognitive benefits of flavonoid rich foods, focussed acute trials are also necessary to 
determine differences in acute and chronic effects.  
 
Few well designed human trials have investigated the acute impact of flavonoid-rich food on 
cognition, and the development of appropriate study protocols is required. Notable gaps in 
existing knowledge relate to potential age differences associated with consumption of 
anthocyanins, variations in health outcomes related to dosage and timing of consumption, as 
well as identification of which cognitive domains are affected and the metabolic fate of 
flavonoid-rich foods.  
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Flavonoid consumption has been linked with cardiovascular benefits (17) and experimental 
studies indicate that the underlying biological mechanisms by which flavonoids regulate blood 
pressure include effects on vascular blood flow and vascular reactivity (18, 19). Regulation of 
blood pressure is an important clinical consideration for maintenance of cognition (20). 
Hypertension has been associated with poorer cognition in older adults (21, 22), which may 
relate to mechanisms that link flavonoid consumption to cognitive functioning. There is some 
evidence that suggests a weaker association between anthocyanin intake and cardiovascular 
outcomes in older adults (18) and additionally, the differences in acute responses between 
younger and older adults have not been adequately addressed.  
 
There is no consensus regarding the quantity of flavonoids needed to induce bioactive effects 
and studies rarely consider a dose-timing analysis, with a few exceptions (23). The dose-
dependent association on blood pressure reduction has not been supported (23) and is largely 
unexplored at the acute level. Studies often administer unrealistically large doses of flavonoid-
containing foods in order to ensure a physiological result (8-10, 23), which limits translation 
into practical nutritional advice or generalisability to usual diets.  
 
6.1.2 Measurement of flavonoid biomarkers in acute trials 
Regarding biomarkers, only a few methods have been developed to measure the intake of 
flavonoids in biological samples, with little consistency in the literature. Flavonoids are quickly 
and extensively metabolised by the gut into phenolic acid metabolites (24), which may have 
different bioactivity to intact flavonoids. Plasma phenolic acids have been promoted as valid 
biomarkers of flavonoid intake (25, 26). Phenolic acids may reflect the absorption and 
metabolism of flavonoid rich foods and may be useful in understanding the metabolic fate of 
specific flavonoid rich foods (27).  
 
The aim of this study was to develop and evaluate methodology to examine the acute impact 
of flavonoids from cherries on cognition and blood pressure; compare acute dose-timing effects 
of flavonoids from cherry juice on cognition and blood pressure in young people, older adults 
and older adults with mild to moderate dementia; and examine dose-timing effects relating to 
the absorption and metabolism of flavonoids from a feasible serving of cherries, over time and 
between groups, using Gas Chromatography/Mass Spectrometry.  
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6.2 Methods 
Ethics approval was awarded by the University of Wollongong Human Research Ethics 
Committee. Participants were recruited through advertisements pursuing young healthy adults 
(18-35y) (n=6), older adults aged (55+y) (n=5) and older adults with dementia (n=5). 
Participants were screened for exclusion criteria of uncontrolled hypertension and dysphagia. 
Dementia diagnosis from a geriatric physician was required for inclusion in the dementia sub-
group. Written informed consent was obtained and consent was provided by a carer when 
appropriate. Consenting participants were randomised to a treatment allocation and cognitive 
assessment order by computer-aided block randomisation by an independent statistician. 
Participants attended the study clinic on two occasions with a one-week washout period 
between visits.  
 
On both occasions, participants fasted for 12 hours and were provided with a standardised 
breakfast with negligible flavonoids (wheat biscuits and milk). Cherry juice was administered 
either as a single 300ml at 0hrs or 3x100ml servings at 0, 1 and 2hrs. Cherry juice was produced 
from a single seasonal batch, underwent novel processing to minimally damage anthocyanin 
content and was frozen at ≤-0.20oC. Oxygen Radial Absorbance Capacity of the cherry juice 
was 58.99 µmol Trolox Equivalent/g and the Anthocyanin content was determined to be 
69mg/100ml using a validated HPLC (28) method. A standardised snack with negligible 
flavonoids (ham and cheese on white bread) was provided at 4 hrs.  
 
6.2.1 Anthropometrics 
Height and weight were measured and BMI calculated. Nutritional status was assessed using 
an interviewer-administered Mini Nutritional Assessment (MNA) (29). Resting blood pressure 
and heart rate were measured using an Omron HEM7200 Deluxe Automatic Blood pressure 
Monitor, while seated, in triplicate and averaged at baseline, 2 and 6 hours post-intervention.  
 
6.2.2 Blood collection 
Blood samples were collected in EDTA tubes at baseline, 2 and 6 hours post-intervention and 
centrifuged within 1 hour, with plasma extracted and stored at -0.80oC until batch analysis. 
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Phenolic acid analysis was performed according to Loke et al, (25) on an Aligent-7000 Gas 
Chromatography/Mass Spectrometer-Triple Quad. Briefly, the collected blood was treated 
with 18 µl of indomethacin (5 mM). The sample was centrifuged at 3000 rpm for 10 min at 4 
°C. Plasma (250µl) was then pipetted to microfuge tubes preloaded with 10 µl of 2mM 
butylated hydroxytoluene (BHT) and frozen at -20 until analysis. Internal standards were added 
to a vial and dried off before 100µl plasma was added. The samples were acidified with 3M 
acetate buffer pH 4.8 (50 µl/ml). To hydrolyse the conjugated compounds in the sample, H. 
Promatia extract with β-glucuronidase and sulfatase activity, was used (25 µl/ml). After 
overnight incubation at 37°C, concetrated HCl (2% v:v) was added and the sample was 
centrifuged for 10 min at 8000 rpm. The supernatant was added to a solid phase column filled 
with diatomaceous earth (100 mg/100 µl), which retains the water-soluble compounds. The 
phenolic acids were eluted with ethyl acetate. The eluate was dried and derivatized by adding 
10 µl of acetonitrile and 30 µl of derivatizing agent N,O-bis-(trimethylsilyl)-trifluoroacetamide 
(BSTFA). Eight anthocyanin-related phenolic acid metabolites were targeted for 
quantification: ferulic, isoferulic, caffeic, p-coumaric, syringic, vanillic, 4-OH benzoic and t-
cinnamic acids. 
 
6.2.3 Cognitive tasks 
Four sensitive and specific cognitive tasks were administered at baseline and at 6 hours to 
reflect acute change. The interview administered tasks were conducted individually by a trained 
research assistant. These tasks were selected on the basis of previous research findings (30, 31) 
which critiqued the application of various cognitive tasks in previous flavonoid interventions 
and provided recommendations for future studies. Specifically, measures of executive 
functioning were recommended, however, the specific cognitive domains affected and the tools 
which are able to measure this change have not yet been elucidated. Consequently the following 
tasks were selected on the basis of previous research and the fact that they were quick to 
administer, and challenging but not cognitive draining. A task switching test measured higher 
executive function by asking participants to alternate between two simple tasks at once (32). 
The Rey Auditory Verbal Learning test (RAVLT) (33) assessed verbal learning and memory 
by asking participants to recall a list of words over 5 trials. Pattern and letter comparison tasks 
(34) assessed speed of processing, asking participants to compare strings of patterns or letters 
as quickly as possible.  
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6.2.4 Statistical analysis 
Statistical analysis was conducted using SPSS statistical program (V17.0: 2006, SPSS, Inc., 
Chicago, II, USA). Descriptive analysis was performed for cognition, blood pressure and 
biomarker variables (mean, SD, range).  
 
Cognitive data were assessed for normality using the Shapiro–Wilk test and found to be 
normally distributed. Mixed ANOVA with repeated measures determined if differences 
between age groups or dosage existed for each of the four cognitive tests. Post hoc analyses 
(Bonferroni correction, p=0.05) were conducted to assess whether outcomes differed between 
time points for either dose. 
 
Blood pressure data were assessed for normality using the Shapiro–Wilk test and found to be 
normally distributed. Mixed ANOVA with repeated measures determined if differences 
between age groups or dosage existed for blood pressure variables (Systolic blood pressure 
SBP, Diastolic Blood Pressure DBP, Heart Rate HR). Post hoc analyses (Bonferroni 
correction, p=0.05) were conducted to assess whether outcomes differed between time points.  
 
A large inter-individual variation in baseline levels of biomarkers between individuals 
(regardless of group) was accounted for by calculating the percentage change (from baseline) 
at 2 and 6 h post-intervention for each biomarker. These variables were assessed for 
normality using the Shapiro–Wilk test, showing that all variables were not normally 
distributed. Variables were transformed using a Log transformation. The percentage change 
at 2 and 6 h post intervention was compared over time for each dose using repeated measures 
ANOVA and Bonferroni post hoc analyses. 
 
6.3 Results 
Sixteen participants were recruited including 6 young healthy participants, 5 older healthy 
adults and 5 older adults with dementia (Table 6-1). Three healthy older adults withdrew before 
the second session. No difference between the three groups at baseline was found for BMI. 
MNA score differed significantly between groups, but mean values fell within the well-
nourished category (MNA>24) for all groups (Table 6-1).  
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Table 6-1 Subject sample characteristics according to group at baseline 
Characteristic 
Average (SD) 
Young group 
n=6 
Older group 
n=5 
Dementia group 
n=5 
p-value †  
Age in years 21.8 (0.97) 74.1 (7.9) 79.8 (3.6) <0.001 
BMI (kg/m2) 26.3 (4.6) 27.6 (4.6) 29.6 (3.2) 0.189 
MNA Score 30 (0) 27.79 (1.0) 25.3 (2.2) <0.001 
† ANOVA for differences between groups 
BMI: Body Mass Index, MNA: Mini Nutritional Assessment. 
 
6.3.1 Cognitive tasks 
One way ANOVA showed significant differences between all groups for all cognitive tasks at 
baseline, except the task switching test, where the older and dementia groups performed 
similarly. No significant differences were found in cognitive performance for the RAVLT, task 
switching test and pattern or letter comparison tasks, with the exception of the task-switching 
test in older adults after the single 300ml dose, which was statistically significantly different 
6h post cherry juice consumption (p=0.021) (Table 6-2). 
 
6.3.2 Blood pressure 
No group effect was observed for change in blood pressure and heart rate over time following 
administration of either dose so groups were analysed together. A single 300ml dose of cherry 
juice resulted in a significant reduction at 2h in heart rate (p=0.024) and diastolic blood pressure 
(p=0.016), and approached significance for systolic blood pressure (p=0.066). A significant 
quadratic trend was evident. Post Hoc analysis using the Bonferroni correction showed no 
significant differences between baseline and 6 hours for any of the blood pressure measures. 
However, a significant difference between baseline and 2h was found for diastolic blood 
pressure (p=0.02) and heart rate (p=0.032), and between 2h and 6h for systolic (p=0.017) and 
diastolic (p=0.046) blood pressure, and heart rate (p=0.013) (Figure 6-1). The 3x100ml dose 
of juice showed a similar but weaker trend and lacked significance.  
 
Table 6-2  Change in performance on cognitive assessments over 6 hours according to group. 
 3x100ml serving over 3h 1x300ml serving 
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RAVLT (total) and (20m delay) = number of words recalled 
Task switching = seconds taken to complete task 
Pattern and letter comparison = number of correct answers in 1 minute 
* p=<0.05 
 
  
Assessment Baseline 
Average (SD) 
Mean 
difference at 
6h 
Baseline 
Average (SD) 
Mean 
difference at 
6h 
Young group  n=6 n=6 
RAVLT (total) 63.7 (6.7) +2.0 62.5 (5.6) +1.5 
RAVLT (20m delay) 12.0 (2.5) +0.5 12.0 (3.2) +1.3 
Task Switching 91.2 (29.9) -143 78.8 (10.2) -3.5 
Pattern Comparison 21.5 (2.1) +1.2 21.2 (3.9) +2.0 
Letter Comparison 13.0 (1.9) +0.67 13.8 (3.3) -0.33 
Older groupa n=2 n=5 
RAVLT (total) 35.0 (2.8) +2.0 44.6 (5.7) -4.8 
RAVLT (20m delay) 5.0 (1.4) -0.5 5.8 (2.7) -0.4 
Task Switching 84.6 (3.4) +0.36 126.6 (28.7) -21.6 * 
Pattern Comparison 14.0 (1.1) -0.5 12.0 (1.3) +1.2 
Letter Comparison 9.5 (2.1) -1.0 8.6 (1.5) +0.8 
Dementia group n=5 n=5 
RAVLT (total) 25.8 (11.6) +1.8 25.0 (11.4) +1.8 
RAVLT (20m delay) 0.00 (0) 0 0.00 (0) 0.00 (0) 
Task Switching 178.1 (130.1) +13.4 132.1 (109.7) -3.5 
Pattern Comparison 9.2 (5.6) -0.6 8.2 (4.8) -0.8 
Letter Comparison 4.0 (2.7) +1.2 4.6 (3.2) +0.6 
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Figure 6-1. Acute change in blood pressure and heart rate over 6 hours after either a single 
300ml dose of cherry juice (a, b, c) or 3 x 100 ml doses over 3 hours (d, e, f) 
 
6.3.3 Phenolic acid biomarkers 
Eight phenolic acids were detected in all plasma samples, with the exception of vanillic and t-
cinnamic acid for older adults at the 3x100ml dose visit (n=2). On both occasions, baseline 
concentrations of plasma phenolic acids were highly variable and differed between groups, 
except for syringic and vanillic acid (Table 6-3). A single 300ml serving of cherry juice resulted 
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in large changes in all plasma phenolic acids at 2 and 6h post intervention (Figure 6-2), 
particularly caffeic acid. The 3x100ml dose of the juice administered over 3 hours resulted in 
smaller plasma phenolic acid fluctuations, and in some individuals, plasma concentrations 
declined from baseline. No significant difference between the absolute plasma phenolic 
concentrations over time was evident for either serving or between groups. Percentage change 
in plasma phenolic acid concentration at 2h and 6h was calculated for each individual, relative 
to the baseline concentration, to mediate individual inter-variability. The mean percentage 
change was calculated for each group at 2h and 6h from baseline (Figure 6-2). 
 
Table 6-3 Mean baseline concentrations of plasma phenolic acids according to group (average 
of two baseline measures) 
Group 
Mean + 
 
Feruli
c 
Acid*  
Isoferulic 
Acid *  
Caffeic 
Acid *  
 
p-
coumaric 
Acid *  
Syringic 
Acid  
Vanillic 
Acid 
4-OH-
Benzoic 
Acid*  
t-
cinnamic 
Acid *  
Young 0.20 0.21 0.084 0.019 0.041 1.047 4.19 0.31 
Older  0.13 0.51 0.0054 0.04 0.027 0.94 8.37 0.059 
Dementia 0.23 0.61 0.027 0.032 0.018 0.70 7.13 0.081 
+ nm/ml, *p<0.001 One way ANOVA 
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Figure 6-2. Percentage change in plasma phenolic and aromatic acid concentration at 2 and 6h 
post intervention; a) young b) old c) dementia for 1x300ml dose and d) young e) old f) dementia 
3x100ml dose over 3h 
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6.4 Discussion 
This exploratory study developed methodology to examine the acute dose dependent impact of 
flavonoids from cherries on cognition and blood pressure, in young people, older adults and 
older adults with mild to moderate dementia. Evaluating the intervention highlights several 
positive and negative characteristics of its design. The intervention was well tolerated, with no 
adverse reactions to the juice. The attrition of three participants in this small cohort was related 
to study burden and length of testing. The cross-over design appears to appropriately account 
for the high intra-individual variations in the metabolism and absorption of flavonoids. 
However, there are limitations associated with this study, including the small number of 
participants, which restricts our interpretation of the comparison between the groups. Also, the 
lack of a control group in this pilot study hinders the inferential interpretation of these results. 
However, it was the aim of this study to describe the differences between two dose-timing 
administrations. The results should be interpreted with caution.  
 
6.4.1 Cognitive outcomes 
Data from this pilot study indicates that a feasible serving of cherry juice, regardless of dose-
timing, does not appear to influence acute cognition. The significant difference over 6h for the 
older group between doses for the task-switching test may be attributed to the attrition of 
subjects in that group. While the cognitive assessment tasks included in this study have 
previously been shown to be sensitive measures for nutrition interventions (30, 35) this pilot 
study is underpowered to detect changes in cognition. However, the cognitive assessment 
battery may be useful for application in a larger study as they were easily applied, interpreted 
and analysed in all patient groups in this study. The single 300ml dose of cherry juice provided 
in our study, and consequent dose of anthocyanins (≈55mg) is lower than doses of flavonoids 
provided through a variety of foods in other studies (36) may also explain the lack of effect. 
Other limitations relate to the lengthy testing sessions, leading to fatigue or lack of motivation, 
which may implicate performance in the cognitive tasks (37). Different versions of each task 
were administered at each time-point; however, trends for improvements in cognition may be 
attributed to a learned practice effect (38). Additionally, the influence of study timing should 
be further considered, whereby blood pressure may be influenced (potentially increased) by the 
timing of cognitive tasks. Therefore, future research should be informed by recent reviews of 
sensitive and specific cognitive tests for nutrition interventions (31, 35). Additionally, it is 
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important to link the hypothesised physiological effects more closely with application of 
cognitive tasks. A cognitive task administered 2h post intervention would reflect the immediate 
absorption of intact flavonoids in the small intestine as well as avoiding testing fatigue; 
however the sensitivity of cognitive tests needs to be improved.  
 
6.4.2 Blood pressure 
A reduction in acute blood pressure and heart rate measurements were seen after a single 300ml 
dose of cherry juice after 2 hours in all three groups similarly, before returning to baseline 
levels at 6h (Figure 6-1). The reduction of blood pressure and heart rate measurements at 2 
hours is supported by data from other acute anthocyanin feeding studies (39), whereby 
anthocyanins reportedly reach the circulatory system within 0.25–2hrs and are excreted by 4hrs 
post-prandially. However the same amount provided in three smaller doses over a 3 hour period 
did not provide the same effect. This highlights potential dose-dependency and suggests that a 
minimum threshold of ingestion or uptake may need to be reached in order to induce bioactive 
effects. However, replication of these results in a larger sample is required. Ambulatory 
BLOOD PRESSURE monitoring may be more precise to accurately explore blood pressure 
fluctuations over 6 hours and could be utilised to measure the extended effects of flavonoid 
rich foods. Our exploratory study did not investigate possible mechanisms for blood pressure 
lowering effects and as fluctuations in plasma phenolic acids generally peaked at 6h post 
intervention, reflecting their uptake in the colon, they are unlikely to have influenced blood 
pressure changes. Given the large body of existing research demonstrating reductions of 
inflammatory and oxidative stress markers and increases to endothelial function associated 
with anthocyanin consumption, these mechanisms should be primary considerations in future 
studies (23). 
 
6.4.3 Plasma biomarkers 
After correcting for baseline plasma concentrations to account for individual inter-variation in 
flavonoid metabolism and absorption (40), the percentage change in plasma phenolic acids 
increases at 2h and 6h post intervention for both the single 300ml and 3x100ml doses of juice. 
However, the relative increase for the single 300ml serving of juice was greater than the single 
300ml serving, indicating a larger uptake of cherry related phenolic acids after the single 300ml 
serving. Older adults and dementia patients showed a lessened response to the 3x100ml serving 
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over 3 hours when compared to younger adults, which may indicate a reduced ability to absorb 
and metabolise flavonoids in this group. This hypothesis requires further investigation on a 
larger and more controlled scale alongside studies of dose-timing relationships for flavonoid 
consumption. 
 
The increase in plasma phenolic acids at 2h post intervention are likely to reflect the absorption 
of flavonoids and phenolic acids from cherry juice in the small intestine, as well as smaller 
absorption from the stomach (41). The increases shown at 6h post intervention are more likely 
to reflect absorption of flavonoid metabolites from the colon (41). The eight phenolic acids 
measured in the study are related with anthocyanin metabolism and should reflect the 
metabolism and uptake of anthocyanins in cherry juice. However, due to the wide spanning 
nature of phenolic acids in foods and diet, and endogenous phenolic acids generated by human 
metabolism that the phenolic acids may have come from other sources, such as the metabolism 
of the standardised breakfast. There was no statistically significant difference in plasma 
phenolic acid concentration between groups or over time for either serving, which is largely 
reflective of their extreme variability in this small cohort. Due to the high intra-individual 
variation of flavonoid metabolism and bioavailability, the fact that phenolic acids are 
influenced by factors other than intake, such as bioavailability and genetic factors, the 
combined use of plasma biomarkers and dietary intake estimates may be the best choice in 
future studies (42). 
 
The methodology piloted in this study provides an indication of both positive and negative 
aspects of its design. An important aspect of the research design is the feasibility of the 
intervention in terms of translation into practice. Small changes to the study protocol will likely 
improve the accuracy of larger trials. This pilot study indicates that acute intake of flavonoids 
in a feasible serving of cherry juice does not change cognitive performance, but may reduce 
blood pressure. A lack of effect for the three small servings of juice over 3 hours suggests dose-
interval administration may influence the bioactive effect of flavonoids, which require further 
investigation.  
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6.4.4 Conclusion 
The findings from this pilot study suggest that further study of cherry juice and dose response 
variations from consumption on vascular and cognitive outcomes is warranted in light of the 
evaluated methodology. Further application of the phenolic acid biomarkers in a larger sample 
should be conducted to assess their ability to reflect flavonoid intake, and confirm the 
absorption and metabolism of cherry-related flavonoids.  
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CHAPTER 7: CONSUMPTION OF ANTHOCYANIN-RICH CHERRY JUICE 
FOR 12 WEEKS IMPROVES MEMORY AND COGNITION IN OLDER 
ADULTS WITH MILD TO MODERATE DEMENTIA 
 
The chapter describes a 12-week randomised controlled trial that aimed to assess whether daily 
consumption of anthocyanin-rich cherry juice changed cognitive function in older adults with 
dementia. Blood pressure and anti-inflammatory effects were examined as secondary 
outcomes. Older adults (+70y) with mild to moderate dementia (n=49) consumed 200ml/day 
of either a cherry juice or a control juice with negligible anthocyanin content. Blood pressure 
and inflammatory markers (CRP, IL-6) were measured at 6 and 12 weeks. Improvements in 
verbal fluency (P=0.014), short term memory (P=0.014) and long term memory (P=<0.001) 
were found in the cherry juice group. A significant reduction in systolic (P=0.038) blood 
pressure and a trend for diastolic (P=0.160) blood pressure reduction was evident in the 
intervention group relative to the control. Markers of inflammation (CRP and IL-6) were not 
altered. Inclusion of an anthocyanin-rich beverage may be a practical and feasible way to 
improve total anthocyanin consumption in older adults with mild to moderate dementia, with 
potential to improve specific cognitive outcomes.  
 
This chapter has been published in the European Journal of Nutrition: 
Appendix B 
Kent, K, Charlton K, Roodenrys S, Batterham M, Potter J, Traynor V, Gilbert H, 
Morgan O, Richards R, 2015. Consumption of anthocyanin-rich cherry juice for 12 
weeks improves memory and cognition in older adults with mild to moderate 
dementia. European Journal of Nutrition DOI: 10.1007/s00394-015-1083-y 
 
Analysis of the baseline dietary and cognitive data has published in the Journal of Aging: 
Research and Clinical Practice: 
Appendix D 
Kent, K, Roodenry, S, Charlton, KE, 2016. Dietary flavonoid intake and cognitive 
performance in older adults with Alzheimer’s type dementia. Journal of Aging: 
Research and Clinical Practice, vol. 5. 
This data was also presented at several National conferences: 
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Caldwell*, K., Charlton, K., Roodenrys, S., Batterham, M., Potter, J., Richards, R., 
Gilbert, H. & Morgan, O. 2014. The impact of fruit flavonoids from cherries on 
memory and cognition in older adults with mild to moderate dementia. Abstracts of 
HSA 2014 Annual Scientific Meeting (pp. 1-1). Australia: HSA. Abstract of a 
presentation that was present at the NSA 2014 Annual Scientific Meeting, 26-28 
November, Hobart, Australia. 
 
Caldwell*, K. & Charlton, K. 2013. Dietary intake and major sources of flavonoids in 
older Australians with Alzheimer's type dementia. Enabling Active Ageing 
Conference Proceedings: The 12th National Conference of Emerging Researchers in 
Ageing (pp. 44-44). 25 and 26 of November 2013, Sydney, Australia. Australia: 
Emerging Researchers in Ageing Australia. 
 
Caldwell*, K., Charlton, K. E. & Roodenrys, S. J. 2013. Estimation of dietary flavonoid 
intake and cognitive performance in older adults with Alzheimer's type dementia. 
Australasian Medical Journal, 6 (11), 612. Abstract presented at The Nutrition Society 
of Australia and Nutrition Society of New Zealand 2013 Joint Annual Scientific 
Meeting, 4-6 December 2013, Brisbane, Australia 
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7  
7.1 Introduction 
Plant-based foods form an integral component of the human diet and their consumption is 
consistently linked to the maintenance of health and the prevention of a vast array of diseases 
(1). A growing body of evidence has shown that phytochemicals, non-nutritive bioactive 
compounds, contribute to the antioxidant activity of individual fruits and vegetables and are 
consequently credited with the observed health benefits (2). Flavonoids are a class of 
polyphenols that have been studied intensively and are categorised into six major classes: 
anthocyanins, flavanols, flavanones, flavones, flavonols, and isoflavones (3). Flavonoids are 
found in particularly high concentrations in fruits and vegetables, wine, tea and cocoa (4). The 
consumption of flavonoids has been associated with a reduction in risk for cardiovascular 
diseases and some cancers (5, 6) and more recently there has been attention directed to their 
potential to protect against neurodegenerative diseases and improve cognitive performance in 
older adults (7).  
 
 
The sub-groups of flavanols, anthocyanins and flavanones have been shown to be the most 
beneficial of the flavonoid family in terms of neuro-protection (8). Specifically, literature 
investigating the impact of fruit flavonoids on cognitive and physical outcomes is 
predominately pre-clinical (9) and while promising, remains inconclusive. Much of the food-
based research has focused on flavonoid-rich blueberries and strawberries (9). The biological 
actions of flavonoids on cognitive function have been attributed to a number of hypothesized 
mechanisms. Their antioxidant actions assist to scavenge free radicals in the brain (8), while 
their neuro-protective effects include protection of vulnerable neurons against inflammation, 
enhancement of existing neuronal function, increased blood flow to the brain and neurogenesis 
initiation in areas of the brain that are associated with cognition (10).  
 
Preliminary dietary supplementation studies have shown that blueberries (11) and concord 
grapes (12, 13) improve aspects of memory in older adults over a 12 and 16 week intervention. 
Cherries, both the sweet and tart varieties, are a rich source of anthocyanins and to a lesser 
extent also contain flavan-3-ols and flavonols (14). Cherries have been found to lower 
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inflammation and scavenge nitrous oxide radicals within the body (15). However the potential 
of cherry flavonoids to influence cognitive function has not been investigated, despite them 
being a commonly consumed fruit in Australia (4) and other countries.  
 
Research to date has investigated the cognitive enhancing effects of flavonoid-rich foods in 
participants with both normal cognitive function (16) and people with mild cognitive 
impairment (11-13) but effects in dementia patients remains under researched (17). In light of 
projections indicating rapid increases in the prevalence of the dementia (18) and in the absence 
of successful treatments, alternative measures to slow the development and progression of 
dementia are imperative. 
 
A randomised clinical trial was conducted to assess changes in cognitive function in older 
adults with mild to moderate dementia after daily consumption of a feasible serving of 
anthocyanin-rich cherry juice over 12 weeks. Secondary outcomes included anti-inflammatory 
effects, changes in functional and physical ability and mood.  
 
7.2 Methods 
7.2.1 Participants 
Participants were recruited from a geriatric outpatient dementia clinic and residential aged care 
facilities in the Illawarra region of New South Wales, Australia. Participants were aged 70 
years or older and had been diagnosed as having mild to moderate dementia Alzheimer’s type, 
as confirmed by the consultant geriatrician responsible for their clinical management (JP). 
Exclusion criteria include non-English speaking, uncontrolled hypertension, uncontrolled 
diabetes, any other unstable physical or mental health condition or dysphagia. Written informed 
consent was obtained. For participants with cognitive impairment deemed by their geriatrician 
to be too severe to provide informed consent, consent was provided by family carers or 
guardians. Consenting participants (Table 7-1) were randomised to a treatment group and 
randomised by computer-aided block randomisation, conducted by a statistician that was 
independent to the research interface (MB) (Figure 7-1). All other researchers were blinded to 
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the grouping. This study was approved by the University of Wollongong Human Research 
Ethics Committee and the Illawarra Shoalhaven Local Health Districts ethics committee 
(HE11/175). This study was registered as a clinical trial through the Australian New Zealand 
Clinical Trials Registry (ANZCTR) and was allocated the ACTRN: ACTRN12614001298606.  
 
7.2.2 Study Procedure 
Over 12 weeks participants received 200ml/day of cherry juice (intervention arm) or 200ml/day 
of commercially prepared apple juice (control arm). Juice was delivered weekly, by a research 
assistant not involved in data collection, to the homes of participants, chilled in 1L plastic 
bottles. Instructions were provided to participants and carers for the juice to be consumed daily, 
at any time in one sitting, using a cup provided that indicated 200ml with a fill line. A weekly 
calendar was provided with the juice, with daily check boxes ticked when the juice was 
consumed. The sweet, Bing cherry juice was produced using a novel method that aims to retain 
the phenolic bioactives, developed by a research company (Agritechnology) based in Orange, 
NSW, Australia. The high antioxidant activity and anthocyanin content of cherries is well 
retained in the juice which had a high Oxygen Radical Absorbance Capacity (3200 µmol 
Trolox Equivalents/g) and contained 69 mg red pigments (anthocyanins) per 100g of juice as 
determined by HPLC (19) (Table 7-2). The apple juice was provided by Appledale, based in 
Orange, NSW, Australia (Table 7-2). Nutritional content of the intervention and control juices 
are shown in Table 7-2. A serving size of 200ml per day was determined as being a feasible 
quantity that could be consumed by an older adult with mild-moderate dementia, and was 
chosen in the absence of empirical research that highlights a dose requirement for anthocyanin 
intake and cognitive outcomes. The serving size provided a more feasible serving of juice than 
has been used in previous similar studies, where the quantity of anthocyanin-rich beverages 
provided may exceed the amount that can be feasibly achieved over the long term, especially 
by older adults living with a neurodegenerative disease (11, 13). No change to regular diet was 
advised. 
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Table 7-1 Baseline characteristics of participants in the study according to group 
Characteristic Control group 
n=25, mean ± 
SD 
 
Intervention group 
n=24, mean ± SD 
Age (years) 80.6 ± 6.6 78.9 ± 5.2 
BMI (kg/m2) 26.6 ± 3.5 25.7 ± 3.4 
Current smokers (count) 1 (4%) 0 (0%) 
Previous smokers (count) 10 (40%) 7 (29%) 
Hand grip strength (kg) 52.1 ± 16.4 62.5 ± 16.1* 
Mid arm circumference (cm) 26.9 ± 4.5 27.2 ± 4.1 
Calf circumference 33.4 ± 3.7 34.9 ± 3.4 
Education (years) 17.5 ± 3.2 18.2 ± 2.4 
Mini Nutritional Assessment 23.4 ± 3.5 25.6 ± 2.8* 
Instrumental Activities of Daily Living  5.7 ± 2.4 7.5 ± 0.8* 
Total flavonoid intake (mg/day) 429.8 ± 384.2 599.0 ± 352.2 
Flavonol intake (mg/day)  20.0 ± 13.2 32.9 ± 26.5 
Flavone intake (mg/day) 0.3 ± 0.3 1.2 ± 1.7 
Flavanone intake (mg/day)* 8.8 ± 16.4 11.7 ± 17.9* 
Flavon-3-ol intake (mg/day)* 382.9 ± 379.6 518.9 ± 338.9* 
Anthocyanin intake (mg/day)  13.1 ± 29.7 34.2 ± 55.6* 
*P<0.05, for differences between groups. 
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Excluded (n=7) 
 Not meeting 
inclusion criteria 
(cognition) (n=5) 
 Declined to 
participate (n=1) 
 Other reasons 
(n=1) 
Analysed at baseline (n= 21) 
 Excluded from analysis  
at 6 and 12wk (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 3) 
 Indefinitely Hospitalized 
(n=1) 
 Study Burden (n=2) 
Allocated to intervention (n= 24) 
 Received allocated  
intervention (n= 24) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 
4) 
 Died (n=1) 
 Moved (n=1) 
 Study Burden (n=3) 
Allocated to control (n= 25) 
 Received allocated  
control (n= 25) 
 
Analysed at baseline (n= 21) 
 Excluded from 
analysis  
at 6 and 12wk (n= 0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=49) 
Enrolment 
Figure 7-1 CONSORT flow diagram of enrolment, allocation, follow up and analysis. 
Assessed for eligibility 
(n=56) 
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 Table 7-2 Nutritional properties of intervention and control juice 
a Trolox Equivalent 
b Iland Method (19). 
c USDA database for the flavonoid content of selected foods (release 3.1) (14). 
 
7.2.3 Measurements 
Outcome variables were measured at three time points: baseline, 6 weeks and 12 weeks with 
all interviews conducted at the same time of the day (am). At baseline and 12 weeks participants 
arrived fasting and a blood sample was collected by a trained phlebotomist. A standardised 
breakfast was offered to participants (cereal, milk, banana, tea and/or coffee) and they were 
instructed to consume the meal ad-libitum, before the remainder of the interview was 
conducted. At 6 weeks, participants arrived at the clinic after having consumed their usual 
breakfast at home.  
 
 At each interview, a questionnaire was administered by a single researcher, with the assistance 
of a guardian or carer, where appropriate, reporting selected demographic characteristics, 
tobacco use, and consumption of alcohol, supplements and medications. Nutritional status was 
assessed using an interviewer-administered Mini Nutritional Assessment (MNA) (20) and 
dietary intake, including flavonoid intake, was assessed using a 24hr dietary recall method, 
 Cherry Juice (100ml) Apple Juice (100ml) 
Energy 395kJ 180kJ 
Protein 1.5g 0.1g 
Fat Total <0.2g 0.1g 
Saturated <0.2g 0.1g 
Carbohydrate Total 21.0g 10.5g 
Sugars 16.0g 9.3g 
Dietary fibre 0.7g 0.0g 
Sodium <1mg 1.0mg 
Oxygen Radial Absorbance 
Capacity  
3200 µmol TE a/ g 15.55 µmol TEa/ g 
Red Pigment (Anthocyanin) content 69 mg b 0.02mg c 
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with the assistance of a carer or guardian. Dietary records were entered into the FoodWorks 
dietary assessment programme to assess nutritional parameters (Xyris Software, Highgate Hill, 
QLD, Australia, Version 5, 2007). To estimate usual flavonoid intake, dietary records were 
cross-referenced with the 2013 USDA database for the flavonoid content of selected foods 
release 3.1 (14). Resting BP and heart rate were measured using an Omron HEM7200 Deluxe 
Automatic BP Monitor, while seated, in triplicate and averaged. To monitor physical outcomes 
over 12 weeks, anthropometric measurements included height, weight, and mid arm and mid-
calf circumference. Lawton’s Instrumental Activities of Daily Living Scale (IADL) (21) 
determined functional impairment and hand grip strength was assessed using a digital Jamar 
handgrip dynamometer (Lafayette Instruments, Indiana, USA). The blood sample assessed 
changes in markers of inflammation (C-reactive protein (CRP) and Interleukin-6 (IL-6) and 
plasma vitamin C levels. Blood samples were prepared and stored at -80oC for batch analysis 
by an independent laboratory where IL6 was measured by High Sensitivity cytokine panel 
(millipore), CRP was measured by hsCRP (Kamiya), and Vitamin C by an in-house method.  
 
7.2.4 Outcome assessment 
Cognitive function was assessed using a battery of seven cognitive tests, including the Rey 
Auditory Verbal Learning Test (RAVLT) (22, 23) , the self-ordered pointing task (SOPT)(24), 
the Boston naming test (25), the trail making test (TMT) (26), digit span backwards task (27) 
and category and letter verbal fluency (28). The RAVLT measured verbal learning and memory 
by the participant learning a list of words over presentation-test and delayed-test trials. The 
SOPT is a test of working memory, and the Boston naming test assessed confrontational 
naming, related to semantic memory. The TMT A and B evaluated executive function and the 
relative difference between B and A was used as the measure. Digit span backwards task 
examined short-term memory storage and executive control processes by requiring participants 
to repeat a series of numbers in the reverse order they were given. Category and letter verbal 
fluency measured executive function, requiring participants to recite as many words as possible 
that belonged to the category “animals” or began with the letter “F” and “A”. The geriatric 
depression scale (GDS) (29) assessed mood state. The battery of cognitive assessments was 
selected on the basis of previous research findings (30) and the suitability of each assessment 
as applied in the dementia cohort. Each task had been previously validated and shown to be a 
sensitive and specific task at measuring the appropriate cognitive domain.  
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7.2.5 Statistical Analysis 
Statistical analysis was conducted using SPSS statistical program (V17.0: 2006, SPSS, Inc., 
Chicago, II, USA). Analysis was completed using the full cohort that completed each of the 
time points. Continuous data are described as the mean and standard deviation (SD) as 
appropriate. Non-normally distributed variables were transformed and treated as normally 
distributed. Baseline differences between the intervention and control group’s characteristics 
and nutrition information were analysed by unpaired t-tests for continuous variables. A 2-way 
repeated measures ANOVA analysed the effect of time, treatment, and time*treatment 
interactions for blood pressure measurements at 6 and 12 weeks. Analysis of covariance 
(ANCOVA) using the baseline data as a covariate was used to analyse the group effect at 6 and 
12 weeks for all cognitive tasks, to isolate the effect of the intervention while controlling for 
group differences at baseline. Repeated measures ANOVA assessed differences in markers of 
inflammation and vitamin C at baseline and 12 weeks. A p value less than or equal to 0.05 was 
considered to indicate statistical significance. Eta-squared (η2) values were calculated to 
indicate the strength of the main effect. The Cohen’s f effect size estimates were characterised 
as small (0·10), medium (0·25) and large (0·40) (31).  
 
7.3 Results 
Forty-nine participants (24 female, 25 male) were recruited and seven participants withdrew 
from the study (2 indefinitely hospitalised, 4 due to study burden and 1 moved away). 
Participants were randomised into the control group (n=25) and intervention group (n=24) 
(Figure 7-1).  
 
7.3.1 Baseline: 
No differences between groups were found for age, BMI and anthropometrics, years of 
education or total flavonoid intake at baseline. Significant differences at baseline were found 
between groups for measures of malnutrition, activities of daily living, and hand grip strength.  
 
Differences in habitual intake of several flavonoid subclasses was found between the groups, 
according to a 24h recall administered at baseline (Table 7-1), with the intervention group 
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consuming more flavonoids than control subjects. Mean total flavonoid intake was estimated 
as 510mg/day. Black tea (80%) was the most significant dietary source of total flavonoids 
followed by green tea (7.5%), red wine (4.5%), apples (1.7%) and oranges (1.6%) with their 
respective fruit juices. Flavonols contributed 5.15% of total flavonoid intake. Dominant 
sources included black and green tea, onion, broccoli and apples. Flavones contributed the 
smallest percentage (0.15%) with the major source being parsley. Total flavanone intake 
provided 2% with major sources including oranges and orange juice, and lemons. Flavon-3-ols 
contributed 88.1% of total intake, with black tea as the major source and wine and apples 
contributing somewhat. Anthocyanins (4.6%) were provided by red wine, red grapes and 
bananas.  
 
At baseline, the only significant difference between the groups for nutrient intake was for 
carbohydrates (p=0.023) and caffeine intake (p=0.03), with the intervention group with a 
higher intake than the control.  
 
7.3.2 Post-intervention: 
A trend for improvement in most of the cognitive tasks is evident as shown by the mean 
difference between baseline and 12 weeks for the intervention group only (Table 7-3). Analysis 
of covariance showed significant improvement in cognitive performance in the intervention 
group relative to the control (Figure 7-2), at 6 and 12 weeks for the Category Verbal Fluency 
task (p=0.014) , RAVLT total (p=0.014) , RAVLT delayed recall (p=0.005) and RAVLT 20 
minute delayed recall (p=<0.001) tasks. The effect sizes for Category Fluency (η2 = 0·711), 
RAVLT total (η2 = 0.713), RAVLT delayed recall (η2 = 0.433) were large and the effect size 
for RAVLT 20 minute delayed recall (η2 = 0.242) was moderate. No significant improvements 
from baseline were found for cognitive performance tasks in the control group. 
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Table 7-3 Mean scores for cognitive performance and mood by group a  
Control group  Intervention group  
  Baseline 
n=25 
12 weeks 
n=21 
Mean 
Differenc
e 
Baselin
e 
n=24 
12 weeks 
n=21 
Mean Difference 
Letter Verbal Fluency 
(executive function) 
13.1 ± 
7.5 
13.1 ± 
7.9 
0.015 ± 
0.4 
18.9 ± 
11.0 
19.0 ± 
10.3 
0.13 ± 0.7 
Category Verbal Fluency 
(executive function) 
8.4 ± 4.5 8.3 ± 4.7 
-0.1 ± 
0.19 
11.9 ± 
4.5 
13.4 ± 
5.1 
1.9 ± 0.17 
RAVLT total (I-V)  
(learning and memory) 
19.3 ± 
9.2 
17.5 ± 
13.1 
-1.8 ± 
3.85 
25.5 ± 
10.6 
29.1 ± 
11.5 
3.9 ± 0.88 
RAVLT delayed recall 
(memory) 
1.2 ± 1.9 1.4 ± 2.2 0.2 ± 0.4 
2.3 ± 
2.6 
3.8 ± 2.9 1.6 ± 0.4 
RAVLT 20m delayed recall 
(memory) 
0.72 ± 
1.2 
0.7 ± 1.2 0 ± 0.07 
0.6 ± 
1.0 
2.3 ± 2.6 1.6 ± 1.4 
Trail making task b 
(executive functioning) 
129.8 ± 
81.1 
128.6 ± 
85.0 
-1.2 ± 4.0 
125.1 ± 
65.0 
101.9 ± 
67.3 
-23.2 ± 2.32 
Self-ordered pointing task 
(working memory) 
1.3 ± 1.3 1.6 ± 1.8 0.3 ± 0.5 
0.6 ± 
1.0 
0.6 ± 0.8 0.0 ± -0.2 
Digit span backwards task 
(short-term memory) 
2.3 ± 1.1 2.8 ± 1.1 0.5 ± 0 
3.0 ± 
1.0 
3.4 ± 1.2 0.4 ± 0.2 
Boston naming task 
(semantic memory) 
33.1 ± 
15.5 
31.9 ± 
13.6 
-1.2 ± -
1.8 
40.6 ± 
13.1 
40.0 ± 
13.6 
-0.5 ± 0.5 
Geriatric Depression Scale b 
(mood) 
7.3 ± 4.7 6.9 ± 3.5 
-0.4 ± -
1.2 
6.9 ± 
4.5 
6.3 ± 4.3 -0.6 ± -0.2 
a Data are given as mean ± SD. Baseline refers to measures obtained at the pre-intervention 
assessment. Final refers to measures obtained during the final week of the intervention. 
Difference = final score (mean) less baseline score (mean).  
b A negative score is indicative of improved outcomes. Otherwise, a positive difference in score 
indicates improved outcomes. 
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Figure 7-2 Significant changes in category fluency (A), RAVLT total (B), RAVLT delayed recall (C) and RAVLT – 20minute delayed recall (D) 
at 6 and 12 weeks post intervention 
*p=<0.05**p=<0.001 
** 
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Table 7-4 Blood pressure and heart rate measurements according to group at baseline, 6 and 12 weeks a 
 Control group  Intervention group  
 Baseline 
n=25 
6 weeks 
n=21 
12 weeks 
n=21 
Baseline 
n=24 
6 weeks 
n=21 
12 weeks 
n=21 
Systolic BP* 140 ± 19.7 138.5 ± 12.3 137.0 ± 10.1 138.2 ± 16.4 133.7 ± 9.9 130.5 ± 12.2 
Diastolic BP 80.6 ± 9.8 81.0 ± 8.0 81.3 ± 11.6 78.6 ± 11.7 77.0 ± 9.9 77.0 ± 12.6 
Heart Rate 70.2 ± 10.2 70.2 ± 11.1 74.2 ± 11.8 67.9 ± 10.7 66.0 ± 7.2 67.5 ± 7.9 
*p=<0.05 
Data are given as mean (mmHg) ± SD.  
aBaseline refers to measures obtained at the pre-intervention assessment. 6 weeks and 12 weeks refers to measures obtained at these time points 
during the intervention.
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Repeated measures ANOVA, with the baseline as a covariate, showed a significant 
difference in systolic blood pressure (p=0.038) at 6 and 12 weeks post baseline, with 
a similar trend evident for diastolic blood pressure (p=0.160) in the intervention group 
relative to the control (Table 7-4). No significant differences in blood pressure are 
evident for the control group. 
 
At follow up, there were no significant between-group differences in nutrient intake 
or for change in nutrient intake from baseline.  
 
Repeated Measures ANOVA showed no significant difference between the 
intervention and control groups for serum vitamin C, IL-6 or CRP at baseline or 12 
weeks (Table 7-5). There were no improvements in serum vitamin C levels after 12 
weeks in either group. Mean levels of plasma CRP and IL-6 were not significantly 
different after the intervention. 
 
Table 7-5 Serum vitamin C and inflammatory markers at baseline and 12 weeks 
 Control group n=25 Intervention group n=24 
  Baseline 12 weeks Baseline 12 weeks 
IL6 (pg/mL)a 4.3±2.9 6.3±5.8 3.7±1.8 3.8±3.5 
hsCRP (mg/L)b 2.0±2.5 2.0±2.3 1.6±1.5 1.7±1.8 
Vitamin C (uM) 19.3±13.1 13.6±8.2 18.2±10.6 13.3±11.0 
aIL-6 Interleukin-6; bhsCRP C-Reactive Protein 
Data are given as mean ± SD 
 
7.4 Discussion 
This study found that daily consumption of a feasible serving of anthocyanin-rich 
cherry juice for 12 weeks improved cognitive performance across almost all tasks in 
older adults with mild to moderate dementia. To our knowledge, this is the first 
controlled human trial examining cognitive and physical responses to a dietary 
intervention involving sweet cherries as a source of flavonoids and anthocyanins.  
 
  
220 
 
Our study suggests that provision of anthocyanins through an achievable and 
acceptable daily quantity of sweet cherry juice over 12 weeks has benefit for cognitive 
function in older adults with Alzheimer’s type dementia. Trends are evident, showing 
improvements in cognitive performance across all tasks with regular cherry juice 
consumption. Statistically significant improvements are seen for category verbal 
fluency and tasks relating to verbal learning and memory (Figure 7-2). The moderate 
and large effect sizes seen for the cognitive tasks highlight the clinical relevance of 
these cognitive improvements. These findings are consistent with those of recent 
human and animal studies showing improvement in cognitive performance in these 
domains with dietary supplementation with other anthocyanin-rich food sources (11-
13, 32-34). Although, we have previously shown that intake of cherry juice does not 
impact acute cognition over 6h (35). The ability of flavonoids to modulate Alzheimer’s 
disease progression is still poorly understood (17). As explored by the hypothesis in 
the current study, flavonoids may be more likely to hinder both normal and disease-
related losses in cognitive performance through their actions on the brain's cellular and 
molecular architecture of memory, rather than halt disease progression.  
 
Some nutritional differences existed between the intervention and control juices 
(Table 7-2). As intended, the ORAC measure of oxidative capacity (3200 vs 15.55 
µmol TE/g) and the red pigment (anthocyanin) content (690mg/L vs 0.2mg/L) is much 
higher in the experimental cherry juice compared to the control apple juice. Apple 
juice was chosen as a control juice as it represents a commonly consumed beverage in 
older adults, but that has negligible anthocyanin. Despite literature indicating 
beneficial effects of apples and apple flavonoids for health outcomes, the juice utilised 
in the experiment was processed in a way that likely degraded the flavonoid content. 
This important aspect of the research design is relevant to translation of the findings 
into dietary messages. However, it is important for future work to investigate whether 
dose-response effects are evident in such nutrition interventions.  
 
Despite randomisation, differences in several anthropometric and nutritional factors 
existed between the intervention and control group at baseline (Table 7-1). We 
attempted to mediate this factor statistically, by applying baseline as a covariate in the 
analyses. However, these differences in general health and baseline cognition may 
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have influenced the outcomes seen for the intervention group. The estimation of total 
flavonoid intake and intake of specific flavonoid subclasses at baseline revealed large 
variability between subjects. This can be principally attributed to variations in tea 
(confirmed by significant differences in caffeine intake between groups), wine and 
other fruit juice consumption, which were the main sources of flavonoids in this 
sample. Total intake and major sources of flavonoids of participants at baseline was 
similar to that reported for Australians aged 65+ years (510 vs 575 vs 683mg/day 
respectively) (4, 36, 37). The higher anthocyanin intake in our sample, compared to 
national estimates, may be explained by a relatively high consumption of red wine in 
the study group. The addition of cherry juice to the diet of the intervention group 
provided them with an additional 138mg anthocyanin/day, which increased their total 
anthocyanin intake to 46 times greater than the national estimate for the daily intake 
of adults aged 65+y (3.02mg/day). In the absence of a Nutrient Reference Value 
(NRV) for flavonoids (38), this magnitude of increase in consumption can be 
considered to be a significant increase above habitual intake levels for this age group.  
 
Secondary outcome measures included anti-inflammatory effects, changes in 
functional and physical ability and depressive symptomatology. There was a 
significant reduction in systolic blood pressure and a trend for diastolic blood pressure 
in the intervention group relative to the control; however the study was not adequately 
powered to detect blood pressure changes. Previous intervention trials have 
hypothesised that the mechanisms relating to the improvements seen in cognitive 
performance after anthocyanin-rich food supplementation are due to a reduction in 
inflammatory markers, resulting in a blood pressure-lowering effect (13). Our study 
showed that markers of inflammation were not significantly altered after cherry juice 
supplementation (Table 7-5) and remained within the clinically normal ranges (CRP 
<5mg/mL; IL-6 <10pg/mL). This finding suggests that the bioactive components 
provided by the cherry juice may provide other benefits, such as stimulating an up-
regulation of signalling cascades in areas of the brain relating to memory (8). 
Additionally, as Alzheimer’s disease is associated with progressive and chronic 
inflammation (39), the disease pathology may mask any potential anti-inflammatory 
effects provided by the cherry juice.  
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Surprisingly, serum vitamin C levels decreased in both groups at 12 weeks of follow 
up (Table 7-5). This difference cannot be explained through changes in dietary patterns 
over the study duration as vitamin C intake did not differ according to 24h diet recall 
data. Additionally, self-reported fruit and vegetable intake was not significantly 
different at baseline and follow up. A possible explanation may be the study juices 
may have replaced consumption of commercial fruit juices that could have been 
fortified with high levels of ascorbic acid. The reported reduction in serum vitamin C 
parameters is not clinically significant as mean levels remained in the clinically normal 
range (11-114 micromoles/L). Although under-researched in humans, some pre-
clinical evidence indicates that high-doses of flavonoids may inhibit ascorbate 
absorption (40), which may explain the reduction in serum vitamin C. Alternatively, 
the reagents that were utilized to prepare the serum prior to Vitamin C analysis may 
have degraded over the study period. 
 
The study limitations include a relatively small sample size and short intervention 
length (12 weeks). However, preclinical studies indicate that flavonoids from berry 
fruits may require only several weeks to accumulate in brain regions associated with 
cognition (41). Despite this, a short time frame limits our ability for observations 
regarding changes in dementia progression. Given the moderate to large effect sizes 
found in this study, a longer duration of follow up with larger numbers would be the 
next progression in research. Another limitation of the study relates to the generally 
better cognitive and physical ability of the intervention group, which is evident despite 
randomisation. Interestingly, the measure of effect for improvements on cognitive 
tasks in the intervention group relative to the control was the same, regardless of the 
cognitive ability of participants.  At the baseline and 12 week visits, a standardised 
breakfast meal was provided, however at the 6 week visit participants arrived at the 
clinic facility in a non-fasted state, after having consumed their usual breakfast at 
home (as a fasting blood sample was not collected). If there was a large difference in 
the nutritional composition of their usual breakfast to the standardised breakfast (e.g. 
a significantly greater intake of caffeine), this may have either positively or negatively 
influenced cognitive performance at this time point. However, this effect was 
minimised by the participants consuming their breakfast at 6 and 12 weeks ad-libitum, 
and as the improvements in cognitive performance seen at 6 and 12 weeks are not 
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significantly different, a difference in breakfast is unlikely to be of great importance. 
Lastly, while it is likely the bioactivity of the cherry juice relates to its high 
anthocyanin content, the potential bioactive effects of other polyphenols cannot be 
excluded.  
 
Regardless of their exact mechanisms, the potential of flavonoids to improve cognitive 
outcomes for older adults with Alzheimer’s type dementia cannot be underestimated 
and a notable strength of this study is the very low possibility of any harm to this 
vulnerable group. Further research is required to improve the knowledge base to 
inform dietary recommendations for this patient group, as an adjunct to traditional 
dementia treatment. For older adults living with reduced cognitive capacity, the 
inclusion of an anthocyanin-rich beverage, in addition to or in replacement of another 
processed fruit juice, may be a practical way to improve their total flavonoid 
consumption, which has been shown to provide positive outcomes for prevention of 
cognitive decline. 
 
7.4.1 Conclusion 
The findings of this study suggest that regular anthocyanin-rich cherry juice 
consumption over 12 weeks can improve cognition in older adults with dementia and 
provides a basis for more comprehensive human trials to study the potential of cherry 
flavonoids to influence neuro-cognitive health. 
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8  
8.1 Overview of core findings 
The research presented in this thesis utilised various methodologies to address the 
central research questions surrounding the measurement of dietary flavonoid intake 
(chapters 2, 3, 4) and the impact of dietary flavonoid supplementation on cognitive 
and physical outcomes (chapter 5, 6, 7).  
 
In order to associate the impact of dietary flavonoids on health outcomes, accurate 
measures of dietary flavonoid intake are fundamental. The gaps in knowledge 
surrounding how dietary flavonoid intake is measured, presented in the introduction 
(chapter 1) to this thesis, indicated the need for improved methods for measuring 
dietary flavonoid consumption. A systematic evaluation of the various methods 
employed by current literature to measure flavonoid intake, and their associated 
limitations were highlighted in a literature review (chapter 2). The review emphasised 
the reliance on studies that utilise flawed or limited dietary assessment methods to 
measure dietary flavonoid intake. Additionally, the review established that despite 
several studies outlining the development and validation of biomarkers of flavonoid 
intake, few studies actually utilised biomarkers as an objective measure of dietary 
flavonoid intake. 
  
In response to the limitations to the current methods of measuring dietary flavonoid 
intake, novel methods of measuring flavonoid intake were developed. Chapter 3 of 
this thesis identified that the measurement of dietary flavonoids in older Australians 
was inadequate and consequently performed secondary data analysis of detailed 
dietary information to describe flavonoid intake in this population (chapter 3.1). 
Consequently, a tool for the estimation of dietary flavonoid intake in this cohort was 
developed based on these findings (chapter 3.2). The tool was adequately validated 
against food records and assessed for reliability in a group of older Australians, and 
proved to be a relatively useful tool for application to measure flavonoid intake in 
future research in older Australians. However, the tool needs to be refined further to 
reduce participant burden (perhaps to shorten in length) and to assess for its usefulness 
beyond that of currently applied dietary assessment tools.   
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A sensitive and specific GC-MS method was developed (chapter 4) with the potential 
to measure around 115 flavonoid-related biomarkers in biological samples. The 
potential application of this method in future research is vast, especially for 
exploratory metabolomics-related studies, in which this GC/MS method could be 
applied to determine the most suitable biomarker related to flavonoid intake depending 
on the research objectives. However, the usefulness of this biomarker assessment 
method for determining total dietary flavonoid intake needs to be addressed. It is 
unlikely that a metabolite profiling approach for the measurement of dietary flavonoid 
intake is a straightforward technique, and therefore its application relative to dietary 
assessment methods must be investigated. 
 
Overall, the dietary flavonoid intake measurement strategies developed by this thesis 
improved upon current methods (1, 2) of measuring flavonoid intake, and contributed 
novel tools with potential for application in future research studies.  
 
In order to inform the development of interventions to assess the impact of dietary 
flavonoid intake on cognitive and physical outcomes, a literature review of relevant 
current findings was required. A literature review (chapter 5) identified a paucity of 
research regarding food-based anthocyanin consumption and cognitive outcomes. 
However, the preliminary findings indicated positive cognitive outcomes associated 
with anthocyanin-rich food consumption. Various methodological limitations were 
highlighted from the acute and longer-term trials included in the review, including 
issues surrounding dosages and cognitive tools employed. The findings of the review 
were utilised to develop acute (chapter 6) and longer-term (chapter 7) intervention 
studies which assessed the impact of a flavonoid and anthocyanin-rich cherry juice on 
cognitive and physical outcomes.  
 
A pilot cross-over study assessed the acute effects on cognitive function, blood 
pressure and plasma biomarkers associated with consumption of a 300ml cherry juice, 
provided either as a single quantity or as 3x100ml doses administered over 2h. The 
methodology used in this acute pilot study contributed to an improved study design 
for flavonoid-based trials of cognition, with the results indicating that the acute impact 
of anthocyanin-rich cherry juice consumption on cognition was not supported. 
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However, a potential dose-timing administration effect may influence acute blood 
pressure outcomes. The application of the GC/MS method developed in chapter 4, 
measured eight related biomarkers of anthocyanin-intake, confirming the metabolism 
and uptake of cherry-related anthocyanins in this study.  
 
The final study of this thesis comprised a longer-term intervention, which was 
conducted to assess whether daily consumption of anthocyanin-rich cherry juice 
changed cognitive function in older adults with dementia, with blood pressure and 
anti-inflammatory effects examined as secondary outcomes. The results of this study 
indicated that anthocyanin-rich cherry juice consumption improved cognitive 
performance and significantly reduced blood pressure, but did not impact markers of 
inflammation in this group. This study contributed significant findings to the limited 
human clinical trial literature regarding flavonoid supplementation and cognitive 
outcomes, in a group of individuals who may be most likely to benefit from 
improvements to cognitive performance. This study provided the first evidence that 
regular consumption of a feasible serving of flavonoid-rich food may have beneficial 
consequences in older adults with Alzheimer’s type dementia, and these findings 
warrant further investigation.  
 
Overall, the findings of these studies support the hypothesis that dietary flavonoids, 
and especially anthocyanin-rich food, is beneficial for cognitive and physical 
outcomes (3).  
 
8.2 Strengths and limitations  
Each study comprising this thesis had its own set of methodological strengths and 
limitations, which have been addressed in the preceding chapters. Consequently, some 
general strengths and limitations are considered here. 
 
This thesis has highlighted that there are considerable limitations relating to the 
accurate measurement of dietary flavonoid intake, which hinders the ability for 
convincing associations between flavonoid intake and health outcomes to be drawn 
(2). Study 1, 2 and 3 of this thesis addressed significant gaps in knowledge surrounding 
  
231 
 
the estimation of dietary flavonoid intake, and the tools developed within these studies 
can be usefully applied in future research. However, the dietary assessment method 
(FFQ) developed and validated to measure dietary flavonoid intake is specific for the 
older Australian population, and thus may have limited generalisability outside of this 
setting. Additionally, the validity of this tool could be further strengthened by 
evaluating its association with flavonoid-related biomarkers through the application 
of the method of triads (4, 5). This work is planned by our research team, in 
conjunction with collaborators at the QLD Government's Department of Agriculture 
and Fisheries and the University of Queensland, Australia, but is outside the scope of 
this thesis.  
 
Our laboratory work has shown that the GC/MS method is able to determine 
flavonoid-related biomarkers, which is suitable in exploratory studies to confirm the 
metabolism and uptake of flavonoids. However, its ability to measure biomarkers as a 
measure of total dietary flavonoid intake required further validation. While similar 
methods have shown to be useful indicators of flavonoid intake associated with pure 
flavonoid supplementation (6), the application of the GC/MS method to measure 
dietary flavonoid intake in population-based research needs further investigation.  
 
This thesis has additionally emphasised the considerable limitations in research that 
investigates the cognitive and physical benefits of flavonoid consumption, and 
specifically foods that are rich in anthocyanins. Study 4, 5 and 6 of this thesis 
addressed significant gaps in knowledge relating to the cognitive and physical benefits 
of anthocyanin-rich food supplementation. Theses studies contribute to evidence for 
the dose-timing administration of flavonoid-rich food supplementation in acute trials, 
the cognitive benefits associated with anthocyanins in a little researched fruit variety 
(cherries) and the first investigations of the neuro-cognitive benefits of anthocyanin-
rich food supplementation in older adults with dementia. While the contributions 
provided by this thesis are promising, the relatively small sample sizes of the 
intervention studies limit the interpretation of the results. The positive results indicated 
in both the acute and longer-term supplementation trials indicate that further research 
on a larger scale is required to confirm the findings. 
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8.3 Future directions 
While this thesis has contributed novel investigations to the literature regarding the 
measurement of dietary flavonoid intake and the impact of flavonoid intake on 
cognitive and physical functioning, it also highlights the need for further research. 
Based on the findings of this thesis, the following recommendations are made for 
future research. 
 
Complete food composition databases for flavonoids and appropriate dietary 
assessment methods are essential for any flavonoid-related research. Future 
investigations attempting to measure dietary flavonoid intake should apply validated 
flavonoid specific dietary assessment methods to ensure greater precision when 
measuring total flavonoid intake and the intake of specific subclasses. Ideally, future 
estimates of flavonoid intake will consider the growth, processing and preparation 
conditions on the flavonoid content of foods. While investigators are responsible for 
selecting appropriate methods for their studies, this step also heavily involves the 
improvement of flavonoid food composition databases. Analytical studies are needed 
to fill existing gaps on commonly eaten flavonoid rich foods, and to ensure that all 
appropriate foods, including values for their cooked and processed alternatives, are 
included in flavonoid databases. The differences between flavonoid intake estimates 
associated with applying different flavonoid food composition databases should also 
be assessed.  
 
Identification of suitable biomarkers of flavonoid intake is imperative for an objective 
measurement of total flavonoid intake, and/or in the intake of flavonoid subclasses. 
The lack of validated biomarkers of total flavonoid intake has been highlighted as a 
significant problem, and has been attributed to inter-individual variation in the 
metabolism of flavonoids (2). Validating estimates of flavonoid intake with a relevant 
biomarker where possible should be considered a priority for future research. 
However, the limitations of biomarker assessment methods should be considered, and 
a burden/benefit analysis of choosing this method over others (e.g. dietary assessment 
methods) should be a priority for studies if crucial advances are not made in the near 
future.  
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The potential therapeutic utility of flavonoid-rich food supplementation in dementia 
has been highlighted (7). However, further elucidation of the practicality of 
anthocyanin-rich food supplementation in the ‘free-living’ environment is needed, 
especially for older adults with dementia for whom nutritional changes may be 
difficult to sustain. Previous research has speculated that the effects of specific fruit 
and vegetable consumption on cognitive outcomes in a general population are likely 
to be subtle (8). The clinical relevance of improvements in cognitive function, or the 
potential for flavonoids to mediate dementia disease progression, in older adults after 
anthocyanin-rich food supplementation needs to be further investigated. The 
differences in outcomes for supplement and food based interventions needs to be 
elucidated. While the use of pure supplements are useful when considering flavonoid 
bioavailability and mechanisms of action, future research needs to consider feasible 
dietary interventions in order to generalise results and inform dietary messages.  
 
As our knowledge of flavonoid–disease relationships becomes clearer, it may soon be 
possible to specify recommended intake levels. Interestingly, recommendations 
associated with phytochemicals are beginning to be included in widely disseminated 
dietary guidelines (9), in addition to guidelines surrounding fruit and vegetable 
consumption. However, much additional work is needed before evidence-based 
recommendations will be possible and public health policy developers must be 
cautious when using information regarding flavonoid consumption specifically. 
 
8.4 Summary 
In conclusion, this thesis has highlighted the current limitations associated with 
estimating dietary flavonoid intake and developed new tools for measuring flavonoid 
intake. Additionally, this research has investigated the current research surrounding 
the cognitive and physical benefits associated with flavonoid intake and assessed the 
impact of anthocyanin-rich food supplementation on acute and longer-term health 
outcomes.  
 
The research constituting this thesis has extended current knowledge regarding the 
assessment of dietary flavonoid intake and the impact of flavonoid supplementation 
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on cognitive and physical outcomes. The culmination of the six studies constituting 
this thesis contributes to the fields of nutrition, psychology, public health and basic 
science, with each study contributing a novel and innovative investigation. Together, 
these studies advance scientific knowledge regarding the most significant gaps 
surrounding dietary flavonoids. In a broader context, these studies ultimately 
contribute to a larger wealth of knowledge regarding how diet and dietary components 
can influence health outcomes in humans.  
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